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Abstract 
The lack of effective disease-modifying treatments and of means to achieve an 
early diagnosis strongly support the search for reliable neurochemical biomarkers 
in neurological conditions like Amyotrophic Lateral Sclerosis (ALS), a fatal 
neurodegenerative disorder. In ALS, the accumulation of protein aggregates 
containing neurofilaments (Nf), the building blocks of axons, leads to motor 
neuron death. Here we investigate the presence of neurofilaments (Nf) in protein 
aggregates in blood, studying a hallmark of neurodegeneration systemically. We 
explore the hypothesis that these circulating protein assemblies may function as 
biomarkers for neurodegeneration in accessible biofluids, which may have future 
application in clinical practice. 
In this thesis, I developed a protocol based on ultracentrifugation for the 
enrichment of protein aggregates from blood and confirmed their enrichment in 
Nf.  Using Mass Spectrometry (MS)-based proteomics, I have obtained data on 
the protein composition and functional relevance of Nf-Containing Hetero-
aggregates (NCHs) in plasma samples from ALS patients, healthy controls (HC) 
and from ALS brains. I have then applied quantitative proteomics analysis using 
a TMTcalibrator™ workflow on plasma samples from ALS patients and HC using 
brain tissue as an internal calibrator. Additional experiments were undertaken to 
evaluate NCHs resistance to proteases digestion and to characterise the specific 
conformation of these macromolecular structures by Transmission Electron 
Microscopy (TEM). Our fluid-brain tissue investigation using a multi-modal 
approach suggests that NCHs may represent a systemic readout of biochemical 
changes identified in neurodegenerative brain pathology and suggest that they 
may acquire altered biochemical properties like protease resistance. The 
changes in NCHs identified in ALS compared to HC are a promising biological 
substrate for the future development of next generation biomarkers of 
neurodegeneration. 
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IQR   Inter-quartile range  
iTRAQ Isobaric tags for relative and absolute quantitation  
KEGG  Kyoto Encyclopedia of Genes and Genomes  
Knn   K-nearest neighbours  
KS   Keratan sulphate  
KSP   Lysine-serine-proline  
LB4X  Loading Buffer 4X  
LC   Liquid chromatography  
LC-MS/MS  Liquid Chromatography coupled with Tandem Mass Spectrometry  
LDL  Low-density lipoproteins  
LF   Loading factor  
LIMMA Linear models for microarray  
LMN  Lower motor neurons  
logFC  Log2fold change  
LPA  Lysophosphatidic acid  
LPS  Lowest-probability subsequence  
m/z  Mass-to-charge ratio  
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MetOH Methanol  
MF  Molecular Functions  
MND  Motor neurone disease  
MS  Mass Spectrometry  
MS/MS  Tandem MS  
MW  Molecular weight  
NBB  Netherlands Brain Bank  
NCHs  Neurofilament-Containing Hetero-aggregates  
Nf  Neurofilaments  
NfH  Neurofilament heavy 
NfL  Neurofilament light  
NfM  Neurofilament medium 
NTA   Nanoparticles tracking analysis  
ON   Overnight  
PA  Phosphatidic acid  
PAPA  Prion Aggregation Prediction Algorithm  
PC   Phosphatidylcholine  
PCA   Principal component analysis  
PD  Proteome Discoverer 1.4  
PE   Phosphatidylethanolamine  
PGs  Proteoglycans  
pI   Isoelectric point  
PI   Phosphatidylinositol  
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PLAAC  Prion-like amino acid composition  
PNS  Peripheral Nervous System  
PPAR  Peroxisome proliferator-activated receptors  
PRL  Progression Rate at Last Visit  
PSMs  Peptide-Spectra Matches  
PTMs  Post-Translational Modifications 
PVDF  Polyvinylidene difluoride  
RBPs   RNA Binding Proteins  
RT  Room Temperature  
sALS  Sporadic ALS  
SDS   Sodium dodecyl sulphate  
SEP  Seprion PAD-beads  
SOD1  Superoxide dismutase 1  
SR  Seprion Reagent  
TB  Transfer Buffer  
TBS   Tris-Buffered Saline  
TEM  Transmission Electron Microscopy  
TFA   Trifluoroacetic acid  
TMT  Tandem Mass Tag  
UA  Uranyl Acetate  
UC   Ultracentrifugation  
UMN   Upper motor neurons  
VLDL  Very low-density lipoproteins  
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WB  Western Blot
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1 Introduction 
1.1 Neurodegenerative disorders: the example of Amyotrophic Lateral 
Sclerosis 
The increasing prevalence of neurodegenerative diseases, in conjunction with 
the so-called silver tsunami of a rapidly aging population, is an alarming challenge 
to health services worldwide. The motor and cognitive impairment that 
neurodegeneration causes strikes right at the centre of our societies and of our 
ways of living: the burden on patients, family and carers is immense and the 
demographic as well as socio-economic scenario of a world facing a rapidly aging 
population with major neurological disabilities is rapidly becoming a reality. 
Prevention and treatment of neurodegenerative disorders is becoming a major 
health priority. However, the lack of biomarkers for early diagnosis and patient 
stratification is a limiting factor in the development of new clinical trials, along with 
the lack of novel therapeutic targets.  The problem has both quantitative and 
qualitative connotations. Among conditions with a relatively slow progression, 
Parkinson’s disease has an expected prevalence of 9 million globally by 2030, 
while Alzheimer’s disease will affect between one third and one half of all 
individuals above the age 80 by 2050, with health expenditure predicted to reach 
1 trillion dollars annually in the US alone (74,75). Motor neurone disease 
(MND)/amyotrophic lateral sclerosis (ALS) prevalence is expected to increase by 
69% by 2040, reaching a global prevalence of about 380,000 (76). However, 
unlike neurodegenerative diseases with slow progression, ALS can have a 
dramatic development to end-stage disease in less than a year from disease 
onset, requiring expensive nutritional and ventilatory support (77) Families, 
shocked with bereavement, are left to piece their lives back together when MND 
strikes. 
ALS is a fatal neurodegenerative disease with no effective treatment, affecting 
motor neurons in the brain and spinal cord and leading to death by respiratory 
paralysis in 3 to 5 years. ALS has an incidence of one or two new cases per year 
per 100,000, with males being more likely affected than females (78). 
The disease clinical expression is unpredictable and can vary dramatically 
between patients as shown in Figure 1.1. However, two main groups can be 
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distinguished as bulbar onset, where bulbar motor neurons are affected from the 
outset, and limb onset, where somatic/spinal motor neurons are affected. Another 
aspect of the disease is the involvement of upper motor neurons (UMN) and lower 
motor neurons (LMN). UMN originate in the motor cortex of the brain and are 
connected to LMN through their axon in the spinal cord at cervical area where 
the LMN cell body is located and they are connected to the muscles through their 
axon. When neurodegeneration starts at the UMN level there are signs of muscle 
spasticity and brisk reflexes, while for LMN degeneration the signs are weakness, 
muscle atrophy and fasciculation (79). The diagnosis of ALS is normally based 
on evidence of involvement of both upper and lower motor neurons, in the same 
or in different anatomic areas. 
 
Figure 1.1. Different onset sites involving upper and lower MNs in ALS patients (79). 
This variety in disease phenotypes, length of survival and the way the 
neurodegeneration is detected in the brain and spinal cord, has generated a 
prion-like hypothesis for ALS, whereby the pathological protein aggregates in 
affected tissues are responsible for disease development and its spread (80,81). 
In fact, the hallmark for ALS, as with other neurodegenerative diseases, is the 
presence of protein aggregates in motor neuron cytoplasm, with TDP-43 as the 
most represented protein within these inclusions. Other proteins have been found 
to be involved in protein aggregation in ALS, such as NfH and Superoxide 
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dismutase 1 (SOD1) (82). Also, these inclusions within neuron bodies seem to 
be subjected to a wide range of chemical and enzymatic modifications (83,84). 
About 10% of the overall ALS cases show a family history for the disease and are 
defined as familial ALS (fALS), while the remaining 90% are defined as sporadic 
(sALS). Among fALS only 68% of the cases are linked to genetic mutations and 
the same set of genes account for only 11% of the sALS (Figure 1.2) (85). 
 
Figure 1.2. Genes involved in sporadic and familial ALS. Adapted from (85). 
The charts show relative percentages of cases with a known genetic cause for fALS and sALS. 
There are different mechanisms proposed for ALS pathogenesis, including 
impaired proteostasis, disturbed RNA metabolism and RNA Binding Proteins 
(RBPs) transcription, defects in cytoskeletal and axon-transport, impaired DNA 
repair, defects in vesicle transport, excitotoxicity related to increased glutamate 
concentration at synaptic level and mitochondrial dysfunction (86). Although all 
these processes seem to intervene in ALS development, it is not yet clear which 
are causative, and which are consequences. 
The diagnosis of ALS is primarily based on the symptoms and signs the physician 
observes in patients and on a series of tests to rule out other diseases, which can 
mimic ALS. This lengthy process results in a diagnostic delay of about 12 to 18 
months from onset.  
Methods to quantify the disease burden in ALS and the accumulation of 
neurological disability have been developed which include the ALS functional 
rating scale revised (ALSFRSR; range 1 to 48 where 48 is a healthy state and 1 
the maximum level of neurological compromise) (87). To estimate rate of 
progression, for the purpose of our investigation we will use an established 
scoring method which is based on the calculation of the slope or loss of 
ALSFRSR points every month from disease onset to the last assessment 
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(Progression Rate at Last Visit – PRL; PRL > 1 fast progressors, PRL< 0.5 slow 
progressors). 
Equally, a measure of the stage of development of the disease is provided by the 
El Escorial Criteria for diagnosis, which are based on the anatomic extension of 
the combination of upper and lower motor neuron signs (88).  
1.2 Neurofilament proteins 
Neurofilament (Nf) proteins are type IV Intermediate Filaments (IF), expressed in 
Central and Peripheral Nervous System (CNS, PNS), and constituted by three 
different proteins, Nf Light (NfL), Medium (NfM) and Heavy (NfH), encoded by 
three different genes. As other IF, they share the same structure with a head 
domain at N-terminus, a rod domain and a tail of different lengths at C-terminus 
(Figure 1.3). 
 
Figure 1.3. Schematic representation of neurofilaments (Nf) structure. 
Neurofilament (Nf) Light (NfL; 543 amino acids (aa), 68 KDa), Medium (NfM; 916 aa, 160 KDa) 
and and Heavy (NfH; 1026 aa, 205 KDa). The cartoon highlights the head domain at the N-
terminal of the protein, the rod domain, which is important during assembly of different Nf isoforms 
(divided in four segments), and the Tail domain at the C-terminal, which varies in length defining 
the three Nf isoforms. Tail and head are subjected to different types of post-translational 
modification and is also made of different numbers of lysine-serine-proline (KSP) repeats (13 in 
NfM and more than 40 in NfH) which are important for regulation of Nf function. 
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The Rod domain is an α-helical, coiled-coil rich region, that can be divided into 4 
different domains (1a, 1b, 2a and 2b), also shared with others IF (1). This central 
domain is responsible for assembly with other Nf proteins through ionic 
interactions (2), firstly generating a dimer in a parallel orientation and then a two 
dimers complex in an anti-parallel orientation giving rise to a tetramer (3). This is 
the block that will form a filament unit, made of eight tetramers interacting with 
each other, while axial polymerization of filament units will form the actual 
filament, with Nf tail domains extending outward from the filament axis (4) (Figure 
1.4). 
 
Figure 1.4. Assembly and formation of Nf.  
In the filament, NfM and NfH tails radiate outward owing to the extensive charges from 
phosphorylated residues. Adapted from (5). 
Nf are the most abundant cytoskeleton component in neurons. Together with 
Microfilaments and Microtubules are important constituents of neuronal structure 
(6). In addition to be a structural component of the cytoskeleton, Nf interact with 
other proteins (e.g. motor proteins), organelles, vesicles, mitochondria and 
plasma membrane (7–12). Nf are implicated in neuronal growth and in the 
maintenance of axonal caliber, playing a central role in axonal conduction 
properties (13,14). 
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During neuronal development, NfL is the first subunit to be expressed replacing 
peripherin (5), this process being followed by the expression of NfM and NfH and 
by a reduction of microtubules density (15–17). However, while NfL seems to be 
necessary in Nf assembly supporting axon and cytoskeleton development, NfM 
and NfH appear to be important in axonal caliber growth (18,19). Experiments 
performed in NfM and NfH knockout mice have shown that retaining either protein 
is enough to increase axon caliber during development and establish a good 
neuronal network, while NfH expression is required for distal to proximal 
development (20). 
An important biochemical feature of Nf is the Post-Translational Modification 
(PTMs) of amino acids which affect their functional properties. Phosphorylation 
at serine and Threonine is the most commonly described PTM which is known to 
affect assembly and transport of Nf and increasingly implicated in the 
pathogenesis of neurodegenerative disorders (21,22). The main phosphorylation 
sites in Nf are the KSP repeats that are very abundant in the tail region, making 
NfM and NfH the isoforms with the highest level of expression of these PTMs. 
Phosphorylation does also occur in the head domain where it is thought to have 
a role in reducing Nf assembly in the cell body, allowing flow of Nf to the axon 
where they are mostly required (23–25). In fact, studies of Nf phosphorylation 
have shown that this PTM is higher in the axon and lower in cell bodies and 
dendrites and this may also be explained by cross-bridges formation between Nf 
subunits and Microtubules which determine axonal caliber (26–28). Ultimately, it 
is thought that the tight regulation of Nf phosphorylation in the head and tail 
domains is an important mechanism thought to protect neurons from abnormal 
Nf accumulation (29). 
Another important PTM is Glycosylation, in particular O-GlcNAcylation at serine 
and threonine residues (in competition with phosphorylation) which can affect Nf 
assembly (30). Glycosylation seems to be an important regulator of Nf  
ubiquitination, whereby a small molecule called ubiquitin is attached to a protein 
which becomes inactivated and signals the protein-transport machinery to ferry 
the target protein to the proteasome for degradation (31). Beside ubiquitination, 
another mechanism proposed for Nf degradation is the activation of Calpain, a 
protein belonging to the family of calcium-dependent, non-lysosomal cysteine 
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proteases (proteolytic enzymes) expressed ubiquitously in mammals and many 
other organisms. Nf chemical cleavage by Calpain would occur as a 
consequence of increased intracellular calcium levels (32). However, it is 
important to point out that different mechanisms that are involved in Nf 
modification may have competing functions. For example, phosphorylation may 
act as a shield against protease-mediated degradation protecting Nf integrity 
(33). The ubiquitin proteasome system has laso been described in Nf 
degradation, while it is unclear if lysosome  and autophagy are involved in Nf 
clearance (34–37). In the context of brain injury, for example, microdialysis 
studies in areas of neuronal injury have shown how the mechanical impact is 
followed by the activation of Pavlov's enterokinase in the human brain, a neuronal 
proteolytic pathway that produces products of NfH cleavage (NfH(476-986) and 
Nf(H476-1026)), which have been used as specific protein biomarkers applicable 
to in vivo monitoring of diffuse axonal injury and neuronal loss in traumatic brain 
injury (38). 
Different bodies of experimental evidence have uncovered another important 
aspect of the behavior of Nf, and in particular of the relative composition of 
combined Nf isoforms in tissues across species. Comparison of the molar ratios 
of neurofilaments and Nf isoforms isolated from rat, bovine and human brain 
shows a variation of each polypeptide contribution to the filament structure, 
suggesting that the molar composition of the neurofilament triplet, may have 
specific molar stoichiometry in each species, both during the developmental 
stage and in brain maturity (39). Recently, Nf subunit stoichiometry calculations 
and Monte Carlo simulations of a coarse-grained Nf brush model have been used 
to look at whether the blood expression of NfL, NfM and NfH isoforms in a rapidly 
progressing and invariably fatal neurodegenerative condition, amyotrophic lateral 
sclerosis (ALS), changes significantly from the physiological Nf subunit 
stoichiometry of 7 : 3 : 2 (NfL:NfM:NfH;) (40). The analysis showed the relative 
over-expression of NfL over the other two subunits, which has been interpreted 
as an energy and time-saving option for motor neurons shifting protein expression 
from larger to smaller (cheaper) subunits, at little or no costs on a protein 
structural level, to compensate for increased energy demands seen in a condition 
of neurodegeneration. 
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1.3 Biomarkers of neurodegeneration and neurofilaments 
There is an important unmet need in modern medicine: the lack of biomarkers for 
neurodegenerative disorders to be used in clinic for diagnosis and prognosis. Due 
to the fact that neurodegenerative disorders present a high level of clinical 
heterogeneity and may also share important feature at presentation, it is currently 
difficult to have timely and accurate diagnoses based solely on clinical 
observation and other paraclinical means of investigations (41). More importantly, 
it is still impossible to anticipate disease onset in order to establish early 
treatments or interventions that could arrest or slow down disease progression in 
individuals at risk of developing a neurodegenerative disorder (42). Another 
important indication for the development of informative disease biomarkers for 
neurodegeneration is the need for tools to establish prognosis, which could be 
employed in the clinical stratification of phenotypic variants of neurodegenerative 
disorders. This has been at the centre of relentless efforts in a prevalent 
neurodegenerative disorder like Alzheimer’s disease (AD) where the aim is an 
improvement design of clinical trials with the identification of a disease stage and  
a proper tool to monitor treatment efficacy (43,44). Similarly, the importance and 
at the same time the difficulty in defining a panel of robust disease biomarkers 
with high diagnostic performance has emerged in a more rapidly progressing and 
clinical heterogeneous neurodegenerative condition like ALS (43).  
The most informative biological fluid to study neurochemical markers of 
neurodegeneration is the Cerebrospinal Fluid (CSF) since it is near the affected 
tissue, it provides the brain and spine with nutrients and eliminates products of 
neurodestruction. There are several proposed biomarkers for neurodegeneration 
in CSF, both representative of axonal and synaptic loss including Nf, Tubulin, 
Actin, Tau, Amyloid precursor protein, α-synuclein and N-acetylaspartic acid (45). 
Nf are released in cerebrospinal fluid (CSF) and blood when neurons and axons 
degenerate, and changes of Nf levels are associated with the progression of 
several neurodegenerative disorders (46–48). However, there are drawbacks in 
the use of this fluid for biomarkers analysis. In particular, longitudinal sampling 
with invasive lumbar punctures would not be practical for monitoring disease in 
clinical practice, given the variety of problems that may arise with disease 
progression including frailty of advanced patients and the lack of collaboration of 
cognitively impaired individuals which may require extreme means of sedation  
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(49). More accessible biofluids like blood and urine may be more suitable for 
disease monitoring and for the requirement of frequent and serial sampling. It is 
now acknowledged that most neurodegenerative conditions would develop a 
compromised blood brain barrier (BBB), enabling the leakage of different size 
molecules linked to neurodegeneration into blood, making this fluid a suitable 
target for biomarkers discovery (50,51). Furthermore, it has also been recently 
established that meninges harbor brain-draining lymph vessels, a novel route 
through which by-product of brain pathology may end up been excreted in the 
peripheral circulation (52).  
Nf have been proposed as good blood biomarker for neurodegeneration by 
several studies in different neurological disorders (46–48). Lu et al. have recently 
shown that the immunodetection of NfH, but not of medium and light chain, when 
tested in increasing dilutions, lacks linearity compared to Nf recombinant 
proteins, a phenomenon described as the hook effect (53). We believe that this 
non-linear dilution curve depends on Nf sequestration by immune-complexes 
and/or by larger molecular hetero-complexes which are disrupted by the dilution 
process. In the context of the work reported in this Thesis, the use of the suffix 
“hetero” to refer to the potential macromolecular formations that sequester Nf in 
circulation, is based on the assumption that the molecules partaking in these 
complexes are of different nature, including proteins like antibodies, but also lipids 
and eventually nucleic acids. It has been recently shown that the creation of Nf 
fragments following degradation by proteases and their release in body fluids has 
been proposed as a mechanism for the generation of autoantibodies in 
neurodegenerative disorders (54), an example of immune reactivity which is 
currently evaluated as a potential source of disease biomarkers. Sample dilution 
is likely to perturb the heterocomplexes homeostasis, changing Nf epitope 
exposure to detection antibodies hence generating non-predictable readings on 
immunodetection (53).  
1.4 Neurofilaments and protein aggregation in tissues and fluids  
The formation of assemblies of proteins that have lost their soluble state is a 
pathological hallmark of several neurodegenerative diseases (55,56). The 
confluence of proteins into aggregates may also occur physiologically as shown 
for the recruitment of RNA-binding proteins into stress granules (57–61). In cells, 
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the aggregation of misfolded proteins is usually kept in check by a quality control 
system, which operates through protein re-folding, autophagy and clearance by 
the proteasome (62,63). Extracellularly, a range of immune mediators may 
contribute to the clearance of misfolded proteins and of their aggregated forms 
(64). It is proposed that in biological fluids, aggregate formation reflects the 
propensity of proteins to assemble naturally or can be experimentally induced 
under conditions of stress (65–67). Depletion of albumin from human plasma, for 
example, leads to a significant increase in protein aggregation, particularly when 
heat and shear stress are applied (68). Recently the presence of soluble sodium 
dodecyl sulphate (SDS) resistant protein aggregates has been reported in 
plasma from older adults and in significantly lower levels in plasma from younger 
individuals (69). Loss of protein homeostasis and the increased rate of intra-
cellular protein aggregation seem to be important hallmarks of aging (69). 
Therefore, aggregates found in circulation may originate from senescent cell that 
have lost their functional integrity. Equally, an age-related failure of the control of 
protein homeostasis (i.e., proteostasis) may condition an increase of 
aggregation-prone proteins in fluid state and the formation of aggregates (69). 
Aggregates, inclusion bodies or aggregosomes described in neurodegenerative 
diseases including amyotrophic lateral sclerosis (ALS) (70), Charcot-Marie-Tooth 
disease (71) and Parkinson’s disease (72), contain Nf suggesting a role in 
neurodegeneration and a possible application in the development of biological 
readouts to help in the diagnosis and prognostic evaluation (46,47).  
As reported in Chapter 3, we suggest that circulating Nf are also present in high 
molecular weight molecular complexes. Therefore, understanding Nf distribution 
between brain tissue and fluids, and between low order oligomers and higher 
order hetero-aggregates in biofluids has significant implications on their utility as 
biomarkers. In ALS Nf form heterogenous protein aggregates (73) and it is 
assumed that these are released, essentially intact, into the blood stream 
following cell death. The de-novo formation of circulating heteroaggregates due 
to a seeding effect of proteins like Nf in the fluid phase cannot be excluded.  
Therefore, the relative representation in biological fluids of Nf isoform and of Nf-
containing heteroaggregates (NCH) depends on the following: 1) different 
kinetics of interaction between Nf and other proteins and/or auto-antibodies 
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(46,53); 2) Nf conformation and/or post-translational modifications which 
condition their immunogenicity and propensity to aggregate (5); and 3) the 
presence in the same milieu of other pro-aggregating proteins which may drive 
the assembly of Nf-enriched aggregates.  
NfH may partake, at a systemic level, in a similar process of assembly in large 
and potentially toxic protein aggregates which can be seen developing within 
degenerating neurons (46,47). Therefore, a better characterisation of circulating 
Nf-containing hetero-aggregates (NCH) will help unravel the real potential of NfH, 
an emerging strong biomarker of neurodegeneration. 
1.5 MS-based proteomics for biomarkers discovery 
An important factor in the study of biomarkers of neurodegeneration in blood is 
the availability of assays capable of detecting very low amounts of 
analyte/epitope. Firstly, the blood-brain barrier blocks the passage of 
degeneration by-products from brain/CSF into blood. Secondly, the blood volume 
is higher than CSF diluting down analytes availability. Moreover, the complex 
blood matrix could interfere with assays requiring extensive validation (45). With 
improvements in Mass Spectrometry (MS) instruments and bioinformatics tools, 
proteomics approaches for biomarker discovery now seem to be a promising 
alternative to immunoassay (89). 
Proteomics aim is to identify, quantify and characterize proteins within a biological 
system. Different factors have enabled a rapid development of this discipline with 
the establishment of more sensitive and robust LC-MS/MS systems and the 
availability of larger gene and genome sequence database as well as the 
development of bioinformatics and data-mining science. A standard workflow for 
MS based Proteomics is shown in Figure 1.5. 
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Figure 1.5. Standard workflow for a MS based Proteomics experiment with different 
strategies for sample preparation (gel based and gel free). 
When analysing a complex biological fluid, tissue or cell lysate, a pre-analytical 
fractionation of the proteome of interest will favor the detection of a higher number 
of proteins and will enable the detection of low abundant proteins, whose 
detection is likely to be masked by more abundant proteins in samples with a 
wide dynamic ranges of protein concentration (90). 
Bottom up proteomics is the most used approach nowadays in proteomic studies 
where the resulting peptides from an enzymatic digestion, typically trypsin, are 
analysed (opposite to the top down proteomic approaches that are based in the 
analysis of the intact proteins) (91). To increase peptide detection at MS level, 
high-resolution chromatography steps have been introduced upstream MS 
measurements to resolve the resulting complex mixture of peptides. 
MS measures the mass-to-charge ratio (m/z) of ions in a gas-phase and operates 
with an ion source to produce gas-phase ions. Any mass spectrometer is 
composed by three basic elements: an ion source, a mass analyzer and an ion 
detector (Figure 1.6). Even if there are many different options and specific 
instrumentation based on the defined characteristic, at present one of the most 
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common setting in MS-based proteomics is Electrospray Ionisation (ESI) coupled 
with Orbitrap. 
 
Figure 1.6. Schematic of MS with possible variants for ion source and mass analyser. 
To improve peptide identification (through peptide sequencing) and 
characterization of PTMs, Tandem MS (MS/MS) is used. In this setting, the 
precursor peptide is fragmented and the resulting ions are measured. There are 
three fragmentation methods depending on the mass analyser and they produce 
different ion types: Collision-Induced Dissociation (CID), Electron-Capture 
Dissociation (ECD) and Electron-Transfer Dissociation (ETD). The generated 
ions, are then exploited to infer amino acid composition of these fragments with 
dedicated computational tools, producing Peptide-Spectra Matches (PSMs) that 
are crucial for protein identifications (92). Each PSM is given a score by the 
algorithm (there are several, such as SEQUEST, MASCOT, MS AMANDA) and 
the highest score assign the spectra to a protein. When all the spectra are 
inspected, the PSMs are then grouped to generate the final protein list. 
Tandem MS allows also quantitative proteomics and many different techniques 
have been developed for this purpose (label free quantification, isotopic labelling, 
and isobaric labelling). In this report, we will focus on the use of isobaric mass 
tags, as the designed technique to be used in this study. Isobaric tags are a series 
of reagents that can be incorporated to the proteins/peptides and present the 
same mass in their original state. These tags, such as Isobaric tags for relative 
and absolute quantitation (iTRAQ) and Tandem Mass Tag (TMT), are composed 
of a mass reporter, which allows quantification, a mass normaliser, to maintain 
the same mass for the labelled precursor and amine reactive group to label 
proteins (Figure 1.7). 
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Figure 1.7. Structure and readout of an isobaric mass tag. 
General structure of the TMT reagents with the different portions responsible for binding the tryptic 
peptides, keep the same weight for the first MS scan and discriminate the different samples in the 
MS2 scan, hence the possibility to quantify different samples in a single run. 
After fragmentation, these tags will generate reporter ions that can be quantified, 
different samples will be labelled with different tags allowing the quantification of 
the relative abundance of a peptide in each labelled sample.  
In conclusion, even if instrumentation and workflow in MS based proteomics is 
quite established, the choice for appropriate sample preparation and protein 
identification strategies is crucial. Low abundant proteins are difficult to detect 
and since in discovery experiments, as in the case of biomarker discovery 
projects, these proteins might be the most interesting it is important to isolate 
clean sub-fractions or deplete very abundant proteins. 
In this study, MS analysis is used for the qualitative comparison of aggregates 
sub-proteome between ALS and healthy controls after enrichment of aggregates 
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from blood. A quantitative analysis will be performed using the TMTcalibrator™ 
(93) workflow with brain tissue as calibrant and purified blood aggregates as the 
‘fluid’ channels, an approach that will potentially allow the detection of low 
abundant peptides in the analytical samples. With this setting, the calibrator 
proteins dominate the overall protein content within the injected fraction. The 
overall dominance of the calibrator signals in the TMT 10plex ensures the vast 
majority of peptides detected are from tissue-derived proteins. During MS 
acquisition, where a peptide is present in both the calibrator tissue and the body 
fluid, we obtain both the peptide sequence and quantitative TMT reporter ion 
signals from all 10 samples within the same MS/MS spectrum. This allows us to 
detect peptides that would otherwise be lower than the limit of detection for 
standard data-dependent acquisition, and results in a list of peptides that are 
common to the calibrator and the analytical samples. Moreover, to confirm NCH 
presence in the material extracted from plasma of patients and controls, we have 
also undertaken analysis by Immuno-gold Transmission Electron Microscopy (IG-
TEM). This approach could also discriminate protein aggregates of different 
shape and nature establishing protein aggregates as possible biomarkers. 
1.6 Aims of the Thesis 
In light of recent observations on the presence of Nf-containing protein 
aggregates in bio-fluids, the work of this PhD studentship has centred around the 
development of methodologies for the isolation of such aggregates and their 
characterisation as disease biomarkers of neurodegeneration. This has been 
accomplished using biological samples from individuals with ALS, an aggressive 
and almost invariably fatal neurodegenerative disorder. 
We hypothesise that neurofilaments may be released under both normal and 
pathological conditions as hetero-aggregates and that the content of these 
formations may differ between neurologically normal and diseased individuals. 
Hence defining the presence and content of NCH in normal individuals is a 
necessary step towards developing their utility as a new source of ALS 
biomarkers. Establishing protocols for NCH isolation and molecular 
characterization is therefore mandatory for any future use of NCH as disease 
biomarkers. 
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Based on the observation that neurofilaments-containing aggregates are 
hallmarks of motor neuron pathology, here we investigate the presence of these 
macromolecular formations in biological fluids, for the purpose of testing their 
potential as disease biomarkers in neurodegeneration. 
The main aims of the experimental work of this Thesis are 1) to establish a robust 
and reproducible methodology for the separation of NCH from blood which 
provide suitable material for further characterization, 2)  to employ 
complementary and new-generation forms of proteomics to study a disease-
related molecular signature of the NCH and to compare the proteomes of NCH in 
biofluids with that of affected brains and 3) to provide an initial morphological 
investigation by electron microscopy and to test biochemical properties like 
protease resistance of the NCH obtained from healthy and affected individuals.
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2 Materials and methods 
2.1 Samples 
2.1.1 Plasma 
All plasma samples used in this study were obtained under ethical approval of 
the ALS biomarkers study (09/H0703/27). After consent, blood was collected 
from the study prticipant by venipuncture in EDTA tubes, processed within 1 hour 
by spinning at 3500 rpm for 10 minutes at 20 °C and later stored at -80 °C. 
2.1.1.1 Sample pools 
To develop and optimize the protocol for the extraction and analysis of 
Neurofilament-Containing Heteroaggregates (NCHs), plasma samples from 
different individuals were pooled together to minimise differences across samples 
and heterogeneity across individuals. 
2.1.1.1.1 Healthy Controls (HC) 
To test the method for isolation of Neurofilament-Containing Heteroaggregates 
(NCHs), a pool of plasma samples from healthy controls (Healthy Controls-
Pooled Plasma sample, HC-PPS) was obtained using plasma from 6 Healthy 
Control (HC) individuals with known amount of plasma Neurofilament Heavy 
(NfH; 7.0 - 42.9 ng/ml). Data  on NfH concentration was available from Dr. C. Lu 
previous work using an in-house ELISA (46). HC samples were selected with an 
age range  (51.2-62.9 years) to be comparable with the age at sampling in 
patients with Amyotrophic Lateral Sclerosis (ALS), which were also sampled for 
the purpose of studying any disease-specific change in neurofilament-containng 
heteroaggergates (NCHs) (94).  
2.1.1.1.1.1 Neurofilament expression in HC-PPS 
To evaluate the presence of Neurofilaments (Nf)-containing high molecular 
weight protein aggregates in HC-PPS by Western Blot (WB; paragraph 2.3), 
plasma aliquots were filtered twice with Amicon filters 100K (Millipore), in order 
to enrich the content of proteins with high-molecular weight in the final test fluid. 
In this step, Nf Light isoform (NfL, ~70 kDa) was likely to be retained by the filter. 
As previously reported and detailed below, conditions known to solubilise plasma 
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aggregates were also employed and their effect on aggregates solubilisation 
tested (53). Pooled plasma samples aliquots prepared for NfH, NfM and NfL 
analysis were divided into three fractions and processed as follows: 1) pre-
treatment with 0.5M urea and Barb2EDTA buffer (60 mM Sodium Barbitone, 10 
mM Barbital, 0.9 mM EDTA) for 1h at RT, 2) dilution 1:1 with Barb2EDTA Buffer 
for 1h at RT and 3) left untreated at +4°C.  
2.1.1.1.2 Amyotrophic Lateral Sclerosis (ALS) plasma samples 
For the extraction of circulating Neurofilament-Containing Heteroaggregates 
(NCHs) from ALS patients, plasma samples from 6 ALS patients were pooled, 
including 3 from fast (ALS1-3) and 3 from slow (ALS4-6) progressing ALS 
patients, where progression rate of the disease was calculated as the decrease 
in the ALS Functional Rating Scale Revised (ALSFRSR) from disease onset to 
the time of sampling (48 – ALSFRSR at the time of sampling) divided for the time 
interval expressed in months (87,95). ALS patients with progression rate lower 
than 0.5 were classified as slow progressors, while patients with rate higher than 
1.0 were classified as fast progressors. Plasma samples from fast and slow-
progressing ALS patients were pooled (ALS-Pooled plasma sample ALS-PPS) to 
obtain a biological substrate representative of the phenotypic heterogeneity of the 
disease. 
2.1.1.2 Individual plasma samples 
Plasma samples from individual ALS patients and HC were also used in this 
study. Individual samples were chosen according to ethnicity, age at sampling, 
El-Escorial criteria for diagnosis (88), anatomic site of clinical onset, ALS 
Functional Rating Scale Revised (ALSFRS-R) (87), rate of progression (95) and 
volume of plasma available. 
2.1.2 Brain tissue 
Pre-central Gyrus brain tissue samples from two individuals affected by ALS 
(Brain1 and Brain2) were included in this project. The brain samples were 
obtained from The Netherlands Brain Bank (NBB), Netherlands Institute for 
Neuroscience, Amsterdam (open access: www.brainbank.nl). Brain had been 
collected from donors from whom written informed consent for a brain autopsy 
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and the use of the material and clinical information for research purposes had 
been obtained (NBB: under ethical permission 2009/148). 
2.1.2.1 Brain tissue homogenization 
Before aggregates enrichment (described below), brain tissue was homogenised 
as follows: a small portion of brain was scraped from frozen samples of Brain1 
and Brain2 and then transferred into the same tube for homogenisation. Samples 
were mechanically fragmented and re-suspended on ice in homogenisation 
buffer (0.8 M NaCl, 1% Triton X-100, 0.1 M Ethylenediaminetetraacetic acid 
(EDTA), 0.01 M Tris at pH 7.4 and proteinase inhibitor cocktail (Sigma)). After 
mixing buffer and sample in a ratio 10:1 (v/w) the mixture was then sonicated at 
max power on ice for 5 minutes and centrifuged at 21000xg for 30 minutes at 4 
°C in a bench-top centrifuge. Supernatant was then collected and pellet re-
suspended in 10 volumes of homogenisation buffer on ice, again sonicated on 
ice at max power for 30 seconds and finally centrifuged at 21000xg for 30 minutes 
at 4 °C. Supernatants were finally pooled and used for aggregates enrichment 
and the pellet, which contains tissue debris, was resuspended in 8 M urea and 
stored at -80 °C. 
2.2 Aggregates enrichment methods 
2.2.1 Seprion PAD-beads (SEP) (Microsens Biotechnologies) 
The Seprion PAD-beads (SEP) isolation method is based on the proprietary 
ligands effect in retaining protein aggregates (96). The proprietary protocol for 
aggregates extraction include the use of different reagents and of beads as 
reported below. 
HC-PPS was mixed with 200 µl Capture Buffer (CB) and 100 µl of Seprion 
Reagent (SR), then 100 µl of SEP beads were added to HC-PPS, CB and SR in 
the same tube. The mixture was incubated for 30 minutes in agitation with a 
rotating mixer at Room Temperature (RT). The beads were washed with the 
proprietary  buffer and collected in a magnetic rack for elution, using Loading 
Buffer 4X (LB4X) (Fisher Scientific), 50 mM Dithiothreitol (DTT) and heat 
treatment at 95°C for 10 minutes. The final SEP aggregate-containing fractions 
were not quantified for total protein concentration as the Loading Buffer was not 
compatible with standard techniques for protein quantification including PierceTM 
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BCA (ThermoFisher Scientific) or Bradford (Bio-Rad) protein assay kits. For 
Transmission Electron Microscopy (TEM) analysis of aggregates separated using 
Seprion, elution was carried out using 20 µl 0.1 M NaOH, 0.1% Triton X-100. 
Beads were removed and elute-neutralized with 1 M Tris-HCl. 
2.2.2 Ultracentrifugation (UC)  
Exploiting the poor solubility of protein aggregates, a sedimentation method by 
ultracentrifugation (UC) was developed to enrich protein aggregates from human 
tissues. Below, two alternative protocols are described that were applied to 
optimise aggregates extraction from plasma (HC-PPS and ALS-PPS) and brain 
samples. The best performing protocol was then applied for NCHs enrichment 
from individual plasma samples. 
2.2.2.1 Brain-Plasma Protocol (BPP) 
To identify the best conditions for enrichment of protein aggregates to be 
extracted from plasma and brain, different detergents (SDS, Triton X-100, 
Sarkosyl), at either 0.5% or 2% concentration as well as different NaCl 
concentrations (0.5 M, 1 M, 1.5 M) for salting in (a process which enhances 
solubility by increasing the ionic strength) were tested. 
111 µl of 20% Triton X-100 were added to 1 ml of plasma (final concentration 2% 
Triton X-100) and incubated in agitation for 10 minutes at RT. For aggregates 
enrichment from Brain sample, the amount of 20% Triton X-100 solution added 
depended on the amount of tissue homogenised (paragraph 2.1.2.1), but the 
Triton X-100 final concentration was kept at 2%. Centrifugation at 21000xg for 15 
minutes was then performed at RT and supernatant was collected for UC. At this 
stage, a 800 µl Sucrose Cushion (1 M sucrose, 50 mM Tris-HCl pH 7.4, 1 mM 
EDTA and 2% Triton X-100) was added into each UC tube (Open-Top/Self-Seal, 
PA, 8x51mm, Science Services GmbH) together with 500 µl of pre-cleared 
plasma onto the Cushion. After balancing the tubes, UC was undertaken using a 
Sorvall Discovery 100SE, equipped with a TFT 80.2 rotor for 2 hours at 50000 
rpm. The rotor was pre-cooled to perform this step at 4°C. The supernatant was 
discarded by inverting the tube and the pellet re-suspended in PBS, 1.5 M NaCl 
and vortexed for 30 seconds for washing.  
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Following an additional UC step of 40 minutes, the final pellet was re-suspended 
in 100 µl PBS. After BPP optimisation, the solubilisation buffer was changed to 8 
M urea, while 500 µl PBS was used for Transmission Electron Microscopy (TEM) 
applications. Samples for TEM re-suspended in PBS were subjected to an 
additional washing and UC step (50,000 rpm for 40 minutes, 4°C). The 
supernatant was discarded and the pellet re-suspended in 100 µl ddH2O. After 
transferring the final sample into a clean tube, sonication on ice at max power for 
5 minutes (Diogenode, Bioruptor) was perfomed to disrupt possible assembly 
produced by the strong g-force. Enriched fractions were stored at -80°C for further 
analysis. 
The same protocol was applied for protein aggregates extraction from brain 
samples after tissue homogenisation as described in 2.1.2.1. 
2.2.2.2 Brain Only Protocol (BOP) 
The following protocol for brain aggregates enrichment is a modified version of 
that published by Greenberg and Davied in 1990 (97). 
Homogenised brain was incubated at RT for 10 minutes with Triton X-100, to a 
final concentration of 1%, and with DTT, to a final concentration of 1 mM. This 
was followed by sonication at max power on ice for 30 seconds. Subsequently, 
using an UC tube, 500 µl of sample was loaded onto 800 µl of the BOP Sucrose 
Cushion1 (1 M sucrose, 50 mM Tris-HCl pH7.4, 1 mM EDTA, 1% Triton X-100 
and 1 mM DTT) and the UC step was performed at 50000 rpm for 2 hours. The 
rotor was pre-cooled to perform this step at 4 °C. 
The first part of the protocol was modified to make it suitable for aggregate 
extraction from plasma. Plasma samples were incubated at RT for 10 minutes 
with Triton X-100, to a final concentration of 1%, and with DTT to a final 
concentration of 1mM. This was followed by centrifugation at 21000xg for 15 
minutes at RT. The supernatant was collected into a new tube and sonicated at 
maximum power for 30 seconds, on ice. At this stage, 800 µl of the BOP Sucrose 
Cushion1 were loaded into an UC tube and 500 µl of the plasma-processed 
sample were added onto the cushion. UC was then run at 50000 rpm for 2 hours 
at 4 °C, using a Sorvall Discovery 100SE equipped with a TFT 80.2 rotor. From 
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this step on the protocol was kept identical for plasma and brain aggregates 
enrichment by BOP.  
After UC the supernatant was discarded. Each pellet was resuspended in 500 µl 
of 0.5% Triton X-100, 0.5% deoxycholic acid and 0.25% Sodium Dodecyl 
Sulphate (SDS) solution and sonicated at max power on ice for 30 seconds. This 
step was followed by UC at 50000 rpm for 2 hours at 4 °C using 800 µl of BOP 
Sucrose Cushion2 (1 M sucrose, 0.5% Triton X-100, 0.5% deoxycholic acid, 
0.25% SDS). The pellet produced was then solubilised in 2% SDS, 8 M urea and 
stored at -80 °C. 
2.3 Western blot analysis 
Samples for Western Blot analysis (WB) analysis were prepared adding LB4X, 
DTT (final concentration of 50 mM) and water (where necessary) protein 
mixtures. Samples were heated for 10 minutes at 95°C before loading into a SDS-
denaturing polyacrylamide gel for electrophoresis (SDS-PAGE). Reagents and 
conditions varied depending on the protein mix under investigation as reported 
below.  
2.3.1 Gradient gels 
Protein samples were loaded into a gradient gel (3-8% Tris-Acetate or 4-12% Bis-
Tris; Fisher Scientific UK Ltd) along with the HiMark™ Pre-stained Protein 
Standard (Fisher Scientific UK Ltd). A current of 60V for 30 minutes was applied 
for electrophoresis and then switched to 120V for 1 hour (for 3-8% gels) or 1 hour 
and 15 minutes (when 4-12% gels were used). After electrophoresis, the gel was 
washed first with cold ddH2O and then with 10% Methanol (MetOH) in 1X Transfer 
Buffer (TB). Proteins were then transferred onto a polyvinylidene difluoride 
(PVDF) membrane, previously activated with MetOH, at 45V on ice for 1 hour 
and 45 minutes with TB 1X, 10% MetOH. Subsequently, the membrane was 
blocked in blocking buffer (5% skimmed milk in Tris-Buffered Saline (TBS) 0.1% 
Tween-20 buffer (TBS-T 0.1%)) at RT for 1 hour. Overnight (ON) incubation was 
performed with primary antibody at 4 °C followed by incubation with secondary 
antibody (horseradish peroxidase (HRP) conjugated) for 1 hour at RT, with 
membrane washes between steps using TBS-T 0.1%. Lastly, the membrane was 
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incubated with enhanced chemiluminescence substrate (ECL) and visualised 
using a Chemi-Doc camera (Bio-Rad). 
2.3.2 Fixed concentration gels 
Protein samples were loaded into a gel with fixed concentration (10% Bis-Tris or 
12% Bis-Tris (Fisher Scientific UK Ltd)) along with the SeeBlue™ Plus2 Pre-
stained Protein Standard (Fisher Scientific UK Ltd). For gel electrophoresis, a 
current of 90V for 30 minutes was applied and then switched to 150V for 1 hour. 
After electrophoresis the gel was washed first with cold ddH2O and then with 
Transfer Buffer (TB) 1X, 20% Methanol (MetOH). Proteins were then transferred 
onto a polyvinylidene difluoride (PVDF) membrane, pre-activated into MetOH, at 
30V on ice for 2 hours with TB1X, 20% MetOH. Subsequently, the membrane 
was blocked in blocking buffer at RT for 1 hour. Overnight (ON) incubation was 
performed with primary antibody at 4 °C followed by incubation with secondary 
antibody for 1 hour at RT, with membrane washes between steps using TBS-T 
0.1%. The membrane was then incubated with ECL and visualised using a 
Chemi-Doc camera (Bio-Rad). 
2.3.3 Antibodies 
The antibodies listed in the following table (Table 2.1), with relative dilutions and 
buffers, were used in this study for WB: 
Primary 
antibodies 
ID antibody Species Provider Working 
condition 
anti-
Neurofilaments 
light (NfL) 
clone EP675Y rabbit Millipore 1:1000 in 
blocking 
buffer 
anti-
Neurofilament 
Medium (NfM) 
AB1987 rabbit Millipore 1:1000 in 
blocking 
buffer 
anti-
Neurofilament 
heavy (NfH) 
N4142 rabbit Sigma-Aldrich 1:1000 in 
blocking 
buffer 
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Primary 
antibodies 
ID antibody Species Provider Working 
condition 
anti-TAR DNA-
binding protein 
43 (TDP-43) 
G400 rabbit New England 
Biolabs 
1:1000 in 
blocking 
buffer 
anti-
Ubiquitinylated 
proteins 
clone FK1 | 04-262 mouse Millipore 1:1000 in 
blocking 
buffer 
anti-
Fibromodulin 
(FMOD) 
CSB-
PA008755GA01HU 
rabbit Generon Ltd 1:1000 in 
blocking 
buffer 
anti-Glypican-4 
(GCP4) 
LS-C375826 rabbit Source 
BioScience 
UK 
1:2000 in 
blocking 
buffer 
anti-Byglican 
(BGN) 
HPA003157 rabbit Cambridge 
Bioscience 
1:250 in 
TBS-T 
0.1%, 
5%BSA 
anti-Cation-
dependent 
mannose-6-
phosphate 
receptor 
(M6PR) 
ARP43519_T100 rabbit Insight 
Biotechnology 
1:500 in 
TBS-T 
0.1%, 
5%BSA 
anti-Protein 
DJ-1 (PARK7) 
HPA004190 rabbit Cambridge 
Bioscience 
1:250 in 
TBS-T 
0.1%, 
5%BSA 
anti-
Endophilin-B2 
(SH3GLB2) 
H00056904-B01P mouse Bio-Techne 1:500 in 
TBS-T 
0.1%, 
5%BSA 
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Primary 
antibodies 
ID antibody Species Provider Working 
condition 
Secondary 
antibodies 
ID antibody Species Provider Working 
condition 
anti-Rabbit IgG P021702-2 swine DAKO 1:50000 or 
1:20000 in 
blocking 
buffer 
depending 
on the 
primary 
antibody 
anti-Mouse IgG A28177 goat Thermo 
Fischer 
Scientific 
1:20000 in 
blocking 
buffer 
Table 2.1. Primary and secondary antibodies used for immunodetection by Western Blot.  
The table lists the antibodies (primary and secondary), the clone or product code (ID antibody), 
the host (species), the provider, the buffer and dilution conditions for each antibody. 
2.3.4 Densitometry analysis 
After membranes visualisation with the Chemi-Doc camera, images were 
acquired and processed by Image Lab (Bio-Rad). Band volumes were obtained 
using the “Volume Tools” function in Image Lab and “Adj. Vol. (Int)” values were 
used for relative quantification of the bands detected. Normalisation, 
quantification and statistical analysis were carried out using the Analysis ToolPak 
in a Microsoft Excel environment. 
2.4 Transmission Electron Microscopy (TEM) 
The TEM work including sample preparation and micrographs acquisition was 
carried out in collaboration with Giulia Mastroianni and Dr. Giacomina Bennardo, 
Queen Mary University of London - TEM facility managers. 
Transmission electron microscopy (TEM) exploits the interaction between a 
specimen adsorbed onto a carbon coated grid and a beam of electrons passing 
through it to generate images of the material. The carbon coated grids are copper 
discs with a mesh which are covered with a very thin layer of carbon film. For the 
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visualisation of small particles, grids with holey carbon film can be used to 
improve micrographs resolution. In our experiments, to improve the contrast, 
hence the quality of the micrographs, negative staining with heavy metals was 
used. The heavy ions, generated from the heavy metal salts, increase the 
contrast by reflecting the electrons coming from the beam. The negative stain is 
performed by incubating the carbon grid carrying the adsorbed sample, with a 
solution containing the heavy metal salt. In our study, Ammonium Molibdate (AM) 
and Uranyl Acetate (UA) were tested as possible heavy metal salts for negative 
staining. 
A glow-discharged 400 mesh grid coated with carbon or holey carbon was 
incubated with a droplet (≈10/20 µl depending on sample concentration) of 
aggregates-enriched sample and after a short time (final condition 10 seconds), 
the excess was removed by carefully touching to the grid edge with filter paper. 
Negative staining was obtained incubating the grid with a droplet (20 µl) of 2% 
w/v uranyl acetate (UA). After washing with ddH2O, the grid was air-dried at room 
temperature and micrographs acquired by a JEOL JEM 1230 electron 
microscope. 
2.4.1 Immunolabelling for immune-gold TEM (IG-TEM) 
After sample loading onto the EM grid as described above, the same grid was 
blocked by incubation with 0.1% w/v BSA in PBS (blocking solution) for 10 
minutes. Immunolabelling with Gold particles (IG-TEM) was performed by 
incubating the grid for 1 hour with the primary antibody which was washed out 
using blocking solution. The grid was then incubated with the gold beads-
conjugated secondary antibody for 1 hour. The subsequent washing step was 
performed with PBS. In order to stabilize proteins interaction, the grid was 
incubated with 1% glutaraldehyde for 5 minutes and subsequently washed with 
ddH2O. Surface was negatively stained with 1% w/v Uranyl Acetate (UA), washed 
with ddH2O and air-dried to perform micrographs acquisition. 
2.4.1.1 Antibodies 
We report below the antibodies and conditions (dilutions and buffers) used for IG-
TEM: 
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Primary 
antibodies 
ID antibody Species Provider Working 
condition 
anti-
Neurofilaments 
light (NfL) 
clone EP675Y rabbit Millipor 1:100 in 
blocking 
solution 
anti-
Neurofilament 
Medium (NfM) 
AB1987 rabbit Millipore 1:100 in 
blocking 
solution 
anti-
Neurofilament 
heavy (NfH) 
N4142 rabbit Sigma-
Aldrich 
1:200 in 
blocking 
solution 
anti-
Apolipoprotein 
A-1 (APOA1) 
MIA1402 mouse Thermo 
Fisher 
Scientific 
1:100 in 
blocking 
solution 
Secondary 
antibodies 
ID antibody Species Provider Working 
condition 
Anti-Rabbit IgG G7402 goat Sigma 1:2000 in 
blocking 
solution 
Anti-Mouse 
IgG 
G7652 goat Sigma 1:2000 in 
blocking 
solution 
Table 2.2. Primary and secondary antibodies employed for immunodetection by IG-TEM.  
Primary and secondary antibodies (clone or product code, ID antibody), species of origin, 
provider, dilution conditions and buffers in the IG-TEM experiments. 
2.5 Shotgun Proteomics 
To evaluate the protein composition of the enriched protein aggregate fractions, 
Liquid Chromatography coupled with Tandem Mass Spectrometry (LC-MS/MS) 
analysis was carried out. Two different sample preparation protocols were used. 
Data were acquired using an Orbitrap Velos Pro or Orbitrap Fusion Tribrid 
(Thermo Scientific). 
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2.5.1 In-gel trypsin digestion 
In-gel trypsin digestion was applied to PPS samples to analyse NCHs 
composition. The protein samples were prepared for electrophoresis by adding 
LB4X, DTT and water and heat-denatured as described above. Samples were 
then loaded into a gel and electrophoresis was performed for protein separation 
as previously described. Gel staining was undertaken using ImperialTM Protein 
Stain (ThermoFischer Scientific) for 1 hour at RT followed by overnight (ON) wash 
with ddH2O. Gel bands were cut out and each band was washed with 100 µl 
50:50 100 mM Ammoniumbicarbonate (Ambic): Acetonitrale (ACN) and kept at 
RT for 10 minutes. After discarding the solution, 100 µl ACN were added and kept 
for 5 minutes to obtain gel dehydration. Subsequently, the liquid was removed 
and gel pieces were dried in a vacuum centrifuge. Subsequently, gel bands were 
rehydrated for disulfide bonds reduction with 100 µl of 10 mM DTT in 100 mM 
Ambic and incubated for 30 minutes at 56 °C in a heating block while shaking. 
Thereafter, tubes were cooled down at RT, the excess of solution removed, and 
100 µl of 55mM Iodoacetamide (IAA) in 100 mM Ambic was added for alkylation 
of the cysteine residues. Tubes were then incubated in the dark at RT for 30 
minutes. Each fraction was again washed and dehydrated to obtain de-staining 
of the gel band pieces. After complete de-staining, each gel piece was rehydrated 
with a minimal volume of a solution 50 mM Ambic, 0.01 µg/µl Trypsin (V542A, 
Promega). Each tube was kept at 4 °C for 20 minutes to absorb the digestion 
enzyme (trypsin) and the excess was removed, while 50 mM Ambic was added 
to cover the gel pieces and keep them wet during enzyme cleavage. Each sample 
was then incubated ON at 37 °C for protein digestion. The following day, 
supernatants were collected into new tubes, gel pieces were dehydrated with 
ACN to extract the tryptic peptides. Then ACN supernatants were recovered and 
added to each of the previously collected supernatants. All samples collected 
were then freeze-dried in a vacuum centrifuge. 
At this stage, each freeze-dried sample was re-suspended in 0.1% trifluoroacetic 
acid (TFA) and cleaned via zip-tipTM (Millipore), a strong cation exchange resin in 
a plastic tip, before injection into the mass spectrometer. Sample cleaning and 
injection was carried out at Proteome Science facilities under close technical 
supervision. Qualitative analysis was performed coupling the mass spectrometer 
to an EASY-nLC 1000 (Proxeon) system. Samples were resuspended in 10 μL 
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of 2% ACN/0.1% formic acid (FA), and a 5 μl aliquot was injected onto a 75 μm 
× 2 cm nanoViper C18 Acclaim PepMap100 precolumn (3 μm particle size, 100 
Å pore size; P/N 164705; Thermo Scientific) with an additional sample loading 
volume of 12 μl of 0.1% Formic Acid (FA) in H2O using the Thermo Scientific 
EASY-nLC 1000 system. Peptides were separated at a flow rate of 250 nl/min 
and eluted from the column over a 60-minute gradient starting with 0.1% FA in 
ACN (5−30% over 50 minutes, then 30−80% between 50 and 54 minutes, 
continuing at 80% up to 58 minutes) through a 75 μm × 50 cm PepMap RSLC 
analytical column at 40 °C (2 μm particle size, 100 Å pore size; P/N ES803; 
Thermo). After Electrospray Ionisation, MS spectra ranging from 350 to 1800 m/z 
values were acquired in the Orbitrap at 30k resolution and the 20 most intense 
ions with a minimal required signal of 5,000 were subjected to MS/MS by rapid 
CID fragmentation in the ion trap. Protein identification was carried out using the 
Thermo Scientific Proteome Discoverer 1.4. 
2.5.2 TMTcalibratorTM 
As previously mentioned, to study any disease-related change in the proteome 
of NCHs using TMTcalibratorTM, plasma samples from a group of six individuals 
with ALS matched to a group of six healthy controls (HC) were selected. In the 
TMTcalibratorTM setting developed by Proteome Sciences (93), it is possible to 
combine in the same multiplex experiment up to ten samples (10plex) which 
function as analytical and calibrant samples. The same Tandem Mass Tags 
(TMT) label reagents are used to label uniformly all the samples in the study 
(Figure 2.1A). The use of TMT labelling and the combination of analytical samples 
with the calibrant sample in the same experiment allows 1) accurate quantification 
of the peptides and protein groups across samples and 2) an enhanced detection 
of peptides with low abundance in the analytical channels due to the prevalence 
of those peptides in the calibrant channels. To achieve this, analytical and 
calibrant samples had to be mixed and injected in a certain ratio in each 10plex 
experiment. The total amount of protein for the analytical channel had to be at 
12X (2X for each analytical sample (n=6)), while the calibrant at 21X, divided in 
four different concentrations (1X, 4X, 6X, 10X) (Figure 2.1B). In addition, the 
calibrant channels worked as reference for the quantification of the analytical 
samples across channels in distinct 10plex experiments. For the characterisation 
of the NCHs proteome, plasma protein aggregate samples were loaded onto the 
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analytical channels, while a mixture 1:1 of Brain1 and Brain2 lysates was loaded 
at different concentrations onto the calibrant channels (Figure 2.1C). 
Plasma aggregates were obtained as described in section 2.2.2.1. Brain lysates 
were processed dissolving brain in SysQuant Buffer (8M urea, phosphatase 
inhibitor (PhosSTOP™, Merck) and protease inhibitor (cOmplete™, Merck)). The 
mixtures with brain and SysQuant Buffer were vortexed for 5 minutes and then 
sonicated for additional 5 minutes at max power on ice to dissolve the tissue in 
the lyses buffer. Tubes were then centrifuged at 21000xg for 10 minutes at 4 °C 
to eliminate cell or tissue debris, and the supernatants were transferred into new 
tubes. The protein concentrations of Brain1 and Brain2 lysates were measure by 
PierceTM BCA assay and the two lysates mixed 1:1 (w/v)/(w/v) (Calibrant). 
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Figure 2.1. TMTcalibrator™ experimental design. 
(A) Tandem Mass Tag (TMT) reagents with relative masses and isotope position. (B) General 
10plex labelling layout after trypsin digestion of the samples; analytical samples and calilbrants 
are mixed in a specific ratio that enhances detection by LC-MS/MS of low abundant peptides in 
the analytical channels thanks to the high calibrant content. (C) Labelling strategy in two 10plexes 
LC-MS/MS runs which includes plasma neurofilament-containing hetero-aggregates (NCHs) from 
amyotrophic lateral sclerosis (ALS) patients and from healthy controls (HC) in the analytical 
channels (orange and blue colour codes) and a mixture (1:1) of brains (Precentral gyrus) lysates 
from two different ALS patients in the calibrant channels (grey colour code). 
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2.5.2.1 Sample preparation  
TMT labelling, sample fractionation and injection was carried out at Proteome 
Science facility, Frankfurt, Germany. Sample fractionation and injection was 
performed under close technical supervision. 
In order to establish the right analytical channels:calibrant ratio for each channel, 
20 µg of total proteins were considered as 1X. Each sample was adjusted for the 
planned protein concentration and to reach the expected volume for TMT 
labelling adding SysQuant buffer.  
0.1M DTT was added to each sample to a final concentration of 5 mM, followed 
by 25 minutes incubation at 56 °C in a heating block while shaking. After cooling, 
IAA was added to each tube to a final concentration of 14 mM and incubated at 
RT for 30 minutes in the dark. The fraction of IAA that did not react with DTT was 
quenched adding a surplus of DTT and using incubation in the dark for additional 
15 minutes. Samples were then diluted 1:5 with 25 mM Tris-HCl pH 8.2 (to reach 
a concentration of urea equal 1.6 M), and trypsin (5 ng/µl) was added to a ratio 
of at least 1:100. Tubes were then incubated for digestion ON at 37 °C in a 
heating block while shaking. The day after, Trifluoroacetic acid (TFA) was added 
to the reaction mixtures (0.4% (v/v) of the total volume) to stop digestion, bringing 
the pH to < 2.0. Tubes were then centrifuged at 2500xg for 10 minutes and the 
pellets discarded, while the supernatants were collected into new tubes and 
processed with a 200 mg SepPak tC18 cartridge (Calibrant) and with 50 mg 
SepPak tC18 cartridge (analytical samples) for peptide desalting. After cartridges 
elution with ACN:H2O (1:1), samples were collected in new tubes and the 
Calibrant volume was divided into four different aliquots with a 1:4:6:10 volume 
ratio (Calibrant channels), followed by a freeze-dry cycle. Calibrant aliquots 
contained enough sample for the two 10plexes. 
Dried samples were re-solubilised in 120 µl KH2PO4 and TMT reagents were 
added combining a specific tag for each sample. TMT tags were previously 
resuspended in ACN to a concentration of 80 mM, and 40 µl of TMT reagents 
were added to each tube and incubated at RT for 1 hour. To stop the reactions, 
hydroxylamine was added in each tube to a final concentration of 0.25% (w/v) 
and incubated for 15 minutes. 
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The four Calibrant samples were pooled into a new vial and let to rest for 15 
minutes. At the same time, six analytical samples for each 10plex were pooled 
into a new tube and incubated for 15 minutes. TFA in a 1:1 (v/v) ratio was added 
to each tube to bring the pH below 2 and H2O to reduce total ACN concentration 
below 5%. Half of the Calibrant sample volume was mixed with the analytical 
samples of 10plex-1 while the other half was mixed with the analytical samples 
of 10plex-2. The samples containing the labelled peptides for the two 10plexes 
were desalted in 200 mg SepPak tC18 cartridge and the elute, containing now 
660 ug of tryptic peptides, was freeze-dried before basic Reverse Phase (bRP) 
fractionation using Pierce™ High pH Reversed-Phase Peptide Fractionation Kit 
(ThermoFisher Scientific). This step generated eight different fractions for each 
10plex allowing higher peptide resolution and increasing the chance to detect 
(and quantify) low abundance peptides in the analytical samples using LC-
MS/MS. All the eluted fractions underwent a further freeze-dried and desalting 
cycle.  
LC-MS/MS analysis was performed in double-shot using a Thermo Scientific™ 
Orbitrap Fusion Tribrid (Thermo Scientific) mass spectrometer coupled to an 
EASY-nLC 1000 (Thermo Scientific) system. The 16 bRP fractions were 
resuspended in 2% ACN, 0.1% formic acid (FA), and then 12 µg from each was 
injected into a 75 μm × 2 cm nanoViper C18 Acclaim PepMap100 precolumn (3 
μm particle size, 100 Å pore size; P/N 164705; Thermo Scientific). Peptides were 
separated at a flow rate of 250 nl/min and eluted from the column over a 5 hours 
gradient starting with 0.1% FA in ACN (5-30% ACN from 0 to 280min followed by 
10min ramping up to 80% ACN) through a 75 μm × 50 cm PepMap RSLC 
analytical column at 40 °C (2 μm particle size, 100 Å pore size; P/N ES803; 
Thermo). After electrospray ionisation, MS spectra ranging from 350 to 1500 m/z 
values were acquired in the Orbitrap at 120 k resolution and the most intense 
ions with a minimal required signal of 10,000 were subjected to MS/MS by HCD 
fragmentation in the Orbitrap at 30 k resolution. Protein identification was carried 
out with Thermo Scientific Proteome Discoverer 1.4. 
2.5.2.2 Bioinformatics 
Bioinformatic analysis of the TMTcalibratorTM pipeline data was performed under 
close supervision of the Proteome Sciences bioinformaticians. MS analysis 
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generated 32 separate files that were submitted to Proteome Discoverer (PD) 
v1.4 (Thermo Scientific) using the Spectrum Files node, where spectra were 
filtered (700-10000 Da precursor mass, total intensity threshold 100, minimum 
peak count 8, S/N threshold (FT-only) 1.5). The SEQUEST-HT node was set up 
to search data against the human FASTA UniProtKB/Swiss-Prot database 
(Database Version: 9606_human_reviewed_170703.fasta) and assigned the 
best scored peptide sequences to the experimental spectra acquired at the level 
of second MS scan. The reporter ions quantifier node was set up to measure the 
raw intensity values for the TMT reporter ions (126, 127N, 127C, 128N, 128C, 
129N, 129C, 130N, 130C, 131). The SEQUEST-HT search engine was 
programmed to search for tryptic peptides (with up to two missed cleavage sites 
allowed) and with static modifications of carbamidomethyl (C), TMT6plex (K) and 
TMT6plex (N-Term). Dynamic modifications were set to deamidation (N/Q) and 
oxidation (M). Precursor mass tolerance was set to 20ppm and fragment (b and 
y ion) mass tolerance to 0.02Da. Protein grouping was performed using 
Parsimony Principle option in the Protein Grouping area within PD (98). All raw 
intensity values were exported to tab delimited text files for further processing 
and filtering using softwares developed by Proteome Sciences. This included: 1) 
Calibrator Data Integration Tool (CalDIT) for peptide quantification and 
multiplexes merging; 2) Feature Selection Tool (FeaST) for quantitative 
comparison of different 10plex experiments and to evaluate significant macro-
features of the data set; 3) Functional Analysis Tool (FAT) for identification of the 
enriched and regulated biological features of the identified proteome. The 
operations performed by the three bioinformatic tools are described below.  
For all peptide-spectrum matches (PSMs), the reporter intensities in all channels 
were corrected for background and cross-talk between reporter ions at MS2. 
Then, reporter ion intensities of six plasma aggregates samples (126, 127N, 
127C, 128N, 128C, 129N) for each TMT10plex were calibrated by a reference 
intensity computed from the average signal across the four brain lysate calibrant 
channels (129C, 130N, 130C, 131). The resulting PSM intensity values were 
log2-transformed. PSMs having no quantitative data were discarded. To generate 
a peptide matrix from all PSMs, the average of log2-ratios was calculated for each 
peptide sequence. Afterwards, peptide features with more than 34% missing 
quantitative values in either ALS or control experimental group were removed 
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from the data sets. The remaining missing quantitative values were replaced by 
values imputed by K-nearest neighbours (Knn) method (K=2) (99).  
In order to reduce the bias introduced by two separateTMT10plexes in the same 
experiment, a batch effect removal procedure was applied. For this, a linear 
model was constructed to weigh the effect of each TMT10plex batch and channel. 
For protein-level analysis, expression values were computed by averaging 
(trimmed mean) peptides that were unique to the gene identifier. Quantitative 
data obtained through the bioinformatic pipeline were controlled using the median 
and the inter-quartile range (IQR) of peptide or protein distributions as quality 
controls. Both metrics are robust and stable to outliers and are therefore good for 
detecting extreme outliers. The median log2 expression and IQR were traced 
using control charts for all datasets at peptide and protein levels. A sample was 
considered as a strong outlier if either quality control metrics values were more 
than three standard deviations from the overall mean. 
To study the variance structure of the data sets, principal component analysis 
(PCA) score and loading plots were generated. This method was used at different 
levels of data treatment to identify factors that influence the data variance (e.g. 
technical factors and/or sample inherent factors). Technical or experimental 
factors which influence the data were characterized in the scores and loading 
plots. The loadings plots allowed assessment of the magnitude and correlation of 
these effects. 
To identify regulated peptides and proteins, a linear model using the R package 
“linear models for microarray (LIMMA)” was applied to perform a multivariate 
statistical analysis. Along with the peptide or protein quantitative values, (A) group 
(ALS/HC), (B) gender (M/F), (C) progression rate and (D) TMT batch 
(TMT01/TMT02) effect were included into the multivariate model to account for 
differences between individuals connected to these factors, and to enable a better 
assessment of the effect of each potential modifier. In order to include the HC 
group in the progression rate PCA, progression rate values close to 0 were 
randomly generated and imputed. Consequently, the influence of the 
experimental group “class” was analysed using the following linear model: 
 logRatio ≈ class + group + gender + progression rate + TMT batch 
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Here logRatioij = log2(Xij/Xref,j), logarithm of ratio of ith sample relative to reference 
for feature j. Log2fold change (logFC) and p-values were calculated for all 
features (peptides, proteins) used for statistical analysis. To consider a feature 
as “regulated”, the significance criterion α was set to 0.005 and a logFC threshold 
of log2(2) for statistical analysis at peptide level, while α was set to 0.05 and a 
logFC threshold of log2(1.5) for statistical analysis at protein level. Multiple testing 
corrections were performed using the Benjamini-Hochberg procedure, which 
provides a false discovery rate (FDR) for every statistical result. PCAs and 
Volcano plots were generated including the data of the significant features to 
visualize the results of the statistical analysis. 
The functional analysis was performed to identify the biological processes driving 
the main differences between the classes of interest (ALS/HC). Two methods for 
analysis were selected: 1) significance of enrichment, evaluated by the Fisher 
exact test and 2) significance of regulation, evaluated by the Mann-Whitney U 
test. Functional terms used in this analysis included: Gene Ontology (GO) 
Biological Processes (BP), GO Molecular Functions (MF), GO Cellular 
Components (CC), Protein Domains/Families, Biological Pathways, microRNA 
substrates, and sequence Motifs. Human-specific annotations were extracted 
from a range of publicly-available data repositories. For the enrichment analysis, 
a two-sided p-value was generated by the Fisher exact test and the Benjamini-
Hochberg method was used for multiple test correction. A minimum of two 
matched identifiers (e.g. gene names) was required for each peptide and terms 
with an adjusted p- value < 0.3 were considered significant. For the regulation 
analysis, a two-sided p-value was generated by the Mann Whitney U test and the 
Benjamini-Hochberg method was used for multiple test correction. In this 
procedure, expression values for all terms were compared to a background 
composed of 1000 randomly-sampled expression values that did not overlap with 
the term. A minimum of three matched identifiers (e.g. gene names) was required. 
Terms with an adjusted p- value < 0.3 were considered significant. All functional 
results were visualised in volcano plots (enrichment or median fold change vs. 
adjusted p-value).  
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2.6 Protease resistance assay 
In recent studies, proteins involved in the pathogenesis of ALS have been 
investigated to evaluate the potential of a prion-like behavior, taking into account 
the pattern of propagation and the involvement of fibrillar protein aggregates in 
the disease progression (81,100). One of the main features of prion proteins is 
their resistance to protease enzyme digestion. Therefore, we have looked at 
whether NCHs present a resistance to protease digestion similarly to prion 
proteins and set up digestion protocols of aggregates enriched fractions with 
different proteases. Four different proteases were tested: Trypsin (V542A, 
Promega), α-Chymotrypsin (Chymotrypsin from now) (C4129, Sigma), Calpain 
(208712, Millipore) and Enterokinase (11334115001, Roche).  
After plasma aggregates enrichment as described in section 2.2.2.1, each 
sample was re-suspended in the buffer (50 µl) recommended for each protease 
enzyme (PBS for Trypsin, 100mM Tris HCl for Chymotrypsin, 50mM Hepes, 
30mM NaCl for Calpain and 50mM Tris HCl for Enterokinase), and 5 µl of 0.5 M 
DTT was added prior to proceeding with sonication on ice for 5 minutes. Protein 
assemblies produced by the strong g-force applied during UC steps, were 
disrupted and disulfide bonds reduced to enhance cleavage sites accessibility. In 
this way it was possible to avoid any protease resistance related to artefacts of 
the proposed digestion protocol. This was specifically important for Trypsin, as 
changes in the dynamic of aggregates digestion would have affected downstream 
LC-MS/MS analysis. Each enzyme was then added into the digestion reaction 
tube in a ratio 1:20 protease:total protein. In addition, 5.5 µl of 0.1 M CaCl2 were 
added to Chymotrypsin and Calpain reaction tubes to activate the enzymes as 
indicated by the manufacturers. The reactions were subsequently incubated ON 
at 37°C to allow digestion. The day after, the reactions were stopped adding 
LB4X, DTT and by heating at 95°C for 10 minutes. Digested samples were then 
stored at -80°C until used for analysis by SDS-PAGE, followed by Zinc staining 
(Life Technologies), and NfH immunodetection, by Western Blot as described in 
2.3.1). 
2.6.1 NCHs profile analysis by SDS-PAGE 
To evaluate differences between ALS and HC groups of NCHs protease digestion 
profiles, ALS and HC digestionproducts were separated and visualised in a SDS-
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PAGE gel stained with Zinc. Six gels were ran each containing ALS and HC 
samples before and after digestion and this process was repeated for all protease 
enzymes. Images were then acquired by Chemi-Doc Camera.  
For intra and inter-gel control, NCHs undigested profiles were used as reference 
to define digestion paterns and total protein content, while protease digestion and 
the undigested NCHs profiles were compared across ALS and HC different 
samples. The images acquired were processed by ImageJ to draw lanes 
boundaries and pre-selecetd lanes were plotted through the Analyze\Gels\Plot 
lanes function. Band intensities were obtained quantifying the area beneath the 
peaks within each lane. All NCHs bands, from digested and undigested samples, 
were also normalised using the Marker (HiMark™ Pre-stained Protein Standard) 
as reference. This allowed comparison of bands at the same MW in different 
samples across gels. Marker intensities were also used to generate correction 
factors to adjust loading differences across samples. Statistical evaluation was 
carried out in a Microsoft Excel Analysis ToolPak environment using a “t-Test: 
Two-Sample Assuming Unequal Variances” function with data analysis package 
in Excel2016. 
2.6.2 NCHs protease digestion profile analysis by western blot against NfH 
WB for NfH detection was performed on protease digested samples as described 
in section 2.6. The blots were acquired with a Chemi-Doc Camera and analysed 
by Image Lab (Bio-Rad). Band volumes were obtained using the “Volume Tools” 
function in Image Lab and “Adj. Vol. (Int)” values were used for relative 
quantification of the bands. Normalisation, quantification and statistical analysis 
were carried out in a Microsoft Excel Analysis ToolPak environment using a “t-
Test: Two-Sample Assuming Unequal Variances” function with data analysis 
package in Excel2016. 
2.6.3 Brain aggregates protease digestion 
The same approach described above to study protein aggregates resistance to 
protease digestion was applied to NCHs enriched from a mixture of Brain1 and 
Brain2 samples, which were previously homogenized as described in section 
2.1.2.1. The results obtained were qualitatively compared to the results obtained 
from plasma NCHs.
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3 Protocol development for the enrichment of 
Neurofilaments-containing heteroaggregates (NCHs) 
3.1 Introduction and aims 
Neurofilaments (Nf) have been already described as part of assemblies of 
proteins and other molecules in brain (aggregates) and also to form aggregates 
in blood. Inclusion of Nf in large molecular complexes in bio-fluids may act as a 
confounder in attempts to obtain measurements of Nf levels for biomedical 
applications, such as in assays to establish diagnosis and prognosis of 
neurological conditions. NF detection may not be accurate, particularly with 
immunodetection which is based on antibody recognition of epitopes which may 
be masked by the assemblement of different proteins (46,53,101). In addition, it 
has been shown that protein aggregates are present in plasma at higher 
concentration in older age, suggesting that the biological processes responsible 
for protein aggregates formation may become more prominent with ageing. 
Ageing is undoubtedly one of the main risk factor for neurodegenerative diseases 
like Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, Parkinson’s 
disease and Huntington’s disease, neurological conditions which have been 
linked pathogenically to the abnormal behaviour of disordered proteins and their 
propensity to aggregate (69).  
In this chapter, I develop a protocol for separation from plasma and enrichment 
of Neurofilament-containing Heteroaggregates (NCHs). Development and 
optimization of the protocol has followed a two-step process. In the first instance, 
I use Seprion PAD-Beads (SEP) and a sedimentation-based approach by 
ultracentrifugation (UC) for NCHs enrichment from a Healthy Controls-Pooled 
Plasma Sample (HC-PPS). This extraction method is defined as Brain-Plasma 
Protocol (BPP) (Paragraph 2.2.2.1), when the same methodology is applied to 
the extraction of NCHs from brain.  Secondly,  I compare two UC-based extraction 
protocols here defined as BPP and Brain Only Protocol (BOP) (Paragraph 
2.2.2.2), for NCHs enrichment from plasma of Healthy Controls Pooled Plasma 
Sample (HC-PPS), Amyotrophic Lateral Sclerosis-Pooled Plasma Sample (ALS-
PPS) and brain tissue (a mixture of two brain tissue samples here called Brain1 
and Brain2). In this Chapter, the methodology of NCHs separation is discussed 
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while qualitative differences in NCHs between ALS and HC are detailed in 
Chapter 4. 
3.2 Neurofilaments expression in plasma 
A pool of plasma samples was used to establish a method for enrichment of 
protein aggregates from blood, to confirm the presence of Nf proteins in these 
aggregates and to study their composition in health and disease in order to 
support any application in biomarkers discovery (Table 3.1). For the purpose of 
methodological development and to test different conditions for the final 
enrichment protocol, we have opted for samples pooling in order to reduce any 
variability across samples. The Healthy Control-Pooled Plasma Sample (HC-
PPS) was obtained merging plasma samples from six different healthy individuals 
with a known concentration of neurofilament heavy chain (NfH) as reported in 
Table 1.  
Sample ID Gender Ethnicity Age at sampling 
(years) 
NfH (ng/ml) 
HC1-PPS F Caucasian 54.08 – 54.75 42.9 
HC2-PPS F Caucasian 60.94 15.4 
HC3-PPS M Caucasian 61.25 – 61.77 7.0 
HC4-PPS M Caucasian 59.55 – 61.77 20.3 
HC5-PPS F Caucasian 62.89 30.8 
HC6-PPS M Caucasian 51.25 – 52.28 24.8 
Table 3.1. List of plasma samples used for the Healthy Control-Pooled Plasma Samples 
(PPS) and demographics of donors.  
For healthy controls (HC) 1, 3, 4 and 6, we report the age of the donors when samples were 
collected (more than one sample was needed to achieve the requested volume). 
Sample ID: Identification code 
Gender: M= Male; F= Female  
Age at sampling: age of the patient at blood sampling (age-range shown if more than one time 
point sample was used)  
NfH (neurofilament heavy; ng/ml): level of NfH are expressed in ng/ml 
Initially the presence of Neurofilament (Nf) proteins in HC-PPS was evaluated by 
Western Blot (WB). Before gel-electrophoresis, two rounds of ultrafiltration with a 
100 KDa cut-off filter (Amicon ultra100K, Millipore) were performed in order to 
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concentrate Nf proteins and increase their detection by WB. Filtration allowed 
retention of all molecules of molecular weight higher than 100 KDa. After Nf 
concentration by ultrafiltration, the samples obtained were divided into three 
different aliquots and treated as previously described by Lu et al. (53): one aliquot 
was incubated for 1 hour at RT with 0.5 M urea in Barb2EDTA buffer, a second 
one was diluted 1:1 with Barb2EDTA buffer and kept for 1 hour at RT, while the 
third aliquot was kept at 4 °C. WB was performed as described in Paragraph 2.3, 
but the transfer was carried out onto a nitrocellulose membrane instead of a 
PVDF membrane (Figure 3.1). Treatment with Barb2EDTA and urea has an effect 
in dissolving protein aggregates, hence allowing an assessment of the proportion 
of Nf retained within these formations. 
 
Figure 3.1. Western blot analysis of neurofilament proteins in healthy controls pooled 
plasma samples (HC-PPS).  
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Western blot analysis of pooled plasma sample (PPS) using anti-neurofilament-High (NfH), anti-
Medium (NfM) and anti-Light (NfL) antibodies after filtration with Amicon 100 filters (100 kDa 
molecular cut-off). Lanes contain in order from left to right: PPS subjected to pre-treatment with 
0.5 M urea and Barb2EDTA buffer for 1 h at RT, PPS diluted 1:1 with Barb2EDTA Buffer for 1 h 
at RT and untreated PPS kept at + 4 °C. The blots show the three neurofilament proteins, with 
NfL appearing at approx. 30 kDa, NfM at 117 kDa and NfH at 238 kDa. No bands with molecular 
weight higher than the expected sizes, indicative of stable Nf-containing aggregates, were 
detected. 
Presence of Nf proteins was confirmed in HC-PPS. Neurofilament Heavy (NfH) 
and Medium (NfM) were detected at the expected molecular weight (MW; 238 
KDa and 117 KDa respectively), while NfL was detected at 30 KDa (expected 
MW 70 KDa). NfL detection at a lower molecular weight may be related to the 
release by the SDS detergent used in the WB procedure of an NfL fragment from 
protein complexes retained by the filter. At the same time, there was no detection 
of SDS-stable immunoreactive bands above 460 KDa, with Nf bands intensity 
and MW appearing comparable across the three treatment conditions. As the 
presence of a NfL band at 30 KDa after ultrafiltration with a 100 KDa cut-off filter 
may have been related to this fragment being part of high-molecular weight 
assembly like a protein aggregates, we have further investigated the presence of 
high molecular weights aggregates in plasma using the reported enrichment 
protocols. 
3.3 NCHs enrichment by Seprion PAD-beads 
The first enrichment method tested was based on a ligand, called Seprion, 
capable of interacting with protein aggregates (96). In this study, we have used 
magnetic beads coated with the Seprion ligand (Seprion PAD-beads; SEP). To 
evaluate optimal binding conditions, different volumes of samples and reagents 
were tested in the final mix (Table 3.2). After SEP enrichment, each condition 
was evaluated by western blot (WB) for Neurofilament proteins (Nf) detection 
(Figure 3.2). 
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    Seprion 
        Enrichment 
           Condition 
 
 
Reagent 1 2 3 4 5 6 7 
Sample (HC-PPS) 
[µl] 
800 400 400 400 400 400 200 
CB [µl] 200 400 200 200 400 400 200 
Water [µl] 0 0 200 200 0 0 400 
SR [µl] 100 200 100 100 100 100 100 
Beads [µl] 100 200 200 100 200 100 100 
Table 3.2. Conditions tested for optimization of plasma aggregates enrichment by SEP.  
CB: Capture Buffer; SR: Seprion Reagent. 
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Figure 3.2. Nf in HC-PPS after aggregates enrichment with Seprion PAD-beads SEP.  
Western Blot (WB) analysis for the detection of (A) neurofilament heavy chain (NfH), (B) 
neurofilament medium chain (NfM) and (C) neurofilament light chain (NfL) in the healthy controls 
pooled plasma samples (HC-PPS) after SEP enrichment. The lanes labelled from 1 to 7 
corresponded to HC-PPS sample enriched following conditions listed in Table 3.2. The chart 
showed in (D) represents the different amount NfH in (A) normalizing the intensities on condition 
1 intensity. 
It was possible to detect NfH at the expected molecular weight (MW) in all SEP-
enriched HC-PPS samples, with the exception of condition 7 (Table 3.2). From 
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this blot, it appeared that the amount of NfH detected depended on the sample 
volume used for SEP. In fact, condition 7 where the smaller amount of HC-PPS 
was loaded (200 µl) showed no detectable NfH, while condition 1 with the highest 
amount of HC-PPS (800 µl) showed NfH expression of about double the intensity 
compared to the next condition tested (2; 400 µl) (Figure 3.2D). None of the NfH 
bands were above 268 KDa, the expected molecular weight for this protein. The 
correlation between volume of sample for SEP extraction and WB signal was also 
confirmed for NfM detection, where condition 1 only showed NfM expression. 
Bands at variable molecular weights were identified when WB was probed for 
NfM detection, with the most intense band detected at 55 KDa, possibly a 
fragment of the full-size protein released from the aggregates recovered by SEP. 
Both for NfH and for NfM, the multiple bands detected could be related to different 
Nf peptides. NfL was not detected in any of the sample volumes used for SEP 
extraction.  
3.4 NCHs enrichment by ultracentrifugation: Brain-Plasma Protocol (BPP) 
Methods based on sedimentation (e.g. ultracentrifugation, UC) have been 
developed to separate  macromolecular protein aggregates in solution which may 
be an unwanted by-product in biopharmaceutical formulations, as well as of small 
particles like exosomes and viruses (102–106). We have applied the same 
principle and developed a UC-based method to separate and enrich protein 
aggregates from plasma. 
The rationale of this protocol is based on increasing the solubilisation of all the 
possible particles present in plasma by adding a detergent at high concentration 
and exploiting the high density of the residual, strong insoluble particles by 
sedimentation at high speed with a cushion of sucrose 1 M, which functions as a 
density cut-off (i.e. 1.127 g/ml). In addition, to further the enrichment of strong 
insoluble aggregates an additional salting in solubilisation step was included in 
the final protocol.  
To identify the best conditions of enrichment by BPP, different detergents (SDS, 
Triton X-100, Sarkosyl) at either 0.5% or 2% final concentration and different salt 
(NaCl) concentrations (0.5M, 1M, 1.5M) for salting in were tested (Table 3.3).  
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Detergents and NaCl concentrations Final 
concentration 
(µg/µl) 
1 ml PPS + 25 µl SDS 20% (final concentration 0.5% SDS) 0.30978 
1 ml PPS + 111 µl SDS 20% (final concentration 2.0% SDS) 0.28813* 
1 ml PPS + 25 µl Triton X-100 20% (final concentration 0.5% 
Triton X-100) 0.86983 
1 ml PPS + 111 µl Triton X-100 20% (final concentration 
2.0% Triton X-100) 0.75391 
1 ml PPS + 25 µl Sarkosyl 20% (final concentration 0.5% 
Sarkosyl) 0.66941 
1 ml PPS + 111 µl Sarkosyl 20% (final concentration 2.0% 
Sarkosyl) 0.53673 
1 ml PPS + 111 µl NaCl 5 M (final concentration 0.5M NaCl) 1.22388 
1 ml PPS + 250 µl NaCl 5 M (final concentration 1.0M NaCl) 0.90196 
1 ml PPS + 430 µl NaCl 5 M (final concentration 1.5M NaCl) 0.6338 
Table 3.3. Conditions of detergents and salt (NaCl) concentration: final protein 
concentration following enrichment of protein aggregates from HC-PPS using BPP. 
Detergents (green colour-code) and salt (grey colour-code) conditions used for enrichment. *= 
SDS interference during protein quantification with Pierce BCA Protein Assay Kit. 
The best detergent and salt condition for enrichment was based on Nf detection, 
both in its soluble form and within high MW forms (Figure 3.3). In fact, during the 
UC step performed at 4 °C, the SDS precipitated as powder at the bottom, 
especially the sample treated with 2% SDS that was not included in the western 
blot. The sample treated with 0.5% SDS showed a different pattern compared to 
the other treatment options with higher expression of NfH and NfM (Figure 3.3). 
It is therefore possible that the SDS concentration is the main factor in the 
enrichment process affecting aggregates solubilisation.  Moreover, the NfM 
profile in the reported treatment condition was similar to the NfM profile showed 
by SEP enrichment in WB (Figure 3.2), suggesting that SDS detergent pre-
treatment increased enrichment of protein aggregates carrying the NfM which is 
normally detected at 117 KDa (Figure 3.3). Pre-treatment of samples with a final 
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concentration of 2% Triton X-100, UC with 1 M sucrose cushion and washing with 
1.5 M NaCl was associated with an overall higher amount of NfL, NfM and NfH 
as shown using WB (Figure 3.3). Under these conditions, NfH was consistently 
present at high MW (significantly above 460 KDa), while NfM and NfL both 
migrated at the same MW (117 KDa and 30 KDa respectively) reported for Nf 
detection in untreated plasma Figure 3.1. The detection of high MW, SDS-stable, 
NfH-containing bands in the enriched fractions was in line with the presence of 
circulating NfH-containing protein aggregates. We have therefore incorporated 
these conditions in the final BPP enrichment protocol (Figure 3.3). 
 
Figure 3.3. WB analysis of Nf isoforms using fractions generated by ultracentrifugation 
and pre-treatment conditions listed in Table 3.  
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11 µg of total proteins in each treatment sample were loaded to evaluate the best enrichment 
method, based on the level of Nf isofom detected. (A) Anti-NfH WB showing presence of high 
MW bands (above the expected NfH MW) for the 0.5X, 2X and 0.5Y conditions. (B) Anti NfM WB 
showing bands at 117 KDa MW for all condition tested and (C) anti-NfL WB showing no bands 
with MW higher than 31 KDa. *: 0.5S WB was associated with residual powder contamination, 
likely be due to poor SDS solubility at 4°C. (D) Abundance (relative density) of NfH, NfM and NfL 
in the WB experiments testing the three Nf isoform enrichment (A, B, C). The 2X condition showed 
the highest overall Nf content for all three Nf proteins. Data were normalised using the 0.5X bands 
density. QC: quality control, bovine neurofilaments (NfL, UmanDiagnostics; NfM and NfH, 
Stratech Scientific Limited). 0.5S: 0.5% SDS; 0.5X: 0.5% Triton X-100; 2X: 2% Triton X-100; 0.5Y: 
0.5% Sarkosyl; 2Y: 2% Sarkosyl; 0.5M: 0.5M NaCl; 1.5M: 1.5M NaCl; QC: bovine Neurofilaments. 
3.5 Comparison between SEP and BPP methods 
The comparison of WB analysis of aggregates enrichment using the SEP and 
BPP methods showed higher expression of Nf species including high molecular 
weight NfH-containing aggregates when using the BPP enrichment protocol 
(Figure 3.1 and Figure 3.3). The BPP enrichment method identified NfL (not 
visible after SEP enrichment) and also high MW bands for NfH suggesting higher 
specificity in isolating macromolecular formations with this method. Further 
analysis by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-
MS/MS) and transmission electron microscopy (TEM) were carried out to 
characterize the enrichment effect offered by the two methodologies and to obtain 
preliminary data on NCHs morphology as well as composition. 
3.5.1 LC-MS/MS 
After aggregates extraction from HC-PPS using the SEP and BPP methods, the 
two enriched fractions were run into a gel to allow in-gel trypsin digestion as 
described in Material and methods (Paragraph 2.5.1). Before cutting the fractions 
for proteomic analysis, the gel was stained with Imperial Blue Comassie to 
identify the electrophoretic protein profiles generated using the two methods 
(Figure 3.4A). Based on these profiles, each of the two lanes was cut into fifteen 
fractions. Fractions were then digested with trypsin and subjected to LC-MS/MS 
analysis to study the composition of the aggregates extracted using the SEP and 
the BPP protocols (Figure 3.4A). 
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Figure 3.4. Aggregates fractions obtained using BPP and SEP methods resolved in SDS-
PAGE and numbers of protein groups identified after LC-MS/MS analysis the fractions 
obtained using the two extraction methods.  
(A) SDS-PAGE showing gel bands cut (fractionation) and subjected to in-gel Trypsin digestion for 
LC-MS/MS (a total of 15 bands for both BPP and SEP). (B) Protein Identification performed with 
Proteome Discoverer 1.4 (PD) generated 369 and 605 proteins unique to BPP and SEP 
respectively; 225 were shared by the two extraction methods (filter criteria for selection: a 
minimum of 2 peptides per protein and a peptide count only in the top scored proteins). LC-
MS/MS: Liquid Chromatography coupled with tandem Mass Spectrometry; SEP: Seprion PAD-
Beads separation; BPP: Brain-Plasma Protocol. 
The mass spectrometry (MS) analysis identified 369 and 605 protein groups for 
the sample enriched by BPP and SEP respectively. However, Nf proteins were 
not detected in the two samples, possibly due to the presence of complex Post-
Translational Modifications (PTMs) and to the low abundance of Nf (see also 
Paragraph 3.8). 30% of the overall detected proteins were observed in both 
samples (Figure 3.4B). The higher number of proteins identified in the SEP-
enriched sample was not due to uneven sample loading: SEP and BPP samples 
had the same number of spectra acquired in the second Mass Spectrometer 
(MS2) and a comparable identification rate (ID rate), calculated as the number of 
Peptide-Spectrum Matches (PSMs) over the total number of spectra acquired 
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(Table 3.4). The higher Coverage% and number of PSMs per protein group in 
BPP (Table 3.4) suggested that this extraction method was more selective in the 
enrichment of specific proteins. The BPP and SEP shared protein pool had higher 
protein coverage and PSMs counts than those seen in either of the individual 
enrichment method, suggesting a higher abundance of these proteins in plasma 
(Table 3.4). Functional analysis of the three protein lists (Figure 3.4B) to define 
Genetic Ontology (GO) terms for Cellular Component (CC) was undertaken 
interrogating the PANTHER database (http://www.pantherdb.org/) (107), and 
KEGG pathway enrichment, using the Webgestalt web tool (http://webgestalt.org) 
(108). 
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Fraction Total 
spectra 
Total 
PSMs 
ID 
rate% 
Protein 
groups 
Coverage% 
/protein group 
(mean) 
#Unique Peptides 
/protein group 
(median) 
#Peptides 
/protein group 
(median) 
#PSMs /protein 
group 
(median) 
BPP 215993 35779 16.56 371 31.2% 5.0 6.0 12.0 
SEP 210875 34865 16.53 609 25.6% 5.0 6.0 8.0 
BPP 
(shared) 
   209 34.7% 7.0 10.0 28.0 
SEP 
(shared) 
   209 35.3% 8.0 10.0 21.0 
Table 3.4. Liquid Chromatography coupled with tandem Mass Spectrometry (LC-MS/MS) analysis of the enriched aggregate fractions obtained using SEP 
and BPP: main features and protein groups defined by Proteome Discoverer 1.4.  
Protein groups identified within the aggregate fractions obtained using the UC-based Brain-Plasma Protocol (BPP) and SEP separately and protein groups “shared” 
by the two enrichment methods. The shared fraction included only the protein isoforms in common and not the parental proteins. The Coverage% values were normally 
distributed and the mean was used for comparison. 
BPP: Brain-Plasma Protocol 
SEP: Seprion PAD-Beads extraction method 
PSM: Peptide-Spectrum Match 
Total spectra: number of spectra acquired at MS2 level 
Total PSMs: number of Peptide-Spectrum Matches identified by PD 
ID rate% (Identification rate): PSMs/total spectra 
Protein groups: number of proteins identified by the Parsimony Principle in PD 
Coverage%/protein group: the coverage% per protein identified (mean) 
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#Unique Peptides/protein group: number of unique peptides per protein identified (median) 
#Peptides/protein group: number of peptides (unique and not unique) per protein identified (median) 
#PSMs/protein group: number of PSMs per protein identified (median) 
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3.5.1.1 Analysis of the BPP and SEP shared proteins  
From the 225 proteins identified in both BPP and SEP datasets, PANTHER 
identified 196 genes accounting for 138 hits within the CC terms (Figure 3.5A). 
From the 196 genes identified by PANTHER, 47 (34.1% of the total hits) were 
classified as cell part (i.e. any constituent part of a cell), with the majority being 
for intracellular proteins (35 genes, 67.3% of the total hits within cell part) and as 
extracellular region (47 genes, 37.1% of the total hits) (Figure 3.5A). The other 
two main CC were macromolecular complexes (15.2%) and organelles (10.9%), 
where ten genes (62.50% of the total hits within organelles) were classified as 
cytoskeleton (Figure 3.5A). The 196 genes were submitted to Webgestalt for 
pathway functional  analysis on KEGG database and among the top10 enriched 
pathways (Table 3.5), six were linked to infection and immune response 
(staphylococcus aureus infection, pertussis, systemic lupus erythematosus, 
pathogenic Escherichia Coli infection, complement, platelet activation) and the 
remaining four were related to cell migration (adhesion), extra-cellular matrix and 
prion disease. As highlighted by PANTHER analysis, the cellular components 
involved in these pathways were closely related to extracellular region and cell 
part terms. 
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Figure 3.5. Pie charts showing cellular component (CC; PANTHER database) terms 
identified using BPP, SEP and using both enrichment methodologies (shared).  
(A) Terms represented in both BPP and SEP shared proteins groups. (B) Terms represented in 
the BPP protein groups. (C) Terms represented in the SEP protein groups. The number of genes 
identified by PANTHER for each group of proteins is reported in bold and under brackets. 
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Gene set Pathway description Number of 
genes in the 
category 
Number of genes 
matched in the 
category 
Expected number 
of genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa04610 Complement and 
coagulation cascades 
79 40 1.23 32.42 0.00E+00 0.00E+00 
hsa05150 Staphylococcus 
aureus infection 
56 13 0.87 14.86 1.72E-12 2.60E-10 
hsa05020 Prion diseases 35 8 0.55 14.63 4.53E-08 4.58E-06 
hsa05133 Pertussis 76 10 1.19 8.42 2.30E-07 1.74E-05 
hsa04510 Focal adhesion 203 14 3.17 4.42 2.78E-06 1.69E-04 
hsa05322 Systemic lupus 
erythematosus 
135 11 2.11 5.22 7.20E-06 3.64E-04 
hsa05130 Pathogenic 
Escherichia coli 
infection 
55 7 0.86 8.15 2.04E-05 8.85E-04 
hsa04145 Phagosome 154 11 2.41 4.57 2.52E-05 9.56E-04 
hsa04512 ECM-receptor 
interaction 
82 7 1.28 5.47 2.71E-04 9.13E-03 
hsa04611 Platelet activation 122 8 1.91 4.20 6.03E-04 1.83E-02 
Table 3.5. Top 10 enriched KEGG pathways in the SEP and BPP shared proteins list.  
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Gene set: KEGG pathway code 
Pathway description: KEGG pathway’s name 
Number of genes in the category: Number of genes included in the given KEGG pathway in Homo sapiens 
Number of genes matched in the category: Number of genes in the submitted list also identified in the given KEGG pathway 
Expected number of genes in the category: Calculated as the number of genes submitted divided by the number of the total Homo sapiens genes involved in all 
the KEGG pathway database and multiplied by the number of genes in the category 
Ratio of enrichment: Calculated as the number of genes matched in the category divided by the Expected number of genes in the category 
p-Value: Statistical significance calculated by the Fisher’s exact test 
FDR (False Discovery Rate): Calculated from the p-Value adjusted with Benjamini and Hochberg method (109) 
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3.5.1.2 Functional analysis of the proteins data identified using BPP  
From the 144 proteins represented in the BPP proteins data, PANTHER identified 
99 genes accounting for 105 hits within the CC terms (Figure 3.5B). From these 
99 genes, 42 (40% of the total hits) were classified as part of the extracellular 
region, 30 (28.6%) as cell part and 27 (25.7%) as macromolecular complex, while 
the rest belonged to extracellular matrix (2, 1.9%) and organelles (4, 3.8%) 
(Figure 3.5B). 8 genes (26.7%) of the cell part component were intracellular 
proteins and 22 (73.30%) were plasma membrane proteins, while 1 (20%) of the 
organelle component was part of the cytoskeleton. The pathway functional 
analysis of the BPP proteins data (Table 3.6) revealed a significant representation 
of features involved in endocrine, metabolic and cell-signalling regulation (PPAR, 
thyroid hormone synthesis, lysine degradation, carbon metabolism, citrate-TCA 
cycle) and pathways specific to ECM-receptor interaction, phagosome and 
adipocytokine signalling.  
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Gene set Pathway 
description 
Number of 
genes in the 
category 
Number of genes 
matched in the 
category 
Expected number of 
genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa00020 Citrate cycle (TCA 
cycle) 
30 3 0.13 23.26 2.69E-04 0.06 
hsa04512 ECM-receptor 
interaction 
82 4 0.35 11.35 3.85E-04 0.06 
hsa04145 Phagosome 154 4 0.66 6.04 4.00E-03 0.40 
hsa01200 Carbon metabolism 114 3 0.49 6.12 1.25E-02 0.95 
hsa05144 Malaria 49 2 0.21 9.50 1.85E-02 1.00 
hsa05130 Pathogenic 
Escherichia coli 
infection 
55 2 0.24 8.46 2.30E-02 1.00 
hsa00310 Lysine degradation 59 2 0.25 7.89 2.63E-02 1.00 
hsa04920 Adipocytokine 
signaling pathway 
70 2 0.30 6.65 3.60E-02 1.00 
hsa03320 PPAR signaling 
pathway 
72 2 0.31 6.46 3.79E-02 1.00 
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Gene set Pathway 
description 
Number of 
genes in the 
category 
Number of genes 
matched in the 
category 
Expected number of 
genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa04918 Thyroid hormone 
synthesis 
74 2 0.32 6.29 3.99E-02 1.00 
Table 3.6. Top 10 enriched KEGG pathways in the BPP proteins list.  
Gene set: KEGG pathway code 
Pathway description: KEGG pathway’s name 
Number of genes in the category: Number of genes included in the given KEGG pathway in Homo sapiens 
Number of genes matched in the category: Number of genes in the submitted list also identified in the given KEGG pathway 
Expected number of genes in the category: Calculated as the number of genes submitted divided by the number of the total Homo sapiens genes involved in all 
the KEGG pathway database and multiplied by the number of genes in the category 
Ratio of enrichment: Calculated as the number of genes matched in the category divided by the Expected number of genes in the category 
p-Value: Statistical significance calculated by the Fisher’s exact test 
FDR (False Discovery Rate): Calculated from the p-Value adjusted with Benjamini and Hochberg method (109) 
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3.5.1.3 Functional analysis of the protein data identified using BPP  
From the 380 proteins represented in the SEP proteins dataset, PANTHER 
identified 306 genes accounting for 202 hits within the CC (Figure 3.5C). From 
the 202 genes, the main component was cell part with 106 genes (52.5% of the 
total hits), of which 102 (79.7%) were intracellular and 23 (18%) were plasma 
membrane proteins, followed by organelle (43 genes, 21.3% of total hits) and 
macromolecular complex (25, 12.4%) components, while extracellular region, cell 
junction, membrane, synapse and extracellular matrix accounted for 28 genes 
(13.9% of the total hits) (Figure 3.5C). Most of the organelle sub-component 
proteins were related to the cytoskeleton (25, 53.2%) (Figure 3.5C). The 
functional analysis of the SEP unique proteins data (Table 3.7) identified features 
related to immune activation (chemokine signaling pathway, focal adhesion, 
shigellosis, platelet activation) and to cell function and structure (tight junction, 
regulation of actin cytoskeleton, vascular smooth muscle contraction). All 
pathways showed enrichments with a FDR < 0.1.   
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Gene set Pathway 
description 
Number of 
genes in the 
category 
Number of 
genes matched 
in the category 
Expected 
number of 
genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa04810 Regulation of actin 
cytoskeleton 
216 27 5.23 5.16 1.11E-12 3.37E-10 
hsa04611 Platelet activation 122 16 2.95 5.42 3.05E-08 3.67E-06 
hsa05131 Shigellosis 65 12 1.57 7.62 3.64E-08 3.67E-06 
hsa04270 Vascular smooth 
muscle contraction 
121 15 2.93 5.12 1.80E-07 1.24E-05 
hsa04921 Oxytocin signaling 
pathway 
159 17 3.85 4.42 2.36E-07 1.24E-05 
hsa04144 Endocytosis 260 22 6.30 3.49 2.46E-07 1.24E-05 
hsa05130 Pathogenic 
Escherichia coli 
infection 
55 10 1.33 7.51 6.07E-07 2.63E-05 
hsa04530 Tight junction 139 14 3.37 4.16 5.87E-06 2.23E-04 
hsa04510 Focal adhesion 203 17 4.92 3.46 7.27E-06 2.45E-04 
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Gene set Pathway 
description 
Number of 
genes in the 
category 
Number of 
genes matched 
in the category 
Expected 
number of 
genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa04062 Chemokine 
signaling pathway 
187 16 4.53 3.53 1.04E-05 3.16E-04 
Table 3.7. Top 10 enriched KEGG pathways in the SEP unique proteins list.  
Gene set: KEGG pathway code 
Pathway description: KEGG pathway’s name 
Number of genes in the category: Number of genes included in the given KEGG pathway in Homo sapiens 
Number of genes matched in the category: Number of genes in the submitted list also identified in the given KEGG pathway 
Expected number of genes in the category: Calculated as the number of genes submitted divided by the number of the total Homo sapiens genes involved in all 
the KEGG pathway database and multiplied by the number of genes in the category 
Ratio of enrichment: Calculated as the number of genes matched in the category divided by the Expected number of genes in the category 
p-Value: Statistical significance calculated by the Fisher’s exact test 
FDR (False Discovery Rate): Calculated from the p-Value adjusted with Benjamini and Hochberg method (109) 
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3.5.2 Immunogold-Transmission Electron Microscopy (IG-TEM) 
It has been reported that the aggregation process leading to the formation of 
macromolecular structures within a fluid can be visualized by transmission 
electron microscopy (TEM), as stated by Ross and Poirier (55). In line with this 
observation, Immunogold Transmission Electron Microscopy (IG-TEM) was 
employed for the purpose of confirming the presence of macromolecular 
formations in the fractions extracted from HC-PPS using the ultracentrifugation 
(BPP) and Seprion (SEP) enrichment protocols and to establish the presence of 
Nf within these macromolecular structures. Aggregate fractions for TEM analysis 
were obtained using SEP (Paragraph 2.2.1) and using BPP (Paragraph 2.2.2.1). 
The use of TEM was intended to demonstrate the presence of electron-dense 
(and likely heterogeneous) macrostructures representing the high molecular 
weight aggregates identified using gel-based methods after enrichment of HC-
PPS. Using TEM it was not possible to infer any information on the overall 
composition of these macromolecular formations apart from the presence of Nf 
proteins based on the binding of gold particles. As a first step, optimal conditions 
for TEM analysis including incubation time for sample absorption onto the grid, 
negative stain using Uranyl Acetate or Ammonium Molybdate and antibody 
dilutions were tested (Figure 3.6).  
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Figure 3.6. Optimisation of the experimental conditions for the study of NCHs using 
Transmission Electron Microscopy (TEM) and Immunogold-TEM (IG-TEM).  
(A) Negative staining: BPP-enriched fraction in the glow discharged grid incubated for 30 seconds 
in Ammonium Molybdate (AM). (B) Negative staining: BPP-enriched fraction in the glow 
discharged grid incubated for 10 seconds in AM and immunolabelling with anti-NfM diluted 1:100. 
(C) Negative staining: BPP enriched fraction incubated for 10 seconds in AM and immunolabelling 
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with anti-NfL diluted 1:100. (D) Negative staining: bovine NfH (bNfH) incubated for 10 seconds in 
Uranyl Acetate (UA) and immunolabelling with anti-NfH diluted 1:100. (E) Negative staining: BPP-
enriched fraction incubated for 10 seconds in UA with anti-NfH diluted 1:200. (F) Magnification of 
a small part of E showing gold particles binding to the electron dense structure. Scale bars are 
indicated at the low right corner of each micrograph. 
In the negative staining with 30 seconds incubation (Figure 3.6A), the electron-
dense material appeared heterogeneous and diffused on to the whole grid 
possibly also as a result of over-loading. The incubation time was decreased to 
10 seconds (Figure 3.6B). 10 seconds incubation time with Ammonium 
Molybdate (AM) gave a good contrast but anti-NfM and anti-NfL gold particles 
linked to the secondary antibodies were not detectable (Figure 3.6B, C). Negative 
staining with Uranyl Acetate (UA) showed a lighter contrast, with immune-gold 
particles detection of bovine NfH (bNfH) and of highly electron-dense 
macrostructures (Figure 3.6D, E, F). For primary antibodies dilutions, anti-NfL, 
anti-NfM and anti-NfH antibodies were initially tested at 1:100 to avoid a high 
background. We could not detect any NfL and NfM signal, while NfH in both bNfH 
and electrondense aggregates was detected at both 1:100 and 1:200 dilutions 
(1:200 was set as final dilution for the lowest background).  
IG-TEM of the BPP fraction showed the presence of globular amorphous 
formations (Figure 3.7A) and all Nf isoforms were detected (Figure 3.7A, C and 
E). While NfM (Figure 3.7C) and NfL (Figure 3.7E) immune-gold signals were 
primarily represented outside the aggregates, NfH (Figure 3.7A) was mainly 
detected within electron-dense formations, which is in line with the consistent 
detection of anti-NfH in high molecular weight bands detected in our WB 
experiments (Figure 3.3A).  
The grids coated with SEP-enriched fractions showed electron-dense 
macromolecular formations confirming the presence of protein aggregates in the 
SEP-processed sample (Figure 3.7B, D and F). However, while BPP-enriched 
fractions appeared with more globular electron-dense features (Figure 3.7A) the 
final product of the SEP enrichment appeared more as a dense network of fibers, 
with evidence of salt retention (Figure 3.7D). The appearance of a fiber network 
could be due to the lack of any pre-treatment in the SEP enrichment method, 
while the presence of salts to the specifics of the elution buffer (0.1 M NaOH, 
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0.1% Triton X-100 and Tris-HCl). Both NfH (Figure 3.7B) and NfM (Figure 3.7D) 
gold particles were within electron-dense formations but also outside which is in 
line with the high molecular weight (MW) bands detected by WB (Figure 3.2B). A 
few NfL (Figure 3.7F) gold particles in contrast with WB data where no NfL band 
was detected (Figure 3.2C), were detected outside the electron-dense areas.  
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Figure 3.7. IG-TEM micrographs to test anti-Nf proteins antibodies on protein aggregates 
from HC-PPS extracted using BPP and SEP.  
The micrographs displayed the presence of amorphous aggregates for both enrichment methods 
with the gold particles (red arrows) showing detection of NfH (A and B), NfM (C and D) and NfL 
(E and F). SEP sample showed also the presence of a fibrous network (blue arrow) (D) and 
impurities (yellow arrow) (F). Scale bars are indicated at the low right corner of each micrograph. 
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3.5.3 Plasma aggregates extraction: general considerations 
To investigate the composition and functional properties of circulating 
Neurofilament-Containing Heteroaggregates (NCHs), understanding how 
selective the chosen enrichment methods are in the process of isolation of these 
formations is of fundamental importance. Sedimentation and binders exploit 
different physical properties in the enrichment process, with the SEP protocol 
based on affinity for proteins involved in different levels of aggregation (110). SEP 
enrichment allowed the identification of a higher number of proteins, an 
observation that may be explained by the ligand’s broader affinity to any 
conformational change, which affect protein-protein interactions. This method 
may in fact be more suitable to the isolation of disordered monomers and/or low 
order multimers and not only of large MW heteroaggregates. On the other hand, 
density was the main feature exploited in the enrichment process by BPP, where 
large and dense aggregates are expected to sediment with ultracentrifugation 
(UC) while low order multimers (which may function as seeds of larger protein 
aggregates) may escape detection. Overall BPP separation appeared to be more 
stringent, generating a smaller and possibly less complex proteome, while 
acquiring, on average, more spectra for the same peptide. This means that 
although the BPP method produced less information from the proteomics 
analysis, identifying a lower number of protein groups, it likely generated less 
false positive information in protein identification compared to SEP.  
Qualitative differences in the protein pools within aggregates extracted using UC 
and SEP have emerged. MS proteomics showed that aggregates extracted with 
both methodologies mostly harbour cellular components, although interspersed 
with extracellular matrix proteins. Functionally, both extraction techniques 
identified proteins networked within molecular cascades crucial to inflammatory 
processes, particularly complement factors, along with phagosome and prion-
related proteins.  UC aggregates are specifically enriched with proteins involved 
in endocrine, metabolic and cell-signaling regulation. It could be speculated that 
these hetero-complexes naturally express biological features which are essential 
in maintaining homeostasis, like inflammation and metabolism. It can also be 
speculated that circulating protein assemblies may act as sinks for the 
sequestration of molecular factors that may have otherwise detrimental effects.  
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Despite the different biological information that could be obtained from the 
analysis of the protein pools obtained using the two methods, BPP was more 
reliable for protein identification by LC-MS/MS and showed a higher compatibility 
to orthogonal techniques. These observations were crucial in the decision of 
adopting BPP as the method choice to carry out other aspects of this study. 
With regards to the immunogold profiles of Nf isoforms, both SEP and BPP 
extraction method showed a predominant co-localization of NfH and aggregates, 
a pattern that was also reproduced in NfM micrograph (Figure 3.7C and D), while 
NfL gold particles appeared only outside the electrondense structures (Figure 
3.7E and F).  It is possible that the different distribution of Nf isoforms within and 
outside protein aggregates may be explained by the interactions between Nf and 
other proteins, which depend on conformation and on Post-Translational 
Modifications (PTMs), and structural properties which can also affect binding with 
the Seprion ligand (111). For the purpose of the research work detailed in this 
Thesis and to visualise the presence of macromolecular structures in the fractions 
obtained by SEP and BPP, we have undertaken IG-TEM optimization process 
with negative staining, but the lack of quality controls does not allow a better 
interpretation of the amorphous and fibrous electron-dense features identified in 
our micrographs. 
3.6 Effect of urea on plasma protein aggregates from HC and ALS patients 
Lu et al. have reported that urea has a disruptive effect on protein aggregates 
and the use of this denaturing agent increases NfH detection by solubilisation of 
NfH-containing aggregates which in turn reduces NfH epitope masking in protein 
assemblies; this process is likely to increase the overall sensitivity of enzyme-
linked immune assays (ELISA) for NFH detection (53). In line with this protocol, 
we have used 8 M urea to resuspend the final pellet obtained by BPP enrichment 
from HC-PPS and ALS-PPS (Figure 3.8). ALS-PPS was created pooling plasma 
samples from six ALS patients with heterogeneous clinical features, including fast 
and slow disease progression rate (Table 3.8).
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Sample 
ID 
Gender Ethnicity Age at 
sampling 
(year) 
NfH 
(ng/ml) 
El-Escorial Clinical 
onset 
ALSFRS-R Progression 
Rate at visit 
ALS1-
PPS 
M Caucasian 76.77 NA Definite ALS R/B 37 5.979 
ALS2-
PPS 
M Caucasian  59.41 – 
59.56 
NA Definite ALS R 25 – 39  1.839 – 3.665 
ALS3-
PPS 
F Caucasian  71.56 NA Probable ALS R\B 33 3.106 
ALS4-
PPS 
M Caucasian  60.67 NA Suspected ALS LL NA 0.000 
ALS5-
PPS 
M Afro-Caribbean 46.12 40.6 Possible ALS LL 47 0.004 
ALS6-
PPS 
M Caucasian 78.48 NA Possible ALS B 46 0.004 
Table 3.8. ALS-Pooled Plasma Sample (ALS-PPS): clinical features and demographics of the selected ALS patients. 
For ALS2, we have identified samples from more than one time point (age at sampling time points are reported)  
Sample ID: Identification code 
Gender: M= Male; F= Female 
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Age at sampling: age of the patient at the time of blood sampling (age-range shown if more than one time point sample was used) 
NfH (ng/ml): level of NfH expressed in ng/ml; NA= data not available 
El-Escorial: diagnostic classification of ALS (88) 
Clinical Onset (site of initial clinical signs): R= Respiratory; B= Bulbar; LL= Lower Limbs 
ALS Functional Rating Scale revised (ALSFRS-R): level of neurological impairment across different clinical domains (1-48, higher neurological impairment with 
lower values); NA= data not available 
Rate of progression at sampling time point: calculated as 48 - ALSFRS-R score at sampling time/disease duration from onset of symptoms to sampling time.
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WB for NfH detection showed high MW bands for both ALS-PPS and HC-PPS 
enriched fractions, confirming the presence of NCHs in both healthy and ALS 
pooled samples (Figure 3.8). The two pooled samples displayed the same WB 
NfH profile, with the ALS-PPS showing a higher NfH intensity in all conditions 
tested. The NfH bands detected in the ALS-PPS fraction showed different 
intensities depending on the buffer used for solubilisation (e.g. PBS vs urea). 8 
M urea increased of approximately 2-fold the intensities of the 238, 117 and 55 
KDa bands, while reducing the intensity of the high MW band situated above the 
expected NfH MW (238 KDa; Figure 3.8). A similar trend was present in the HC-
PPS fraction resuspended in 8 M urea (Figure 3.8). This observation may indicate 
that NCHs composition differs in ALS compared to healthy control, hence their 
susceptibility to urea. Extension of urea treatment to a larger number of samples 
from healthy controls and ALS patients will be needed to confirm this preliminary 
observation. We have therefore used 8 M urea in experiment of subilisation of 
BPP final pellets. 
 
Figure 3.8. Western blot (WB) for NfH detection: urea effect on protein aggregates after 
BPP enrichment.  
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WB shows NfH content after resuspension in PBS and 8M urea of the BPP-enriched fractions 
obtained from Healthy Conrol-Pooled Plasma Sample (HC-PPS) and ALS-Pooled Plasma 
Sample (ALS-PPS). ALS-PPS enriched fractions are represented in lane 1 and 2 (from left to 
right), using 8M urea (1) and PBS (2) to resupend the sample after enrichment process. HC-PPS 
enriched fractions are represented in lane 3 and 4, using 8M urea (3) and PBS (4) as buffer. 
Lanes 5 and 6 show NfH content, in ALS-PPS (5) and HC-PPS (6) samples, after the first round 
of ultracentrifugation (UC) in the BPP protocol. Lanes 7 and 8 show the NfH content in the pellet 
after the benchtop centrifugation step, for ALS-PPS and HC-PPS respectively, while 9 and 10 
show the NfH content in HC-PPS and ALS-PPS (before enrichment). The effect of the urea buffer 
in NfH detection is showed in the chart, where the ratio between the band intensities obtained 
using urea and PBS is plotted for both HC-PPS and ALS-PPS samples. 
3.7 An alternative method for NCHs enrichment by ultracentrifugation: 
Brain Only Protocol (BOP) 
The Brain Only Protocol (BOP) protocol was used to extract protein aggregates 
from brain for the TEM applications. The protocol was based on previously 
published data (Greenberg and Davied paper (97)) and adapted to NCHs 
extraction alongside the aforementioned  BPP protocol.  
3.7.1 NCHs extraction from brain using BPP and BOP 
Brain1 and Brain2 samples were homogenised and mixed as described in 
Paragraph 2.1.2.1 BOP and BPP protocols (Paragraph 2.2.2.1 and 2.2.2.2) were 
then used for NCHs extraction from the brain homogenate. Following extraction, 
quantification of total protein concentration showed a lower protein concentration 
for the fraction enriched in protein aggregates obtained by BOP ((BPP= 0.336 
µg/µl; BOP= 0.297 µg/µl). This difference was probably related to the presence 
of a second UC step with a sucrose cushion in the BOP protocol. To evaluate 
further the differences between BPP and BOP, SDS-PAGE and WB against NfH 
were performed loading 5 µg of the final extraction products (NCHs enriched), 
together with the original brain sample homogenate and the intermediate 
products of the two extraction processes (brain debris collected after the 
benchtop centrifugation, supernatant and pellet after the first UC step in the two 
protocols; Figure 3.9). The SDS-PAGE stained with Imperial Blue Comassie 
showed very faint bands, limiting any further in-depth evaluation of the 
enrichment processes (Figure 3.9). Conversely, it was possible to evaluate the 
presence of NfH in the BOP and BPP NCHs enriched fractions, with the BPP 
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NCHs enriched fraction showing a higher intensity of NfH staining compared to 
the BOP NCHs enriched fraction (Figure 3.9, lanes 1 and 4). 
 
Figure 3.9. Analysis of brain NCHs extracted using BOP and BPP: SDS-PAGE and anti-NfH 
WB.  
NCHs enriched fractions isolated using BOP and BPP protocols, together with samples collected 
from the intermediate steps of the extraction oricesses were loaded (5 µg) onto a 3-8% Tris-
Acetate gels (SDS-PAGE, left hand side) and used for Western Blot to test NfH expression (right-
hand side). Few and faint bands were detected at MW lower than 55 KDa on the SDS-PAGE (left-
side), while NfH was detected at different MW bands in the WB (right-hand side). BPP NCHs 
enriched fraction (lane 4) showed a more intense NfH band than BOP NCHs enriched fraction 
(lane 1). Lanes: 1, BOP NCHs enriched fraction; 2, BOP pellet after the first ultracentrifugation 
(UC) step; 3, BOP supernatant after the first UC step; 4, BPP NCHs enriched fraction; 5, BPP 
pellet after the first UC step; 6, BPP supernatant after the first UC step; 7, Brain sample; 8, Brain 
sample debris; Marker, HiMark MW marker. 
After testing the BPP and BOP extraction methods on brain samples, BOP was 
also used for NCHs extraction from HC-PPS and ALS-PPS (Figure 3.10) and 
compared to the NCHs extraction obtained with BPP (Figure 3.8). NfH was 
detected in un-processed pooled plasma (Figure 3.10 lanes 9 and 10). High 
intensity NfH bands were detected in plasma debris, the pellet obtained after the 
initial plasma benchtop centrifugation at 21000xg (Figure 3.10, lanes 7 and 8), 
(Figure 3.10, lanes 9 and 10). In the final extraction products by BOP, NfH was 
detected in the NCHs enriched fractions at a single 238/268 KDa band and also 
at higher MW (Figure 3.10, lanes 1 and 2), while bands lower than 238 KDa were 
not present as previously shown in the final products of extraction by BPP (Figure 
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3.8, lanes 1 and 2). In the supernatant and the pellet collected after the first UC 
step, only bands below 71 KDa were detected by the anti-NfH antibody (Figure 
3.10, lanes 3-6). Stringency in the BOP extraction method appears to increase 
with the second UC step (Figure 3.10, lanes 1 and 2), where NfH bands at the 
expected and at much higher molecular weight were detected (and not the two 
bands at 55 and 41 KDa present after the first UC step). 
 
Figure 3.10. NfH presence in plasma NCHs enriched fractions from ALS-PPS and HC-PPS 
isolated by BOP.  
Western Blot (WB) analysis shows NfH at the expected MW (238/268 KDa) in both HC-PPS and 
ALS-PPS (lanes 9 and 10), in the plasma debris (lanes 7 and 8) and in the final products (lanes 
1 and 2) of extraction by BOP. NfH was also detected at a lower MW (< 71 KDa) in lanes 3 to 10, 
but not in the final NCHs enriched fractions (lanes 1 and 2) obtained by BOP. Only the final 
products of extraction by BOP (lane 1 and 2) showed high MW bands likely to represent NCHs. 
Lanes: 1, HC-PPS NCHs enriched fraction; 2, ALS-PPS NCHs enriched fraction; 3, HC-PPS 
supernatant after the second ultracentrifugation (UC); 4, ALS-PPS supernatant after the second 
UC; 5, HC-PPS pellet after the first UC; 6, ALS-PPS pellet after the second UC; 7, HC-PPS 
plasma pellet after benchtop centrifugation (debris); 8, ALS-PPS plasma debris; 9, HC-PPS; 10, 
ALS-PPS. 
After WB evaluation of the NCHs extraction protocols and having confirmed the 
presence of NCHs in the final products of extraction from both plasma and brain 
using BOP, LC-MS/MS proteomics was performed to compare the composition 
of NCHs obtained using BPP and BOP enrichment from brain and plasma. The 
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final extraction products from HC-PPS and ALS-PPS were loaded into a gradient 
gel and after electrophoresis, ten fractions were cut from each lane and in-gel 
trypsin digestion performed. For brain NCHs proteomic analysis, BOP and BPP 
NCHs enriched fractions were loaded into the gel and electrophoresis blocked to 
concentrate the samples in one single band after they had entered completely in 
the upper edge of the gel. The two bands, one containing BOP NCHs and the 
other BPP NCHs, were cut and in-gel trypsin digestion was performed. Following 
protein identification as previously described, the protein content of NCHs 
obtained using BOP and BPP protocols were compared for each sample type 
(ALS-PSS, HC-PSS and Brain) (Figure 3.11, Table 3.9 and Table 3.10).  
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Figure 3.11. Number of proteins identified in NCHs extracted from ALS-PSS, HC-PSS and 
Brain and their distribution based on BPP and BOP enrichment.  
The Venn diagrams show the number of NCHs proteins identified using BPP and BOP extraction 
methods for (A) HC-PPS, (B) ALS-PPS and (C) Brain sample (mixed homogenate of Brain1 and 
Brain2). Within each section of the Venn diagrams, we report the number of proteins (and their 
percentage of the total proteins detected under brackets) that are either unique to one of the 
extraction methods or shared by the two (only proteins identified by a minimum of 2 peptides and 
a peptide count only in the top scored proteins). HC-PPS BPP: NCHs enriched fraction obtained 
from HC-PPS sample with BPP protocol; HC-PPS BOP: NCHs enriched fraction from HC-PPS 
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sample with BOP protocol; ALS-PPS BPP: NCHs enriched fraction from ALS-PPS sample with 
BPP protocol; ALS-PPS BOP: NCHs enriched fraction from ALS-PPS sample with BOP protocol; 
Brain BPP: NCHs enriched fraction from Brain sample with BPP protocol; Brain BOP: NCHs 
enriched fraction from Brain sample with BOP protocol. 
Protein identification in HC pooled samples detected 382 proteins by BPP and 
306 by BOP, with 248 proteins in common, which corresponded to the 56.4% of 
the total amount of identified proteins using both extraction methods (Figure 
3.11A). The enriched fraction from ALS-PPS showed the same trend, with 395 
proteins detected after BPP enrichment and 297 after BOP, and 232 (50.4% of 
the total proteins identified) proteins in common (Figure 3.11B). Brain NCHs 
showed a distinctively different picture, with 52 and 51 proteins identified in the 
BPP and BOP-NCHs enriched fractions respectively, and only 27 (35.5%) 
proteins in common (Figure 3.11C). A more informative way to look at LC-MS/MS 
performance in the analysis of the fractions produced using BPP and BOP 
enrichment methods to look broadly at the main protein identification features of 
each sub-group showed in Figure 3.11 (Table 3.9 and 10). In HC-PPS and ALS-
PPS plasma samples (Table 3.9), BPP had slightly better outcomes (higher ID 
rate and coverage). However, when considering the fraction of shared proteins, 
BPP outperformed BOP showing a considerable higher coverage, number of 
unique peptides, total peptides and PSMs per protein group, in both ALS and HC 
samples. With regards to the data from brain NCHs (Table 3.10), BOP showed 
higher coverage per protein group, while BPP performed better in number of 
unique peptides, total peptides, PSMs and identification score per protein group 
in the shared proteins fraction.  BPP showed an ID rate% that was almost double 
that of BOP (27.87% in BPP against 15.17% in BOP) which indicated that it was 
possible to obtain more PSMs, and therefore more information, from the same 
amount of spectra acquired by the Mass Spectrometer (possibly because of a 
higher quality of the spectra generated).  
While LC-MS/MS analysis provided an in-depth profile of the protein composition 
of the enriched fractions obtained using different extraction protocols, it did not 
identify Nf proteins in the BPP and BOP- plasma NCHs, in contrast to the 
confirmation of Nf expression obtained by WB in these samples. Conversely, the 
analysis of brain samples enriched fractions obtained with both extraction 
protocols showed all Nf proteins (NfH, NfM and NfL). NfH was detected as NfH 
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isoform 2, with a 17.96% total sequence coverage by BPP (a score of 179) and 
a 12.67% total sequence coverage by BOP (a score of 53.7). NfM was detected 
by BPP with a 19.76% coverage (a score of 206.02) and by BOP with 14.74% 
coverage (a score of 66.55). NfL showed the highest difference of the coverage 
detected by the two extraction methods, with a 24.49% coverage and a score of 
64.41 for BPP and a 5.16% coverage and a score of 9.70 for BOP. The 
discrepancy in the LC-MS/MS analysis of Nf in brain and in plasma samples may 
be explained by the differences in abundance of these proteins in brain and 
plasma but also by the way proteomics identifies and process signals related to 
defined proteins. The higher Nf abundance in brain enriched fraction compared 
to plasma, clearly translate into a higher level of detection Nf peptides in the ionic 
form (parental ion) during the first MS scan (MS1), which is then further enhanced 
by peptide fragmentation and spectrum acquisition in the second MS scan (MS2). 
In consideration of the better performance of BPP as shown by the overall protein 
coverage, number of unique peptides, total peptides, PSMs and score for protein 
group (Table 3.9 and Table 3.10), we have selected this enrichment protocol for 
those  experiments where quantitative proteomics is used for further 
characterization of NCHs in brain and plasma. To achieve this, as reported in the 
Chapter 5, we will use a pioneering proteomic technique, which allows 
simultaneous analysis of brain tissue and plasma samples, quantitative 
determination of protein expression and the identification of low-abundance 
proteins in the plasma matrix that are known to be expressed in and be relevant 
in brain function. 
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Sample Total 
spectra 
Total 
PSMs 
ID 
rate% 
Protein 
groups 
Coverage%/ 
protein group 
(mean) 
#Unique 
Peptides/ protein 
group (median) 
#Peptides/ 
protein group 
(median) 
#PSMs/ 
protein group 
(median) 
HC-PPS 
BPP 
325811 24577 7.54 382 29.09 5.00 7.00 10.00 
HC-PPS 
BOP 
296876 20834 7.02 306 28.67 5.00 6.00 13.00 
HC-PPS 
BPP 
(shared) 
   248 35.69 8.00 9.00 20.50 
HC-PPS 
BOP 
(shared) 
   248 31.19 6.00 8.00 18.00 
ALS-PPS 
BPP 
348125 32808 9.42 395 30.33 5.00 6.00 12.00 
ALS-PPS 
BOP 
283357 20469 7.22 297 28.69 5.00 6.00 13.00 
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Sample Total 
spectra 
Total 
PSMs 
ID 
rate% 
Protein 
groups 
Coverage%/ 
protein group 
(mean) 
#Unique 
Peptides/ protein 
group (median) 
#Peptides/ 
protein group 
(median) 
#PSMs/ 
protein group 
(median) 
ALS-PPS 
BPP 
(shared) 
   232 38.16 9.00 11.00 28.00 
ALS-PPS 
BOP 
(shared) 
   232 31.38 7.00 8.00 20.00 
Table 3.9. Liquid Chromatography coupled with tandem Mass Spectrometry (LC-MS/MS) analysis of the NCHs enriched fractions obtained from the Healthy 
Control-Pooled Plasma Sample (HC-PPS) and ALS-Pooled Plasma Sample (ALS-PPS) using the BPP and BOP enrichment protocols: proteomic 
performance and protein groups defined by Proteome Discoverer 1.4 (PD). 
Protein groups (proteins in which the peptides identified by LC-MS/MS are grouped as result of sequence redundancy) identified within the aggregate fractions obtained 
from HC-PPS and ALS-PPS using BPP and BOP methods. The shared fractions included only the protein isoforms in common and not the parental proteins. The 
Coverage% values were normally distributed and the mean was used for comparison. 
HC-PPS BPP: NCHs enriched fraction obtained from HC-PPS by BPP protocol 
HC-PPS BOP: NCHs enriched fraction obtained from HC-PPS by BOP protocol 
ALS-PPS BPP: NCHs enriched fraction obtained from ALS-PPS by BPP protocol 
ALS-PPS BOP: NCHs enriched fraction obtained from ALS-PPS by BOP protocol 
PSMs: Peptide-Spectrum Matches 
Total spectra: number of spectra acquired at MS2 level 
Total PSMs: number of Peptide-Spectrum Matches identified by PD 
107 
 
ID rate% (Identification rate): PSMs/total spectra 
Protein groups: number of proteins identified by the Parsimony Principle in PD 
Coverage%/protein group: the coverage% per protein identified (mean) 
#Unique Peptides/protein group: number of unique peptides per protein identified (median) 
#Peptides/protein group: number of peptides (unique and not unique) per protein identified (median) 
#PSMs/protein group: number of PSMs per protein identified (median) 
Sample Total 
spectra 
Total 
PSMs 
ID 
rate% 
Protein 
groups 
Coverage%/ 
protein group 
(mean) 
#Unique 
Peptides/ 
protein group 
(median) 
#Peptides/ 
protein group 
(median) 
#PSMs/ 
protein 
group 
(median) 
Score 
(mean) 
Brain BPP 4916 1370 27.87 52 11.67 5.00 8.00 13.00 59.85 
Brain 
BOP 
4939 749 15.17 51 12.81 2.00 6.00 10.00 54.77 
Brain BPP 
(shared) 
   27 13.91 8.00 10.00 22.00 71.76 
Brain 
BOP 
(shared) 
   27 9.92 5.00 7.00 9.00 32.39 
Table 3.10. Liquid Chromatography coupled with tandem Mass Spectrometry (LC-MS/MS) analysis of the NCHs enriched fraction obtained from the Brain 
sample with BPP and BOP enrichment protocols: proteomic performance and protein groups defined by Proteome Discoverer 1.4 (PD). 
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Protein groups (proteins in which the peptides identified by LC-MS/MS are grouped as result of sequence redundancy) identified within the aggregate fractions obtained 
from the Brain sample using BPP and BOP methods. The shared fractions included only the protein isoforms in common and not the parental proteins. The Coverage% 
values were normally distributed and the mean was used for comparison. 
Brain BPP: NCHs enriched fraction obtained from Brain sample by BPP protocol 
Brain BOP: NCHs enriched fraction obtained from Brain sample by BOP protocol 
PSMs: Peptide-Spectrum Matches 
Total spectra: number of spectra acquired at MS2 level 
Total PSMs: number of Peptide-Spectrum Matches identified by PD 
ID rate% (Identification rate): PSMs/total spectra 
Protein groups: number of proteins identified by the Parsimony Principle in PD 
Coverage%/protein group: the coverage% per protein identified (mean) 
#Unique Peptides/protein group: number of unique peptides per protein identified (median) 
#Peptides/protein group: number of peptides (unique and not unique) per protein identified (median) 
#PSMs/protein group: number of PSMs per protein identified (median) 
Score: score given by the SEQUEST-HT algorithm in PD per protein identified (mean) 
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3.8 Conclusion 
In this chapter, we have tested methodologies for the extraction and for the 
molecular characterization of protein aggregates containing neurofilaments in 
blood and in brain tissue.  To this end, we have used gel-separation and 
immunodetection by western blot (WB) to confirm the presence of high-molecular 
weight circulating neurofilament-containing heteroaggregates (NCHs) in blood 
and applied TEM to obtain a visual confirmation of the presence of these 
macromolecular structures and of their content in neurofilaments in enriched 
fractions from pooled plasma. Finally, LC-MS/MS was used to define the protein 
composition of these aggregates and to look at how these protein profiles differ 
between healthy and pathological state, as well as between blood and brain 
tissue. 
As the conceptual framework of disease biomarkers evolves, circulating protein 
aggregates may become increasingly important as they convey information on 
proteinopathies and may relate to specific organ pathologies. Most of the 
experimental work produced so far on the detection and quantification of protein 
aggregates was undertaken in tissues and cell systems (112–115). In the field of 
neurodegeneration, for example, protein aggregates are formed starting by 
specific “seed” proteins like Tau, Abeta and amyloid-like polyglutammine which 
are normally isolated using ultracentrifugation, membrane filter assays and 
magnetic‐bead immunoaffinity pulldowns, with little attention for the wide range 
of other co‐aggregated proteins (112–115). The emerging evidence that different 
stages of protein aggregation can be seen also in biofluids and the idea that this 
phenomenon could somehow reproduce brain pathology moved this field of 
investigation towards the characterisation of the fibrillary and aggregated state of 
proteins as potential disease biomarkers (116). The development of sound 
methodologies for the isolation and characterization of protein aggregates from 
biofluids is therefore critical not only for diagnostic purposes but also for the study 
of protein aggregates forming as by-products of industrial production protein-
based therapies, a major problem in the commercialisation of new monoclonal-
antibodies (Ab) therapies (117,118). 
Our data not only show unequivocally that Nf proteins are entangled within high 
MW complexes in plasma as previously anticipated (46,53), but also strengthen 
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the hypothesis that NfH is more likely to be sequestered into these circulating 
aggregates, while smaller and perhaps less complex Nf isoforms like NfL do not, 
in line with the reported NfL linearity when tested by immunodetection in dilution 
curves compared to the hook effect seen with NfH in the same experiments (47). 
However, despite the fact that the gel-based separation and WB analysis of Nf 
isoforms confirm Nf proteins inclusion (particularly of NfH) in high molecular 
weight formations extracted from plasma, our proteomic MS study did not identify 
Nf proteins in the NCHs protein mix obtained from plasma, while these three Nf 
isoforms were detected in brain derived NCHs. A part from the low abundance of 
Nf proteins in plasma in respect of the entire plasma proteome, failure to identify 
Nf in NCHs by proteomics may be also explained by the fact that these proteins 
are subjected to a variety of PTM (119,120). The KSP (Lysine-Serine-Proline) 
repeats positioned in the Nf tail is the site of most post-translational modifications 
in Nf peptides which may escape detection using MS-based proteomics (121–
123). To test this hypothesis, in a second run of bioinformatic analysis the 
unmatched spectra were searched against a database inclusive only of Nf 
sequences, targeting the two main PTMs: phosphorylation and N-glycosilation. 
This approach did not generate good PSMs as statistical analysis was weakened 
by the relatively small size of the source database. In fact, due to the redundant 
nature of the Nf-enriched database, decoy sequences deriving from this database 
would be biased, estimating a wrong False Discovery Rate (FDR). Another 
obstacle to the Nf identification by proteomics was the effect of tryptic digestion 
on KSP repeat. This is known to generate a considerable number of small 
peptides (between 3 and 5 aminoacids) which are not readily detectable by MS 
proteomics, in particular in the case of NfH where KSP repeats are more 
abundant than in other Nf isoforms. It is also possible that plasma Nf escaped 
detection by proteomics because of lower digestion yield by trypsin, generating 
peptides that are too big for the parameters set for proteomics analysis (69). To 
this end, it can be hypothesized that Nf found in circulating protein complexes 
may have a modified protease resistance which conditions their propensity to 
form aggregates. This concept will be further explored in the work detailed in this 
Thesis. 
In this part of the study, the project was focused on assessing the existence of 
blood NCHs, in line with the observation that protein aggregation and the 
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formation of NCHs may occur physiologically. It is possible to hypothesise that 
any organ-specific or systemic pathological state involving protein catabolism or 
homeostasis may be reflected on the composition and eventually conformation 
of these circulating complexes, providing a potential disease signature for clinical 
monitoring and therapeutics. Also, in addition to gel-based separation which has 
allowed the sizing of these circulating complexes, TEM has provided further 
insight into the structure of these macromolecular formations whose appearance 
on EM may depend also on the methodology used for aggregate separation from 
the pooled plasma. While these aggregates appear mostly as globular 
electrondense complexes when extracted by UC, the SEP methodology seems 
to generate more fibrous structures. As already mentioned, the use of affinity 
capture with the SEP binders may cover a broader range of proteins and 
polymers in different stages of aggregation which end up in the final extraction 
product. The presence of salt contaminants in the final pellet (Figure 3.7F) may 
also play a part in the conformation of the macromolecular complexes found in 
the pellet. Additional TEM analysis will have to be undertaken in order to better 
define these circulating macromolecular structures. Our preliminary IG-TEM 
analysis will need to include a range of quality controls, including aggregates 
generated by heat and sheer stress of Nf proteins and of 
immunoglobulins/immunocomplexes. Nevertheless, the role of TEM in our study 
was to confirm the presence of macromolecular formations supporting our 
enrichment strategy and the data obtained by gel-separation. Further 
experiments by IG-TEM aimed at obtaining a better characterization of Nf 
proteins content in NCHs will be needed to optimize this technique for detection 
and characterization of NCHs. These experiments will have to include quality 
controls in the form of standard proteins and aggregate formations that can be 
obtained out of heat or shear stress treatment of protein, antibodies or 
immunocomplexes (REFERENCE https://microsensbp.com/wp-
content/uploads/2015/08/Generation-of-protein-aggregates.pdf and confidential 
communication by Diagenode). The use of sizing technologies exploiting light 
diffraction like dynamic light scattering (DLS) or newer tracking methodologies for 
poly-disperse nanoparticles like nanoparticles tracking analysis (NTA) may also 
be  used in the analysis of NCHs, particularly if conformational changes of these 
112 
 
formations which may have an impact in the disease progression are expected 
to occur in the development of a pathological state (124). 
To conclude, BPP appears to be superior to other extraction methods and it 
provides higher quality of the data on NCHs acquired by LC-MS/MS. Since MS-
based proteomics is the main methodological approach in this project, BPP will 
be used as the method of choice for NCHs enrichment. This extraction method 
will support further investigations outlined in this Thesis into NCHs as potential 
biological substrates of neurodegeneration. A reliable method to extract these 
macromolecular complexes from biological fluids is essential to further our 
knowledge on the role of these formations in health and disease. However, the 
experimental data acquired so far do not answer questions related to the specific 
origin of the aggregates constituents and about the tissue/fluid environmental 
conditions which facilitate their formation.   
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4 Neurofilaments-containing hetero-aggregates (NCHs) 
in ALS and Healthy Controls plasma samples 
4.1 Introduction and aims 
The presence of protein aggregates in brain is a hallmark of neurodegeneration 
(125). However, the assemblement of molecules into macromolecular structures 
can be observed also in blood and may occur also under non-pathological 
conditions (126). Circulating aggregates in blood contain proteins that can be 
relevant as biomarkers of neurodegeneration, such as Neurofilaments (Nf), but 
as previously shown in Chapter 3, they also include proteins that are involved in 
physiological responses like inflammation and metabolism, as well as in a number 
of biochemical changes which are known to occur in defined pathological 
conditions at a systemic and cellular level. 
In this chapter, we aim at providing a biological interpretation of the data outlined 
in Chapter 3. We will define the changes in Neurofilament-Containing 
Heteroaggreagates (NCHs) protein composition which occur in a 
neurodegenerative condition like Amyotrophic Lateral Sclerosis (ALS), using the 
NCHs proteome of HC as reference. Our goal is also to incorporate in the 
comparative analysis of protein aggregates those extracted from brain, extending 
from the preliminary data anticipated in Chapter 3. 
To study NCHs and evaluate changes related to the establishment of a 
pathological state like amyotrophic lateral sclerosis (ALS), pooled plasma sample 
from ALS patients (ALS-PPS; Table 3.8) and from healthy controls (HC-PPS; 
Table 3.1) were investigated along with NCHs extracted from brain of patients 
suffering from ALS. The brain NCHs analysis did not include a comparison with 
a healthy brain. Nevertheless, brain aggregates composition in ALS was used as 
the reference to evaluate any molecular feature in circulating NCHs that could 
mirror brain pathology and be specific of neurodegeneration. 
4.2 NfH in pooled plasma samples (PPS) 
Western Blot (WB) and immunogold transmission electron microscopy (IG-TEM) 
data to evaluate the NCHs enrichment process has shown that Neurofilament 
Heavy (NfH) has a higher tendency to assemble within aggregates than other Nf 
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proteins including Nf medium chain (NfM) and light chain (NfL). For this reason, 
NfH was chosen as target Nf isoform for the experiments described below (Figure 
4.1). 
Unprocessed pooled plasma samples from ALS and HC showed the same NfH 
bands profile with the highest band at 460 KDa which may represent a NfH dimer 
in blood (Figure 4.1, lane 9 and 10). When comparing ALS-PPS and HC-PPS 
products of extraction (final pellets) resolved in urea and PBS it was possible to 
appreciate a different profile: ALS-PPS and HC-PPS presented NfH bands at 238 
KDa and at much higher MW, while only ALS-PPS showed bands at 117 and 60 
KDa which may represent NfH fragments (Figure 4.1, lane 1 and 2). 
 
Figure 4.1. Neurofilament Heavy (NfH) content in ALS-Pooled Plasma Sample (ALS-PPS) 
and Healthy Control-Pooled Plasma Sample (HC-PPS).  
NfH Western Blot (WB) (left hand side; already reported in Figure 3.8), showing Neurofilament-
Containing Heteroaggregates (NCHs) enriched from HC-PPS and ALS-PPS (lane 1 to 8, from left 
to right hand side). Lanes 9 and 10 show the NfH content in pooled plasma samples from ALS 
and HC before enrichment. Lane 7 and 8 show the NfH content in the pellet after the plasma 
benchtop centrifugation, lanes 5 and 6 show the NfH content in the pellet after the first 
ultracentrifugation (UC) step, while lanes 1 to 4 show the NfH content in the final NCHs enriched 
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fractions using two different buffers to resuspend the pellets: PBS (lanes 2 and 4) and 8 M urea 
(lanes 1 and 3). The different NfH level in ALS-PPS and HC-PPS is shown in the chart (right hand 
side). The bars represent the ALS/HC ratio of the sum of all the intensities obtained from anti-NfH 
bands in plasma samples and NCHs enriched fractions lanes treated with both PBS and 8 M 
urea. ALS/HC ratio is always higher than 1, which indicates that NfH content in ALS-PPS is always 
higher than HC-PPS in all the fractions under investigation. 
The NfH content in ALS-PPS unprocessed plasma was higher than the HC-PPS 
sample (ALS/HC intensity ratio = 1.35) (Figure 4.1). This observation was in line 
with previous NfH plasma analysis performed on big ALS and HC cohorts 
(46,127,128). This datum also supports the use of ALS-PPS and HC-PPS as test-
bed for preliminary data acquisition because they represent ALS/HC differences 
already described in the literature. The same magnitude of difference was shown 
by the NfH NCHs resuspended in PBS, supporting the idea that plasma NCHs 
can carry information related to neurology conditions (Figure 4.1). Using 8 M urea 
to resuspend plasma NCHs increased significantly NfH detection (as described 
in Paragraph 3.6) as well as the ALS/HC intensity ratio in ALS-PPS sample 
(Figure 4.1), supporting the hypothesis that NCHs carries valuable biomarkers 
for diagnosis of neurodegenerative processes. Unfortunately, the use of 8 M urea 
is not compatible with the chemical conditions required for immunodetection in 
high throughput techniques such as ELISA. 
4.3 Different NCHs composition in ALS and healthy states 
As previously reported in Paragraph 3.7.1, NCHs enriched from ALS-PPS and 
HC-PPS were analysed by Liquid Chromatography coupled with tandem Mass 
Spectrometry (LC-MS/MS) after in-gel trypsin digestion. Briefly, the two samples 
were run by electrophoresis in a gradient gel for protein separation, followed by 
fractionation in ten gel parts for each sample. Each fraction underwent disulphide 
bonds reduction with dithiothreitol (DTT) and alkylation with iodoacetamide (IAA) 
and then protein digestion by trypsin. The peptides generated were extracted by 
dehydration-hydration steps and the samples obtained freeze-dried. Each 
fraction was then reconstituted and injected into the instrument and protein 
identification was then performed with Proteome Discoverer 1.4 (PD). 
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Figure 4.2. Protein groups identified by Proteome Discoverer 1.4 (PD) in NCHs enriched 
from ALS-PPS and HC-PPS.  
The Venn diagram shows the number (with relative percentage of the total number of proteins) of 
proteins uniquely identified by MS-based proteomics of ALS-PPS and HC-PPS, with the 
intersection of the two groups displaying the number (and percentage) of proteins identified in 
both samples. The criteria of peptide selection: minimum peptide confidence: High; minimal 
number of peptides: 2; count only rank 1 peptides: false, count peptide only in top scored proteins: 
True. 
Following protein identification with PD and filtering out for keratins 
(contaminant), 367 protein groups were identified in NCHs from ALS-PPS and 
363 in NCHs from HC-PPS (Figure 4.2). No Nf proteins were detected in either 
of the two samples. 264 (57.9% of the total) proteins were shared by the two 
samples (here defined as shared), while 103 (22.6%) were found only in ALS-
PPS (defined as unique ALS) and 89 (19.5%) in HC-PPS (defined as unique 
Controls) (Figure 4.2). Secondary isoforms (defined by alternative splicing of the 
same gene) of the three protein lists were generated for unique ALS, unique HC 
and shared protein groups and then converted into the main isoforms by altering 
the Uniprot ID (e.g. P02679-2 was converted into P02679) before any functional 
analysis. This was done because web tools such as Webgestalt or PANTHER do 
not recognize isoform IDs, effectively introducing a bias in the functional analysis 
by ignoring part of the information acquired by LC-MS/MS.  
We now examine the differences between the ALS and healthy control state in 
NCHs protein compositions, to pinpoint the biochemical pathways underpinned 
by the protein aggregation process in ALS-PPS and HC-PPS. In order to define 
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the biological differences, functional analysis was performed on Webgestalt (108) 
for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment 
(Table 4.1, Table 4.2 and Table 4.3). 
The ALS-PPS and HC-PPS shared proteome functional analysis showed the 
enrichment of pathways  related to the immune system and its activation 
(complement and coagulation cascades, staphylococcus aureus infection, 
pertussis, systemic lupus erythematosus, pathogenic Escherichia coli infection, 
phagosome and amoebiasis, Table 4.1), while the remaining pathways were 
mostly linked to cell to cell interaction (ECM-receptor interaction and focal 
adhesion) and prion diseases. Looking at the statistical significance, FDR values 
for the top10 pathways were below the usual cut-off of statistical significance 
(FDR < 0.1) (Table 4.1). Other biochemical pathways were significantly enriched 
in the shared protein list including vitamin digestion and absorption, malaria, 
peroxisome proliferator-activated receptors (PPAR) signalling pathway and 
African trypanosomiasis.  
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Gene set Pathway 
description 
Number of 
genes in the 
category 
Number of 
genes matched 
in the category 
Expected 
number of genes 
in the category 
Ratio of 
enrichment 
p-Value FDR 
hsa04610 Complement and 
coagulation 
cascades 
79 45 1.40 32.06 0.00E+00 0.00E+00 
hsa05150 Staphylococcus 
aureus infection 
56 15 0.99 15.08 2.07E-14 3.13E-12 
hsa05133 Pertussis 76 14 1.35 10.37 4.04E-11 4.08E-09 
hsa05020 Prion diseases 35 10 0.62 16.08 2.74E-10 2.08E-08 
hsa05322 Systemic lupus 
erythematosus 
135 16 2.40 6.67 1.45E-09 8.80E-08 
hsa04512 ECM-receptor 
interaction 
82 11 1.46 7.55 1.72E-07 8.68E-06 
hsa05130 Pathogenic 
Escherichia coli 
infection 
55 9 0.98 9.21 4.21E-07 1.82E-05 
hsa04145 Phagosome 154 13 2.74 4.75 2.94E-06 1.11E-04 
hsa04510 Focal adhesion 203 14 3.61 3.88 1.29E-05 4.33E-04 
hsa05146 Amoebiasis 100 9 1.78 5.07 6.44E-05 1.95E-03 
Table 4.1. Top10 enriched KEGG pathways identified in the ALS-PPPS and HC-PPS share proteins. 
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Gene set: KEGG pathway code 
Pathway description: KEGG pathway’s name 
Number of genes in the category: number of genes included in the given KEGG pathway in Homo sapiens database 
Number of genes matched in the category: number of genes identified in the given KEGG pathway 
Expected number of genes in the category: calculated as the number of genes submitted divided by the number of the total homo sapiens genes involved in all 
the KEGG pathway database and multiplied by the number of genes in the category 
Ratio of enrichment: calculated as the number of genes matched in the category divided by the expected number of genes in the category 
p-Value: statistical significance calculated by the Fisher’s exact test 
FDR (False Discovery Rate): calculated from the p-Value adjusted with Benjamini and Hochberg method (109)  
120 
 
Gene set Pathway description Number of 
genes in the 
category 
Number of genes 
matched in the 
category 
Expected number 
of genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa04512 ECM-receptor 
interaction  
82 8 0.63 12.61 1.72E-07 5.23E-05 
hsa04610 Complement and 
coagulation cascades  
79 5 0.61 8.18 3.35E-04 3.49E-02 
hsa03050 Proteasome  44 4 0.34 11.75 3.46E-04 3.49E-02 
hsa04510 Focal adhesion 203 7 1.57 4.46 8.82E-04 6.68E-02 
hsa04145 Phagosome  154 6 1.19 5.04 1.13E-03 6.84E-02 
hsa04611 Platelet activation 122 5 0.94 5.30 2.40E-03 1.21E-01 
hsa04640 Hematopoietic cell 
lineage 
97 4 0.75 5.33 6.52E-03 2.82E-01 
hsa05150 Staphylococcus 
aureus infection  
56 3 0.43 6.92 9.09E-03 3.44E-01 
hsa00030 Pentose phosphate 
pathway  
30 2 0.23 8.62 2.23E-02 7.49E-01 
hsa04810 Regulation of actin 
cytoskeleton  
216 5 1.67 2.99 2.51E-02 7.60E-01 
Table 4.2. Top10 enriched KEGG pathways identified in the Unique ALS-PPS protein list. 
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Gene set: KEGG pathway code 
Pathway description: KEGG pathway’s name 
Number of genes in the category: number of genes included in the given KEGG pathway in Homo sapiens 
Number of genes matched in the category: number of genes identified in the given KEGG pathway 
Expected number of genes in the category: calculated as the number of genes submitted divided by the number of the total homo sapiens genes involved in all 
the KEGG pathway database and multiplied by the number of genes in the category 
Ratio of enrichment: calculated as the number of genes matched in the category divided by the expected number of genes in the category 
p-Value: statistical significance calculated by the Fisher’s exact test 
FDR (False Discovery Rate): calculated from the p-Value adjusted with Benjamini and Hochberg method (109)
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KEGG database is generally used for the analysis of groups of genes and of 
genome information to uncover their functional role in biological systems. It 
contains information on several organisms and it is extensively used in different 
areas of research (131). Most of the pathways identified through KEGG analysis 
of the proteins contained in plasma NCHs from ALS patients are also represented 
among those identified in the shared protein list (Table 4.1 and Table 4.2), 
including ECM-receptor interaction, complement and coagulation cascades, focal 
adhesion, phagosome and staphylococcus aureus infection. These are mostly 
linked to the immune system and its activation (Complement and coagulation 
cascades, phagosome, platelet activation, hematopoietic cell lineage and 
staphylococcus aureus infection) but also to cell to cell interaction (ECM-receptor 
interaction, focal adhesion and regulation of actin cytoskeleton), protein 
degradation (proteasome) and energetic metabolism (pentose phosphate 
pathway) (Table 4.2). Importantly, when setting the significance level cut-off at 
false discovery rate (FDR) < 0.1, the proteasome pathway was the only pathway 
uniquely enriched in the ALS-PPS and not shared with the HC-PPS (Figure 4.3). 
 
Figure 4.3. Proteasome KEGG pathway (hsa03050).  
The figure shows the proteasome KEGG pathway with squared rectangles representing gene 
products (e.g. proteins). The boxes filled in green indicate the genes/proteins involved in the 
pathway in Homo sapiens and those in outlined in blue and filled in red are the genes/proteins 
identified in our ALS-PPS proteome. The subunits of the Core Particles in the 20S proteasome 
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α2, α5, α6 and β6 are linked to proteasome subunit alpha type-2 (PSMA2), proteasome subunit 
alpha type-5 (PSMA5), proteasome subunit alpha type-6 (PSMA6) and proteasome subunit beta 
type-1 (PSMB1), respectively.
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Gene set Pathway description Number of 
genes in the 
category 
Number of genes 
matched in the 
category 
Expected number 
of genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa00010 Glycolysis / 
Gluconeogenesis  
67 7 0.54 13.02 8.73E-07 2.65E-04 
hsa01200 Carbon metabolism 114 8 0.91 8.75 2.93E-06 3.43E-04 
hsa00030 Pentose phosphate 
pathway  
30 5 0.24 20.77 3.39E-06 3.43E-04 
hsa01230 Biosynthesis of amino 
acids  
75 5 0.60 8.31 3.12E-04 2.37E-02 
hsa03010 Ribosome  135 5 1.08 4.62 4.36E-03 2.64E-01 
hsa05134 Legionellosis  55 3 0.44 6.80 9.56E-03 4.83E-01 
hsa04510 Focal adhesion  203 5 1.63 3.07 2.28E-02 8.63E-01 
hsa00020 Citrate cycle (TCA 
cycle)  
30 2 0.24 8.31 2.38E-02 8.63E-01 
hsa04512 ECM-receptor 
interaction  
82 3 0.66 4.56 2.77E-02 8.63E-01 
hsa00051 Fructose and mannose 
metabolism  
33 2 0.26 7.55 2.85E-02 8.63E-01 
Table 4.3. Top10 enriched KEGG pathways identified in the Unique HC-PPS protein list. 
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Gene set: KEGG pathway code 
Pathway description: KEGG pathway’s name 
Number of genes in the category: number of genes included in the given KEGG pathway in Homo sapiens 
Number of genes matched in the category: number of genes identified in the given KEGG pathway 
Expected number of genes in the category: calculated as the number of genes submitted divided by the number of the total homo sapiens genes involved in all 
the KEGG pathway database and multiplied by the number of genes in the category 
Ratio of enrichment: calculated as the number of genes matched in the category divided by the expected number of genes in the category 
p-Value: statistical significance calculated by the Fisher’s exact test 
FDR (False Discovery Rate): calculated from the p-Value adjusted with Benjamini and Hochberg method (109)
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Fewer enriched pathways (Table 4.3) were identified in the HC-PPS gene list 
which were also detected in the shared list (focal adhesion and ECM-receptor 
interaction (Table 4.1) and in the ALS Unique list (pentose phosphate pathway) 
(Table 4.2). Most of the enriched pathways found in the HC-PPS gene list were 
related to energy metabolism, including glycolysis/gluconeogenesis, carbon 
metabolism, pentose phosphate pathway, TCA cycle and fructose and mannose 
metabolism, with a smaller number linked to cell to cell interaction like focal 
adhesion and ECM-receptor interaction, legionellosis, biosynthesis of amino 
acids and ribosome (Table 4.3). With a significance level set at FDR < 0.1, only 
glycolysis/gluconeogenesis (Figure 4.4), carbon metabolism (Figure 4.5), 
pentose phosphate pathway (Figure 4.6) and biosynthesis of amino acids (Figure 
4.7) were found to be enriched only in the HC sample.  
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Figure 4.4. Glycolysis/gluconeogenesis KEGG pathway (hsa00010).  
The figure shows the Glycolysis/gluconeogenesis pathway with squared rectangles representing 
gene products (e.g. proteins), rounded rectangles representing maps (e.g. other pathways) and 
small circles representing chemical compounds. Filled head arrows point to molecular interactions 
or relations and empty head arrows represent link to or from another map. The objects filled in 
green indicate the genes/proteins involved in the pathway in Homo sapiens, and those outlined 
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in blue and filled in red indicate genes/proteins identified in our ALS-PPS proteome. 5.4.2.2, 
5.3.1.9, 4.1.2.13, 5.3.1.1, 2.7.2.3, 5.4.2.11, 1.1.1.27 represent phosphoglucomutase-2 (PGM2), 
glucose-6-phosphate isomerase (GPI), fructose-bisphosphate aldolase A (ALDOA), 
triosephosphate isomerase (TPI1), phosphoglycerate kinase 1 (PGK1), phosphoglycerate 
mutase 1 (PGAM1), L-lactate dehydrogenase A chain (LDHA), respectively. 
 
Figure 4.5. Carbon metabolism KEGG pathway (hsa01230).  
The figure shows the Carbon metabolism pathway with circles representing the intermediate 
molecules and the number within the circle representing the number of carbons for each 
intermediate, while arrows represent the reactions carried out from the enzymes involved in this 
pathway. The green  arrows indicate the enzymes involved in the pathway in Homo sapiens, while 
the red arrows point to those proteins/enzymes which belong to the HC-PPS unique protein list  
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(triosephosphate isomerase, TPI1; fructose-bisphosphate aldolase A, ALDOA; phosphoglycerate 
kinase 1, PGK1; phosphoglycerate mutase 1, PGAM1; dihydrolipoyllysine-residue 
succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial, DLST; 
transketolase, TKT; glucose-6-phosphate isomerase, GPI; 2-oxoglutarate dehydrogenase, 
mitochondrial, OGDH). 
 
Figure 4.6. Pentose phosphate KEGG pathway (hsa00030).  
The figure shows the Pentose phosphate pathway with squared rectangles representing gene 
products (e.g. proteins), rounded rectangles representing maps (e.g. other pathways), small 
circles representing chemical compounds, while filled head arrows indicate molecular interaction 
or relation and empty head arrows the links to or from another map. The objects filled in green 
indicated the genes/proteins involved in the pathway in Homo sapiens and those outlined in blue 
and filled in red indicate the genes/proteins found in the HC-PSS proteome. 5.3.1.9, 4.1.2.13, 
2.2.1.1, 4.1.2.4, represented glucose-6-phosphate isomerase (GPI), fructose-bisphosphate 
aldolase A (ALDOA), transketolase (TKT), deoxyribose-phosphate aldolase (DERA), 
respectively. 5.4.2.2 and 5.4.2.7 were both representing phosphoglucomutase-2 (PGM2). 
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Figure 4.7. Biosynthesis of amino acids KEGG pathway (hsa01200).  
The figure shows the Biosynthesis of amino acids pathway with circles representing the 
intermediate molecules while arrows indicate the reactions carried out by the enzymes involved 
in this pathway. The green arrows indicate the enzymes involved in the pathway in Homo sapiens, 
while the red arrows point to the proteins/enzymes identified in the HC-PPS proteome, including 
triosephosphate isomerase, TPI1; fructose-bisphosphate aldolase A, ALDOA; phosphoglycerate 
kinase 1, PGK1; phosphoglycerate mutase 1 and PGAM1; transketolase, TKT. 
Interestingly, none of the proteins belonging to the “biosynthesis of amino acids” 
pathway were directly involved in the biosynthesis of amino acids but were mostly 
key molecules in the production of ribose-5 phosphate and phosphoenolpyruvate, 
which are also intermediates in the other pathways found to be enriched in our 
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Unique HC-PPS proteome. This may indicate that the biosynthesis of amino acids 
pathway is identified in the functional analysis only because of proteins frequently 
recurring in other pathways and not because of the identification of proteins which 
are exclusively represented in this pathway. 
An enrichment analysis was performed to highlight over-represented functional 
terms within each of the datasets, taking all human protein-coding genes as the 
basis and theoretical background for the analysis (132). A specific KEGG 
pathway was considered enriched if the number of genes represented in that 
category (k) was higher than the expected enrichment value (ke). This value is 
calculated by the number of genes in the submitted gene list (n) (e.g. the 103 
genes represented in the unique ALS protein list) divided by the number of genes 
in the reference gene list (m) (e.g. the 6979 genes representing the entire KEGG 
pathway database) and multiplied by the number of genes represented in a given 
category within the reference gene list (j) (e.g. the 44 genes involved in the 
proteasome pathway in the KEGG pathway database).  
𝑘𝑒 =
𝑛
𝑚
∗ 𝑗 
Since the gene sets are independent, if ke is lower than k then the category is 
considered enriched and based on statistical analysis by Fisher’s exact test (132).  
However, in our analysis the aim was to evaluate if the proteins exclusively 
identified in one of the two samples were representative of exclusive pathways in 
one of the two conditions (ALS or HC) rather than a bigger and wider proteome, 
like the one represented by the KEGG pathway database. For this reason a 
subsequent enrichment analysis was performed where the entire protein list 
obtained from the ALS sample was considered as the reference gene set and the 
unique ALS protein list was the submitted gene list. For this evaluation only the 
enriched KEGG pathways listed in Table 4.2 with FDR < 0.1 were considered. As 
a result, the “complement and coagulation cascades” pathway was no longer 
considered enriched as the number of genes represented in this pathway was 
lower than the expected value (k < ke). Because in our specific analysis the two 
gene data sets were not independent,  to test the enrichment at a statistical level, 
we have performed a hypergeometric test (132). The proteasome pathway 
emerged as the only one with a significant p-value (p=0.028), while ECM-receptor 
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interaction (p=0.084), focal adhesion (p=0.177) and phagosome (p=0.204) were 
not statistically significant. The same was applied to the HC data set using the 
entire protein list as the reference gene set to evaluate the enrichment in the 
Unique HC list. All pathways with FDR < 0.1 (Table 4.3) were again found 
enriched, but after significance of enrichment analysis as reported above, only 
glycolysis/gluconeogenesis (p=0.009), pentose phosphate pathway (p=0.003) 
and carbon metabolism (p=0.008) were considered significantly enriched, while 
biosynthesis of amino acids (p=0.08) was not significant. This approach provided 
a strong basis to consider these four pathways as representative for the 
difference in NCHs composition between ALS and healthy state.  
4.4 LC-MS/MS analysis of Brain NCHs 
The methodology for extraction of NCHs from brain has already been detailed in 
Paragraph 2.2.2.1. Briefly, two brain samples (Brain1 and Brain2) were 
homogenised and pooled as described in Paragraph 2.1.2.1 and NCHs 
enrichment performed according to the Brain-Plasma Protocol (BPP; Paragraph 
2.2.2.1). The final product of NCHs enrichment and the samples collected during 
the intermediate steps of the extraction process were evaluated by WB for the 
presence of Nf proteins (Figure 4.8). 
 
Figure 4.8. Neurofilament (Nf) content in aggregate fractions extracted from Brain 
examined by Western Blot analysis (WB): neurofilament-containing heteroaggregates 
(NCHs) 
Each fraction obtained using the Brain-Plasma Protocol (BPP) aggregate enrichment protocol 
and products obtained in the intermediate steps of enrichment were loaded into a gradient gel to 
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evaluate Nf Heavy (NfH; A), Nf Medium (NfM; B) and Nf Light (NfL; C) protein content. The anti-
NfH blot (A) showed the presence of NfH at the expected molecular weight in each fraction (lanes 
1 to 5), with the main band at around 238/268 KDa. Anti-NfM blot showed a band between 117 
and 171 KDa in lanes 1, 2, 4 and 5, while anti-NfL blot detected NfL bands at approximately 55 
Kda only in lanes 1 and 2. Lanes: 1, Brain aggregates enriched fraction; 2, pellet after the first 
ultracentrifugation (UC) step; 3, supernatant after the first UC step; 4, Brain sample after 
homogenisation; 5, Brain debris after homogenization as described in 2.1.2.1. 
NfH was detected at different MW with the most intense band at the 238/268 KDa 
(Figure 4.8A). A band was also detected at around 50 KDa in Brain debris (lane 
5, Figure 4.8A), in the brain sample (lane 4, Figure 4.8A) and supernatant after 
the first ultracentrifugation (UC) step of the Brain-Plasma Protocol (BPP, lane 3, 
Figure 4.8A), but not in the pellet after the first UC and final NCHs enriched 
fraction (lane 2 and 1; Figure 4.8A). In addition, brain homogenate and brain 
supernatant after the first UC (Figure 4.8, lane 3 and 4) showed a smear (more 
evident in lane 4) of the main band and also additional faint bands below 460 
KDa, suggesting the presence of several NfH species (e.g. dimers) and 
complexes or NfH, which may have a different profile of post-translational 
modifications (PTMs) (Figure 4.8A).  
Importantly, the brain aggregates enriched fraction (lane 1) and the pellet after 
the first UC (lane 2) showed a long smear for high MW formations, confirming the 
enrichment of neurofilament-containing heteroaggregates (NCHs) in Brain 
(Figure 4.8A). All Nf protein isoforms seemed to be highly represented in the final 
fraction enriched with protein aggregates from Brain sample (lane 1 and 2, Figure 
4.8). NfM and NfL   were detected in the final fractions (lanes 1 and 2, Figure 4.8B 
and C) in the extraction process but had a very low expression (NfM; lane 3-5, 
Figure 4.8B) or were totally absent (NfL; lane 3-5, Figure 4.8B) in all intermediate 
products of the enrichment process. Overall, the analysis of Nf isoforms content 
in brain indicated, as already shown for circulating NCHs, that unlike NfM and 
NfL, NfH was present within high molecular weight complexes. 
4.4.1 Macromolecular structures in Brain NCHs 
In addition to the characterization of NCHs presence in brain by western blot, the 
same samples were analysed by transmission electron microscopy (TEM) to 
assess presence of macromolecular structures (Figure 4.9). Because of the high 
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background obtained in the varoious attempts of IG-TEM in plasma NCHs, 
immunolabelling was not performed with brain samples but analysis was limited 
to structure analysis by negative staining. 
 
Figure 4.9. TEM analysis of aggregates fraction extracted from brain. 
A representative micrograph showing an amorphous electron-dense formation on the left-hand 
side of the figure. The micrograph also shows the presence of short filamentous and small 
rounded formations. Scale bar on the low right corner of the figure. 
TEM analysis showed the presence of amorphous, globular electron-dense 
material in the aggregates enriched fraction prepared from ALS brain samples 
confirming the presence of macromolecular formations. In addition, brain 
micrograph showed other structures that were not revealed in plasma NCHs 
(Figure 4.10). These included filamentous shape with a curved appearance and 
rough-looking surface (Figure 4.10). These filamentous structures had a length 
ranging from 150 nm to more than 1 µm, while diameter ranged between 10 and 
15 nm. The other particles looked donuts-like, rounded with a hole in the middle 
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(Figure 4.10). These donut-like particles showed a diameter ranging between 20 
and 25 nm. 
 
Figure 4.10. Electron-dense formations identified in brain NCHs: filamentous and 
“donuts”-like appearance. 
The micrograph shows details of the filamentous and rounded structures in the aggregates 
enriched from brain. Scale bar on the low right corner. 
4.4.2 Analysis of brain NCHs proteome  
Further evaluation of the LC-MS/MS proteome of the aggregate-enriched fraction 
from ALS brains was undertaken (Paragraph 4.4). Following spectra acquisition, 
proteins were identified using proteome discoverer 1.4 (PD) and keratin proteins 
filtered out, generating a final list of 48 protein groups (Table 4.4). Selection 
criteria were the following: minimum peptide confidence: high; minimum number 
of peptides: 2, count only rank 1 peptides: false, count peptide only in top scored 
proteins: true. The three Nf protein isoforms were all identified in the proteome of 
the brain aggregates fraction. In particular, NfH was identified as isoform 2 with 
a sequence coverage of 19.52%. NfM had a sequence coverage of 20.85% and 
NfL 24.49%. Other ALS-relevant proteins such as Superoxide dismutase 1 
(SOD1) or TAR DNA-binding protein 43 (TDP-43), known also to be within 
pathological protein aggregates, were not identified. 
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Uniprot ID Protein name Score Coverage
% 
Proteins Unique 
Peptides 
Peptides PSMs 
O14594 Neurocan core protein  29.64 6.06 1 7 7 13 
O15020-2 Isoform 2 of Spectrin beta chain, non-erythrocytic 2  16.61 3.51 2 5 7 7 
O43301 Heat shock 70 kDa protein 12A  11.16 8.15 1 4 4 5 
O60641-4 Isoform 4 of Clathrin coat assembly protein AP180  46.88 10.38 2 8 8 17 
P04350 Tubulin beta-4A chain  65.81 26.35 1 4 10 27 
P07196 Neurofilament light polypeptide  65.78 24.49 1 10 13 26 
P07197 Neurofilament medium polypeptide  192.52 20.85 1 13 16 85 
P08670 Vimentin  8.20 6.44 1 2 3 4 
P11137-3 Isoform 3 of Microtubule-associated protein 2  62.12 7.9 2 11 11 22 
P12036-2 Isoform 2 of Neurofilament heavy polypeptide  158.61 19.52 2 14 17 66 
P12109 Collagen alpha-1(VI) chain  10.13 3.31 1 3 3 4 
P12110 Collagen alpha-2(VI) chain  16.05 5.59 1 5 5 7 
P12111-4 Isoform 4 of Collagen alpha-3(VI) chain  41.47 4.94 3 12 12 16 
P13611-4 Isoform V3 of Versican core protein  42.82 14.35 5 8 8 20 
P35579-2 Isoform 2 of Myosin-9  22.36 5.64 2 2 7 10 
P35580-3 Isoform 3 of Myosin-10  39.83 6.46 5 5 11 21 
P35749-4 Isoform 4 of Myosin-11  26.65 4.85 4 2 9 12 
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Uniprot ID Protein name Score Coverage
% 
Proteins Unique 
Peptides 
Peptides PSMs 
P46379-4 Isoform 4 of Large proline-rich protein BAG6  5.06 1.99 5 2 2 2 
P46459-2 Isoform 2 of Vesicle-fusing ATPase  7.07 6.68 2 3 3 4 
P60709 Actin, cytoplasmic 1  4.93 7.47 2 2 2 3 
P68363 Tubulin alpha-1B chain  71.92 32.82 1 3 11 29 
P68366-2 Isoform 2 of Tubulin alpha-4A chain  53.98 31.87 2 2 10 23 
Q00610-2 Isoform 2 of Clathrin heavy chain 1  602.89 57.72 2 66 66 282 
Q01082 Spectrin beta chain, non-erythrocytic 1  252.70 25.55 1 47 49 115 
Q01484 Ankyrin-2  48.98 4.9 1 17 17 23 
Q01813-2 Isoform 2 of ATP-dependent 6-
phosphofructokinase, platelet type  
6.05 2.71 2 2 2 2 
Q05193-3 Isoform 3 of Dynamin-1  30.73 10.58 4 8 8 11 
Q13813-3 Isoform 3 of Spectrin alpha chain, non-erythrocytic 1  301.11 29.2 3 58 58 130 
Q13885 Tubulin beta-2A chain  54.56 24.49 1 4 10 23 
Q14204 Cytoplasmic dynein 1 heavy chain 1  117.01 9.54 1 37 37 66 
Q15149-7 Isoform 7 of Plectin  115.33 8.99 8 35 35 45 
Q16352 Alpha-internexin  46.03 20.64 1 7 10 17 
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Uniprot ID Protein name Score Coverage
% 
Proteins Unique 
Peptides 
Peptides PSMs 
Q6DN90-2 Isoform 2 of IQ motif and SEC7 domain-containing 
protein 1  
4.95 2.14 2 2 2 2 
Q7Z4S6-6 Isoform 6 of Kinesin-like protein KIF21A  35.99 5.98 5 8 8 16 
Q8TDJ6 DmX-like protein 2  14.34 2.24 2 4 4 5 
Q8WXD9 Caskin-1  5.19 2.45 1 2 2 2 
Q92752 Tenascin-R  82.10 15.83 1 14 14 36 
Q96GW7 Brevican core protein  34.22 9.55 1 8 8 17 
Q99250 Sodium channel protein type 2 subunit alpha  10.27 1.75 2 3 3 4 
Q99490-2 Isoform 2 of Arf-GAP with GTPase, ANK repeat and 
PH domain-containing protein 2  
4.69 2.63 2 2 2 2 
Q9H2M9 Rab3 GTPase-activating protein non-catalytic 
subunit  
5.64 1.22 1 2 2 2 
Q9H2X9-2 Isoform 2 of Solute carrier family 12 member 5  31.31 9.77 2 10 10 19 
Q9H4G0-4 Isoform 4 of Band 4.1-like protein 1  2.97 4.28 3 2 2 2 
Q9UQM7 Calcium/calmodulin-dependent protein kinase type 
II subunit alpha  
8.65 5.23 2 2 2 3 
Q9Y2J2-2 Isoform 2 of Band 4.1-like protein 3  14.45 4.05 3 3 3 5 
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Uniprot ID Protein name Score Coverage
% 
Proteins Unique 
Peptides 
Peptides PSMs 
Q9Y4E6-2 Isoform 2 of WD repeat-containing protein 7  8.31 2.06 2 3 3 3 
Q9Y4I1-2 Isoform 2 of Unconventional myosin-Va  89.72 13.18 2 19 19 44 
Q9Y6D5 Brefeldin A-inhibited guanine nucleotide-exchange 
protein 2  
6.20 1.12 2 2 2 2 
Table 4.4. List of proteins identified by LC-MS/MS in brain aggregate fraction using Proteome Discoverer 1.4 (PD). 
The table shows proteins identified in brain aggregates by LC-MS/MS and relative detection features (e.g. score). The selection criteria applied were the following: 
minimum peptide confidence: high; minimal number of peptides: 2, count only rank 1 peptides: false, count peptide only in top scored proteins: true.  
Uniprot ID: Uniprot database protein identifier 
Protein name: protein full name recommended by Uniprot  
Score: sum of the scores computed using the PD SEQUEST-HT algorithm for the individual peptides 
Coverage%: percentage of coverage calculated by dividing the number of amino acids in all peptides detected by the total number of amino acids in the entire 
protein sequence 
Proteins: number of proteins identified matching the identified peptides 
Unique Peptides: number of peptide sequences unique to a protein group 
Peptides: number of distinct peptide sequences in the protein group 
PSMs (Peptide Spectrum Matches): total number of identified peptide sequences for the protein including redundant pepetides
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4.4.2.1 Functional analysis of the brain aggregates proteome 
Protein groups identified in Brain NCHs as secondary isoforms were converted 
into the main protein isoforms before using Webgestalt (132) for KEGG pathway 
enrichment analysis (Table 4.5). 
The pathways identified as enriched in the Brain NCHs proteome were mostly 
related to  cell to cell interaction (tight junction, ECM-receptor interaction, gap 
junction, focal adhesion and synaptic vesicle cycle) and to the immune system 
activation (pathogenic Escherichia coli infection, phagosome and salmonella 
infection), but also to ALS and apoptosis, the only pathway with FDR > 0.1 (Table 
4.5). The three Nf isoforms were found only in the ALS pathway and not in the 
other enriched pathways. Examples of protein represented only in defined 
pathways included Vesicle-fusing ATPase (NSF), Clathrin heavy chain 1 (CLTC), 
and Dynamin-1 (DNM1) for the synaptic vesicle cycle pathway and Myosin-11 
(MYH11), Band 4.1-like protein 1 (EPB41L1) and Band 4.1-like protein 3 found in 
the tight junction pathway. 
4.4.3 Comparison between plasma and brain NCHs proteomes 
The pathway enrichment analysis in brain NCHs showed shared features with the 
plasma NCHs functional analysis. Four KEGG pathways (pathogenic Escherichia 
coli infection, phagosome, ECM-receptor interaction and focal adhesion) were 
represented in both Brain NCHs and the pathways shared by ALS and HC plasma 
NCHs (Table 4.1 and Table 4.5). However, only few proteins were in common 
between brain and plasma NCHs (Figure 4.11). Only five proteins (actin 
cytoplasmic 1, tubulin alpha-4A chain isoform 2, clathrin heavy chain 1 isoform 2, 
collagen alpha-1(VI) and plectin isoform 7) were shared by Brain, HC and ALS 
NCHs, while only one protein (cytoplasmic dynein 1 heavy chain 1) was 
expressed in ALS and Brain NCHs only and one (collagen alpha-2(VI)) between 
HC and Brain NCHs only. 
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Figure 4.11. ALS-PPS, HC-PPS and Brain NCHs shared protein hits (LC-MS/MS analysis).  
Venn diagram showing proteins identified by LC-MS/MS analysis and shared by the brain, HC 
and ALS NCHs. Keratin proteins were filtered out from the lists, while protein isoforms were kept. 
Five proteins were expressed in all NCHs groups, while Brain NCHs shared only one protein with 
each of ALS NCHs and HC NCHs. 
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Gene set Pathway 
description 
Number of 
genes in the 
category 
Number of genes 
matched in the 
category 
Expected number 
of genes in the 
category 
Ratio of 
enrichment 
p-Value FDR 
hsa04530 Tight junction  139 7 0.64 10.98 2.37E-06 6.55E-04 
hsa05130 Pathogenic 
Escherichia coli 
infection 
55 5 0.25 19.83 4.33E-06 6.55E-04 
hsa04145 Phagosome  154 6 0.71 8.50 5.90E-05 5.96E-03 
hsa04512 ECM-receptor 
interaction  
82 4 0.38 10.64 4.96E-04 3.27E-02 
hsa05132 Salmonella 
infection  
86 4 0.39 10.14 5.94E-04 3.27E-02 
hsa04540 Gap junction  88 4 0.40 9.91 6.48E-04 3.27E-02 
hsa05014 Amyotrophic lateral 
sclerosis (ALS)  
51 3 0.23 12.83 1.57E-03 6.80E-02 
hsa04510 Focal adhesion  203 5 0.93 5.37 2.10E-03 7.97E-02 
hsa04721 Synaptic vesicle 
cycle  
63 3 0.29 10.39 2.89E-03 9.71E-02 
hsa04210 Apoptosis 140 4 0.64 6.23 3.61E-03 1.09E-01 
Table 4.5. Top10 enriched KEGG pathways in the Brain NCHs proteome. 
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Gene set: KEGG pathway code 
Pathway description: KEGG pathway’s name 
Number of genes in the category: number of genes included in the given KEGG pathway in Homo sapiens 
Number of genes matched in the category: number of genes identified in the given KEGG pathway 
Expected number of genes in the category: calculated as the number of genes submitted divided by the number of the total Homo sapiens genes included in 
the KEGG pathway categories and multiplied by the number of genes in the category 
Ratio of enrichment: calculated as the number of genes matched in the category divided by the expected number of genes in the category 
p-Value: statistical significance calculated by the Fisher’s exact test 
FDR (False Discovery Rate): calculated from the p-Value adjusted with Benjamini and Hochberg method (109)
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4.5 Comparing NCHs data with models of protein aggregation 
We have looked at our NCHs proteomic data to investigate molecular mechanism 
which are reported to influence the susceptibility of proteins to aggregate. To this 
end, we have used datasets from existing in vivo and in silico models which are 
based on data acquired studying yeast models and prion proteins (133–138). 
4.5.1 Algorithms for modelling aggregation tendency 
An and Harrison (135) identified possible human and yeast-prion-like proteins by 
different computational methods, including the lowest-probability subsequence 
(LPS) (139), the Prion Aggregation Prediction Algorithm (PAPA) (140) and prion-
like amino acid composition (PLAAC) (141). Using these tools, they have 
generated a list of prion-like proteins in common between human and yeasts. We 
have compared this prion-like protein list  with the lists of proteins identified in the 
plasma and brain NCHs proteomes (Figure 4.12). 
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Figure 4.12. Overlap between proteins identified in Brain and plasma NCHs and predicted 
human prion proteins. 
ALS Brain NCHs, ALS and HC plasma NCHs protein lists obtained by LC-MS/MS were compared 
with (A) the human lowest-probability subsequence (LPS) 1e-10 representing the list of human 
prion-like proteins computed by LPS (p-value threshold of 1e-10), (B) the human prion-like amino 
acid composition (PLAAC) list of human prion-like proteins computed by PLAAC, (C) the human 
Prion Aggregation Prediction Algorithm (PAPA) list of human prion-like proteins computed by 
PAPA and (D) the human yeast-prion-like proteins as reported by An and Harrison (135). The 
different grey scale is proportional to the percentage of proteins included in each diagramm 
intersection. Keratin proteins were filtered out and secondary isoforms were converted into main 
isoforms. 
The final list of human yeast-prion-like proteins reported by An and Harrison is 
significantly enriched in cytoskeletal proteins (135). A good proportion of the 
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proteins we have identified in the Brain NCHs proteome were also of cytoskeletal 
proteins (20% of the total) were included in the cytoskeleton cellular component 
category identified by PANTHER database. However, the overlap between 
computed human prion-like proteins and those we have identified in the ALS brain 
NCHs, and in the ALS and HC plasma NCHs was very poor (Figure 4.12). Eleven 
proteins were shared between the human LPS list (Figure 4.12A) and the 
plasma/brain NCHs proteins, where one protein was shared among all the lists 
(Plectin), three proteins were shared between LPS and ALS NCHs (Cornulin, 
Semenogelin-1 and Ribosome-binding protein 1), three between LPS and HC 
NCHs (Envoplakin, Involucrin and Periplakin), and four between ALS and HC 
NCHs (Desmoplakin, Apolipoprotein A-IV, Hornerin and Filaggrin-2). This level of 
comparability was also seen when the human PLAAC and the PAPA lists of 
human prion-like proteins were used (Figure 4.12B), which shared one protein 
only with Brain NCHs (Neurofilament Light), one with plasma ALS NCHs (Myc 
target protein 1), two with plasma HC NCHs (ATP-dependent RNS helicase and 
Alpha-amylase 1) and four with plasma ALS and HC NCHs together (Hornerin, 
Filaggrin-2, Complement component C7 and Coagulation factor V; Figure 4.12C). 
Using the final list of human and yeast prion-like proteins produced by An and 
Harrison (135) (Figure 4.12D), only two of these prion-like proteins were found in 
(Hornerin and Filaggrin-2) in our plasma ALS and HC NCHs lists.  
4.5.2 Yeast model for protein aggregation 
In the attempt to acquire a better understanding of mechanisms involved in 
protein aggregation, Weids, Ibstedt et al. studied protein aggregation in yeast 
under different type of stress and the associated physicochemical properties, 
such as protein size, isoelectric point (pI) and hydrophobicity, all considered to 
be involved in the aggregation process (136). Using the same approach, we have 
studied the proteins identified in the ALS Brain, ALS and HC plasma NCHs 
proteomes to define their protein size (obtained from Uniprot) (Figure 4.13), pI 
(obtained by ExPASy, Compute pI/Mw web tool (142)) (Figure 4.14) and 
hydrophobicity by the GRAVY (average hydrophobicity and hydrophilicity) score 
(143) using the GRAVY Calculator (http://www.gravy-calculator.de) (Figure 4.15). 
This analysis was undertaken using the entire Uniprot human proteome 
(reviewed sequences only) as reference, which is also the database used for 
protein identification with Proteome Discoverer v1.4 (PD). 
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Looking at MW distribution (Figure 4.13), the HC NCHs plasma proteins and 
those shared between ALS and HC NCHs showed a similar distribution compared 
to the Human proteome, while the ALS NCHs plasma proteins were clearly more 
distributed towards higher MW. The ALS Brain NCHs proteins group had a shape 
similar to the Human proteome but, as seen for the ALS NCHs plasma proteins, 
they appeared shifted to the right (higher MW). Overall, these data showed a 
tendence for higher MW size for those proteins identified in the ALS NCHs (both 
brain and plasma) compared to the entire human proteome, while the  HC NCHs 
plasma proteins showed a lower average protein size (ALS 1.76, HC 1.61, 
Shared 1.71, Brain 2.10, Human proteome 1.66 - KDa log10). The only 
statistically significant shift using the human proteome as reference was for the 
ALS Brain NCHs proteins (unpaired Mann-Whitney-Wilcoxon U-tests and Holm-
Bonferroni p-value adjustment, 9.38e-16). 
 
Figure 4.13. Molecular weight distribution of the proteins identified in the plasma and brain 
NCHs by LC-MS/MS and of the human proteome. 
The graphic on the left-hand side shows the distribution of the average protein molecular weights 
(KDa log10) of the HC, ALS NCHs plasma proteins, of the ALS brain NCHs proteins with reference 
to the whole genome protein MW distribution. The boxplot (right-hand side) shows the median, 
first and third quartiles, upper and lower limits, and the points beyond (empty circles) the limits. 
ALS: NCHs Unique ALS protein list; HC: NCHs Unique HC protein list; Shared: NCHs Shared 
protein list; Brain: Brain NCHs protein list; Human proteome: Homo Sapiens Uniprot reviewed 
protein list. 
With regards to the isoelectric point, proteins identified in the HC/ALS plasma 
NCHs distributed differently from the human proteome. The ALS brain NCHs 
proteins showed a narrower pI distribution compared to the proteins identified in 
plasma NCHs (Figure 4.14). Overall, the proteins identified in the plasma NCHs 
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showed a consistently and statistically significant lower pI compared to the human 
proteome (unpaired Mann-Whitney-Wilcoxon U-tests and Holm-Bonferroni p-
value adjustment, 5.93e-12, 1.15e-9, <8.80e-16, 2.70e-10, respectively for ALS, 
HC, Shared and Brain protein lists) (Figure 4.14).  
 
Figure 4.14. Isoelectric point (pI) distribution of the proteins identified in the plasma and 
brain NCHs by LC-MS/MS and of the human proteome. 
The graphic on the left-hand side shows the distribution of pIs of the HC, ALS NCHs plasma 
proteins, and of the ALS brain NCHs proteins with reference to the whole genome. The boxplot 
(right-hand side) showed the median, first and third quartiles, upper and lower limits, and the 
points beyond (empty circles) the limits. ALS: NCHs Unique ALS protein list; HC: NCHs Unique 
HC protein list; Shared: NCHs Shared protein list; Brain: Brain NCHs protein list; Human 
proteome: Homo Sapiens Uniprot reviewed protein list. 
Observing the distribution of the hydrophobicity measured as GRAVY index, the 
protein groups generated by the proteomic analysis showed a similar distribution, 
with similar average values (ALS -0.34, HC -0.33, Shared -0.35, Human 
proteome -0.34) (Figure 4.15). The only exception was represented by the ALS 
Brain NCHs protein list which showed statistically significant lower GRAVY values 
(average -0.50; unpaired Mann-Whitney-Wilcoxon U-tests and Holm-Bonferroni 
p-value adjustment, 0.03) (Figure 4.15). 
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Figure 4.15. GRAVY index distribution of the proteins identified in the plasma and brain 
NCHs by LC-MS/MS and of the human proteome. 
The graphic on the left-hand side shows the distribution of hydrophobicity, as GRAVY index, of 
the HC, ALS NCHs plasma proteins, and of the ALS brain NCHs proteins with reference to the 
whole genome. The boxplot (right-hand side) shows the median, first and third quartiles, upper 
and lower limits, and the points beyond (empty circles) the limits. ALS: NCHs Unique ALS protein 
list; HC: NCHs Unique HC protein list; Shared: NCHs Shared protein list; Brain: Brain NCHs 
protein list; Human proteome: Homo Sapiens Uniprot reviewed protein list. 
4.6 NCHs resistance to protease digestion with trypsin 
In neurodegenerative diseases, it is thought that disordered proteins are prone to 
form aggregates, behaving in a prion-like manner. This concept arises from the 
observation that neurodegenerative diseases including ALS, may follow a similar 
pattern of progression of the disease due to propagation of the pathology in the 
affected tissues. This progression from an anatomic area to a contiguous one 
seen in different neurological conditions recalls the way prion proteins diffuse, 
extending the hallmarks of neurodegeneration to contiguous areas 
(100,144,145). Another important characteristic of the biochemical behavior of 
prion proteins is the resistance to cleavage by protease K and trypsin (146), which 
in turn may be at the basis of prions proteins enhanced tendency to form protein 
aggregates. It is therefore possible to postulate that protein aggregates in general 
may include proteins manifesting the same or various degrees of protease 
resistance and that this biochemical characteristic may be prominent when 
protein aggregation occurs in a pathological state like for example ALS. In order 
to confirm whether altered protease resistance could also be found in the NCHs 
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and be correlated to ALS pathology, digestion with trypsin was performed on 
brain and plasma NCHs (Figure 4.16). 
 
Figure 4.16. Neurofilament-containing heteroaggregates (NCHs) before and after digestion 
with Trypsin. 
NCHs extracted from brain, ALS-PPS and HC-PPS were digested overnight with trypsin. NCHs 
proteins show a complete and homogeneous trypsin digestion across plasma and brain subgroup. 
The arrow on the left-hand side highlights the presence of the retained protease enzyme used for 
aggregates digestion (rather than a digestion fragment). NCHs: neurofilament-containing 
heteroaggregates (NCHs); ALS-PPS: amyotrophic lateral sclerosis pooled plasma sample; HC-
PPS: healthy control pooled plasma sample.   
After ALS brain NCHs digestion, it was possible to detect a defined band at 49 
KDa, whereas the rest of the plasma NCHs (HC-PP and ALS-PP) digested 
samples showed a very faint smear going from 98 KDa MW to the bottom of the 
gel, suggesting a degree of resistance to digestion with trypsin (Figure 4.16). As 
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discussed later on, the presence of a degree of protease resistance may 
influence the proteomic results and affect negatively the detection of other ALS 
relevant proteins like TDP-43 and SOD1.  
In order to evaluate protein-specific resistance, WB against NfH (Figure 4.17), 
TDP-43 (Figure 4.18) and ubiquitinated proteins (Figure 4.19) was also 
performed on the same brain and plasma-derived aggregates from ALS and HC. 
 
Figure 4.17. Western blot analysis of NfH in brain and plasma NCHs digestion with trypsin.  
The WB shows the NfH content in ALS-PPS (lane 1 and 2), HC-PPS (lane 3 and 4) and Brain 
NCHs (lane 5and 6) and the effect of trypsin digestion. The blot indicates that trypsin entirely 
digests NfH contained in NCHs. Brain NCHs profile is different from plasma, with a significantly 
different expression of bands above and below the expected molecular weight. Brain NCHs 
presented a long smear from 268 to 117 KDa, with the main band below 238 KDa and another 
distinct band between at 41 KDa. Plasma NCHs showed two bands at around 238-268 KDa and 
other bands at 55 and 41 KDa. Lanes: 1, ALS-PPS NCHs digested with trypsin; 2, undigested 
ALS-PPS NCHs; 3, HC-PPS NCHs digested with trypsin; 4, undigested HC-PPS; 5, ALS Brain 
NCHs digested with trypsin; 6, undigested brain NCHs. 
NfH did not show any resistance to trypsin protease digestion in either ALS brain 
and HC/ALS-derived plasma NCHs (Figure 4.17). This refutes our initial 
hypothesis that NfH could not be detected by MS because of intrinsic resistance 
to trypsin digestion. ALS Brain and plasma NCHs showed a different WB pattern 
with regards to NfH content. NfH was detected in plasma samples in four different 
bands at defined MWs (268, 238 and between 55 and 41 KDa), while Brain NCHs 
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WB analysis of NfH appeared more as a smear around the levels of more defined 
MW bands, including from 268 to 117 KDa and at lower MW at around 41 KDa 
(Figure 4.17). One potential explanation for the reported NfH distribution in Brain 
could be a higher level of post-translational modifications (PTMs), which may 
result in a broad number of NfH species detected at different MW (147,148). This 
could also be true for NfH circulating in blood, where the presence of defined 
species identified by WB may also relate to the PTM profile. 
 
Figure 4.18. Western blot analysis of TDP-43 in brain and plasma NCHs before and after 
digestion with trypsin.  
The WB showed the TDP-43 content in HC-PPS, ALS-PPs and Brain NCHs and the effect of 
trypsin digestion. The blot shows absence of TDP-43 in NCHs obtained from plasma samples, 
while TDP-43 in Brain NCHs at 43 and 171 KDa. Brain NCHs digested with trypsin did not show 
any positive band for TDP-43, against any evidence of protease resistance. Lanes: 1, undigested 
HC-PPS; 2, HC-PPS NCHs digested with trypsin; 3, undigested ALS-PPS NCHs; 4, ALS-PPS 
NCHs digested with trypsin; 5, undigested brain NCHs; 6, brain NCHs digested with trypsin. 
The two separate brain samples (here referred to as Brain1 and Brain2) which 
were pooled for the purpose of the experiments detailed in this Thesis, were 
obtained from the Netherlands Brain Biobank and were both reported to be 
positive for TDP-43 inclusions after post-mortem analysis. Western blot analysis 
of TDP-43 in NCHs extracted from brain confirmed the presence of this protein in 
the Brain at the expected (43 KDa) and higher (171 KDa) MW, suggesting the 
potential inclusion of this protein in brain aggregates and confirming the quality 
of the enrichment method we have applied (Figure 4.18). TDP-43 was not 
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detected in plasma NCHs from HC and ALS patients (Figure 4.18). In addition, 
NCHs digestion with trypsin did not show any TDP-43 resistance to digestion. 
This may indicate that failure to detect TDP-43 by MS in our proteomic 
experiment is not related to resistance to trypsin digestion, the proteolytic enzyme 
used in the MS procedure, but rather  to the presence of PTMs which may 
interfere with TDP-43 detection with the proteomic pipeline setting utilized in our 
experiments (149). 
Misfolded proteins can be degraded within cells via the proteasome system or 
through other  proteolytic pathways within the lysosomes (150,151). Ubiquitin 
plays a central role in all these pathways and it is also involved in protein 
aggregates removal (152–155). ALS and other neurodegenerative diseases 
where protein aggregation is a major pathological hallmark, such as Alzheimer’s, 
Parkinson’s and Huntington’s disease, are known to show presence of 
ubiquitinated proteins within protein aggregates in affected tissues (156–158). To 
evaluate the degree of protein ubiquitination in the NCHs from HC-PPS, ALS-
PPS and in ALS Brain, we have performed a WB against ubiquitinated proteins 
(Figure 4.19). 
 
Figure 4.19. Western blot analysis of ubiquitinated proteins in brain and plasma NCHs after 
digestion with trypsin. 
Western Blot (WB, left-hand side) analysis shows the presence of ubiquitinated proteins and the 
effect of trypsin digestion in NCHs from ALS-PPS (lane 1 and 2), from HC-PPS (lane 3 and 4) 
and from ALS Brain (lane 5 and 6). Plasma NCHs (lanes 1-4) show ubiquitinated proteins at a 
154 
 
MW of 71 KDa, while Brain NCHs (lane 5 and 6) ubiquitinated proteins were expressed at a MW 
range between 268 KDa to 171 KDa and at higher MW (above 460 KDa). In the samples we have 
examined, only ALS Brain NCHs show ubiquitinated proteins resistance to trypsin digestion (high 
MW in lane 6, highlighted by the red box). The chart (right-hand side) shows the densitometric 
analysis of the bands containing ubiquitinated proteins found in ALS-PPS (lane 2) and HC-PPS 
NCHs (lane 4). Lanes: 1, ALS-PPS NCHs digested with trypsin; 2, undigested ALS-PPS NCHs; 
3, HC-PPS NCHs digested with trypsin; 4, undigested HC-PPS; 5, Brain NCHs digested with 
trypsin; 6, Brain NCHs undigested.  
Ubiquitinated proteins were detected in NCHs extracted from ALS-PPS, HC-PPS 
and Brain. Only Brain showed ubiquitinated proteins resistance to trypsin 
digestion (high molecular weight band, lane 5, Figure 4.19), while NCHs 
ubiquitinated proteins from ALS-PPS and HC-PPS showed no resistance to 
trypsin digestion (Figure 4.19). The WB analysis of ubiquitinated proteins in 
plasma NCHs showed a band at 71 KDa, with the NCHs from ALS-PPS 
displaying more than the double of the intensity compared to HC-PPS (Figure 
4.19). Brain NCHs showed ubiquitinated proteins at a high MW (above 460 KDa) 
and a smeared band going from above 268 KDa to 171 KDa. WB analysis of 
ubiquitinated proteins in brain NCHs digested with trypsin showed also a band at 
high MW suggesting a degree of resistance for a portion of ubiquitinated 
aggregates of higher molecular weight (Figure 4.19) (159,160). Taken together, 
the results of this trypsin digestion experiment would suggest that ubiquitin could 
be co-localised with NfH and TDP43 in the same aggregates (Figure 4.17-Figure 
4.19). Therefore, the inclusion of ubiquitination as PTM would probably increase 
peptide and protein identification after LC-MS/MS analysis through the 
identification of this specific PTM. 
4.7 Conclusion 
The work highlighted in this Chapter relates to the characterisation of NCHs, 
extracted from plasma of HC and ALS patients and from ALS brains. We have 
looked at NCHs protein composition by MS and at their biochemical properties 
testing their resistance to trypsin protease digestion. While the information we 
have gathered represent an initial step towards new and potentially informative 
biomarkers of neurodegeneration, our preliminary findings require further 
refinement and validation. So far, we have opted for an investigation of pooled 
samples coming from patients who differed in terms of age of onset of the disease 
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and rate of disease progression. The work was so far conducted on pooled 
plasma samples missing any specific molecular feature linked to each affected 
individual’ phenotypic aspect and proteomic analysis did not provide any 
quantitative determination and information about specific candidate’s regulation 
in the disease state. In the comparative analysis of plasma NCHs with brain 
aggregates, we have studied the expression of biological features in association 
with ALS and how protein profiles of aggregate fractions in brain and plasma 
compare. In addition, we have so far looked at how the specifics of the proteomes 
we have acquired depend on the experimental set-up, which include the specific 
MS workflow and the extraction method.    
NfH has already been described as an important biomarker for 
neurodegeneration in ALS (46,127,128). Other studies highlighted potential 
problems in the detection of this neurofilament isoform using immunodetection 
methods like ELISA, due to its propensity to form immunocomplexes or to 
assemble in other protein aggregates (53). The solubilisation of NCHs derived 
from plasma, which was carried out with 8 M urea, showed that NfH is present at 
higher levels in NCHs from ALS patients than from HC, similarly to what seen in 
plasma NCHs solubilised with PBS (Figure 4.1). The higher NfH expression in 
ALS NCHs compared to HC NCHs showed in Figure 4.1 suggests that the NfH 
included in protein aggregates could be more informative as biomarker of 
neurodegeneration than simple NfH measurements in plasma. On the other 
hand, solubilisation with 8 M urea may not be compatible with antibody-based 
high throughput techniques, such as ELISA, reducing the possible application of 
this finding for large-scale biomarkers analysis. Further investigation including 
larger cohort of ALS and control individuals may be needed to unravel the real 
potential of aggregate-phase NfH as biomarker and its applicability to clinical 
practice. 
Electron microscopy (EM) was used in this study simply to highlight the presence 
of macromolecular formations which corresponded to the high molecular bands 
seen in the gel separation experiment. IG-TEM for this type of experiments will 
have to be set with the inclusion of quality controls to overcome these difficulties. 
The IG-TEM findings on NfH preferential localisation in fluid aggregates may also 
derive from aspecific binding.  
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To date, there are no comprehensive electron microscopy studies on circulating 
protein aggregates and none on macromolecular formations taken from blood 
stream of ALS patients. The biochemical environment in a fluid state may 
certainly affect aggregates composition, shape and size, making any TEM 
analysis very difficult to interpret when compared to any determination performed 
in tissue (161,162). The NCHs extracted from ALS brains in part had a 
filamentous and donut-like appearance unlike the more amorphous, globular and 
at times fibrous appearance of plasma aggregates. While it is clearly impossible 
to elaborate on these differences and to infer any biological interpretation, it may 
be possible to speculate on the chemical-physical environment in brain as a 
potential modifier of aggregation in brain (Figure 4.10). The donut-like particles 
could be related to the deposition of which is considered a contaminant in brain 
homogenates as extensively reported in the literature (163–165). Quintana et al. 
(163) also showed that ferritin binds to tau filaments. As we have not performed 
any immunolabelling with ALS Brain NCHs, we cannot speculate the relative 
contribute of Nf to the composition of the aggregates found in brain. We can only 
speculate that the rough and curved surface of the filaments identified in our TEM 
analysis of brain aggregates does not match with the smooth and linear shape of 
intermediate filaments appreciable by TEM (165). However, the micrographs 
published by Zhou et al. (166) may resemble the small fragments detected in our 
TEM experiment. In this study, the Authors have used Ficoll 70 at 300 g/l, a 
polysaccharide utilized to create a crowded cell environment, a very similar 
condition to the sucrose cushion used in the BPP aggregates enrichment protocol 
applied in our experiments (our sucrose cushion has a sucrose concentration of 
1 M, equal to 342 g/l). It is tempting to speculate on the similarity of our 
filamentous structures and the micrographs available in literature which portray 
the main features of prion proteins (165–167). It is also important to add that in 
our experiments the brain NCHs samples underwent sonication before TEM 
analysis, a procedure which may have broken the filaments in smaller particles, 
justifying the absence of long branched (more prion-like) structures (167). 
From a biochemical and imaging perspective, to better characterise the 
macrostructures we have identified in plasma, it will be necessary to assess 
protein aggregation in neurodegenerative diseases in the affected tissue, such 
as brain, and compare these formations with those enriched from plasma, thus 
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extending our preliminary work to a more systematic assays of the conformational 
and biochemical properties of aggregates in different states in the same 
pathological context (168–171).  
So far, using LC-MS/MS proteomics we have defined the protein composition of 
aggregate fractions from ALS and HC PPS. The proteins identified in ALS and 
HC were only partially overlapping and it was possible to identify 103 proteins 
uniquely in the ALS and 89 uniquely in HC PPS. KEGG pathways functional 
analysis highlighted a clear distinction in the nature of the enrichment of different 
pathways in the ALS compared to HC samples. Using stringent definition of 
enrichment by Webgestalt and a hypergeometric test for statistical evaluation 
(paragraph 4.3), the proteasome pathway was the only enriched feature in the 
NCHs from ALS-PPS, while in the HC-PPS NCHs, glycolysis/gluconeogenesis, 
pentose phosphate pathway and carbon metabolism emerged as consistently 
enriched pathways. The enrichment of pathways for glucose-dependent ATP 
production in the healthy state NCHs and their absence in ALS may indicate an 
imbalance in ATP production already described in ALS (172,173). The presence 
of a prominent proteasome signal in the enriched KEGG pathways from ALS 
pooled plasma aggregates is another relevant finding. The change in this 
pathway involved in the critical process of scavenging of disordered and 
potentially toxic proteins may be the very reason for the presence of motor neuron 
protein inclusions in this ALS (174,175). Interestingly, all reported alterations in 
proteasome activity are so far shown in brain, spinal cord and neuronal cell lines, 
but not systemically or more specifically, in blood. Our data support the the 
hypothesis that protein degradation through the proteasome may be critical in 
ALS and detectable as a systemic response together with a clear propensity of 
proteins involved in this important pathway to assemble in circulation. To our 
knowledge, there is no previous description of this phenomenon in the literature. 
LC-MS/MS analysis of the NCHs extracted from plasma (HC-PPS and ALS-PPS) 
showed very little convergence with the analysis performed in brain NCHs. Only 
a few proteins were shared, and only one (cytoplasmic dynein 1 heavy chain 1, 
DYNC1H1) was found both in brain and plasma NCHs from ALS individuals. Any 
interpretation of these findings at this stage may be difficult. It may be possible 
that brain and plasma-borne heteroaggregates are formed in their respective 
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environments through processes that are completely independent, but still driven 
by the aggregogenic properties of some key proteins like neurofilaments that may 
seed aggregation in different biological contexts. DYNC1H1 mutations have been 
linked with neurological disorders, such as Charcot-Marie-Tooth, spinal muscular 
atrophy and mental retardation (176–178), but genetic studies in European 
populations have not identified a connection with ALS (179). However, a mouse 
model for motor neuron diseases including mutations for DYNC1H1 and SOD1 
seem to connect this protein to ALS, suggesting a role in mithocondria 
homeostais and interaction with SOD1 toxic species (180). Unfortunately, brain 
and plasma samples in this analysis have not been screened for DYNC1H1 
mutations. These data support the involvement of this protein in biochemical 
changes occurring during neurodegeneration and the need for further 
investigations aimed at deepening out understanding of DYNC1H1 as potential 
biomarker of ALS.  
The lack of similarities in the composition of brain and plasma aggregates may 
also be related to the limits of proteomic techniques, whereby low abundance 
proteins may be masked by those with high abundance and detection confounded 
by the presence of post-translational modifications. Therefore, to address these 
potential shortfalls and gather more information on the nature of brain and 
circulating aggregates in health and disease, we have undertaken further 
experiments using a TMTcalibrator™ workflow (discussed in the following 
chapter), where brain proteins were used to enhance detection of the same 
proteins in plasma NCHs (93).  
A poor overlap was also found comparing the final lists of proteins identified in 
circulating NCHs, from both ALS and HC, those in brain NCHs and the final list 
of human/yeast-prion-like proteins produced by An and Harrison (Figure 4.12) 
(135). Prion-like proteins are supposed to have an intrinsic tendency to 
aggregation and therefore it would be expected to find these proteins in any 
aggregate formation, in the healthy or pathological states. It is difficult to explain 
the lack of protein sequences with prion-like characteristic among NCHs proteins. 
This may once again be related to the limits of the MS-based proteomics 
approach employed or to the presence of PTMs in the proteins of interest. Of 
relevance, cytoskeletal proteins were significantly enriched in both the reported 
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prion-protein general inventory (135) and in our NCHs protein lists, hinting at the 
importance of these protein species in the aggregation process. The absence of 
similarity between the NCHs proteins we have detected and those computed 
prion-like proteins is testimony of the lack of a full understanding of the 
mechanisms and factor influencing aggregation and of the translation of this 
knowledge into computational models that can interpret large datasets. 
However, our review of the main features presented by the proteins included in 
the Brain and plasma (HC and ALS) NCHs by comparison with the human 
proteome obtained from Uniprot (reviewed sequences only) showed how our 
protein hits presented features shared by proteins with high tendency to 
aggregate, in  line with what reported by Weids, Ibstedt et al. (136). On average, 
proteins included in our NCHs had bigger size (Figure 4.13) and a decrease in pI 
(Figure 4.14), as well as a different trend for hydrophobicity compared to the 
entire human proteome database of protein-coding genes (Figure 4.15). 
Interestingly, Brain NCHs proteins were different from those in plasma NCHs in 
physicochemical properties. Subgroups of plasma NCHs plasma proteins, 
including those shared and unique to ALS and HC, did not show significant 
differences among themselves. This would suggest that the physicochemical 
parameters of the proteins within the NCHs are not affected by the condition (ALS 
vs HC), but that proteins with specific features (as reported above) tend to 
become part of protein aggregates, a process which may also depend on the 
biological environment where these proteins are constitutively expressed or 
released to. The fact that no significant difference was found between proteins 
identified in plasma NCHs and the human proteome might be related to the fact 
that plasma contains the largest variety of proteins (compared to more tissue-
specific mixes) resembling the features of the entire human proteome. 
In the attempt to characterize the propensity to aggregate of the proteins 
identified in our NCHs, we have explored another important aspect: the 
susceptibility to digestion that NCHs proteins have or acquire. Resistance to 
proteases digestion has been described as a feature of pro-aggregating prion 
proteins; hence we have tested the hypothesis that in a pathological state like 
ALS,  proteins partaking in plasma and brain NCHs may acquire resistance to 
proteases digestion (100,144–146). The smear produced after NCHs trypsin 
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digestion shows an incomplete degradation of the aggregates with this protease 
(Figure 4.16), while those proteins known to be involved in aggregation, such as 
NfH and TDP-43 do not show any sign of resistance to digestion (Figure 4.17 and 
Figure 4.18). Conversely, ubiquitinated proteins in brain NCHs showed a low 
degree of resistance (Figure 4.19), confirming the role of this PTM in aggregation, 
perhaps conferring a lower degradation activity of NCHs  in ALS which may relate 
also to their toxicity (156–158,174,175,181). In order to better assess NCHs 
resistance to digestion and build on our preliminary data, plasma and brain NCHs 
resistance to protease digestion will be tested using other proteases including 
chymotrypsin, calpain and enterokinase. 
Moreover, in the following chapter we will extend our preliminary analysis to a 
larger number of samples which will be tested individually and with a technique 
which allows the simultaneous assessment of brain and plasma. Segmenting our 
observations to incorporate each individual samples NCHs proteomic profile will 
allow a better definition of the relation between phenotype (for example speed of 
disease progression) and systemic molecular features of protein aggregation. 
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5 Brain derived proteins and their differential regulation 
in plasma NCHs from ALS and healthy individuals 
5.1 Introduction and aim 
Drawing on to the initial characterization of circulating neurofilament-containing 
heteroaggregates (NCHs) from Amyotrophic Lateral Sclerosis (ALS) and healthy 
control (HC) pooled plasma samples (ALS-PPS; HC-PPS), here we apply a novel 
and more sensitive mass spectrometry (MS) proteomic method to detect the full 
spectrum of brain-specific proteins in NCHs and to define quantitative differences 
in the composition of these proteins in the healthy and pathological state.  
Brain proteins are not expected to be found in high concentration in plasma and 
they tend to escape detection because of the high dynamic range of plasma 
proteins, where high-abundance proteins like albumin represent the main bulk of 
the total protein content in plasma. As previously reported, detection of 
neurofilament proteins (Nf) in plasma-derived NCHs by mass spectrometry (MS) 
analysis was not possible. Therefore, to increase signal for detection of low-
abundance proteins using MS-based proteomics, an innovative approach, the 
TMTcalibrator™ workflow, will be used for the purpose of our study (93). This 
method combines plasma NCHs with brain tissue analysis in the same 
experiment to enhance detection of tissue-derived proteins in biofluid. This 
workflow was developed by Proteome Sciences plc (182) to quantify low 
abundant peptides and proteins in matrices with a high degree of biological 
complexity (93). TMTcalibrator™ uses Tandem Mass Tag (TMT) (Figure 5.1) 
label technology to analyse simultaneously in a 10-channel experimental setting 
six analytical samples and four from a tissue-derived standard called calibrator 
channels. The latter representing a source of peptides that boosts detection of 
the same peptides in the analytical samples while functioning as reference for 
samples quantification.   For this purpose, it is important to develop the 
experiment based on suitable ratio between analytical and calibrator samples 
which in our case was set at 2X for each analytical sample, along with a ratio of 
1:4:6:10 for the four calibrator channels. With this set-up and within each 
proteomic experiment, the calibrant generated more than half of the total MS-
acquired intensity signals. The dominant signal intensity generated by the tissue 
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derived peptides (calibrator channels) enhanced the detection of the same 
peptide signals in plasma NCHs, thus ensuring 1) the identification of tissue 
(brain)-derived peptides in plasma which would normally be below the limit of 
detection and 2) their quantification using the calibrant internal tissue as the 
standard reference across different experiments using the same calibrator.  
To investigate the presence of brain proteins in plasma NCHs, we designed two 
identical tenplex experiments: in each tenplex, we used Netherlands Brain 
Biobank (BNN) post-mortem brain tissue from ALS patients for the calibrator 
channels and plasma NCHs from three ALS patients and three HC. Based on our 
previous experiment results, outlined in Chapter 4, and on the only marginal 
overlap between brain and plasma NCHs protein profiles (Paragraph 4.4.3), we 
have opted for whole brain lysate rather than brain NCHs as tissue calibrator. 
This was done to increase the detection of brain-specific proteins in plasma over 
and above the 48 identified in the MS proteomic experiment of brain NCHs (Table 
4.4). 
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Figure 5.1. Tandem Mass Tag (TMT) 10 reagents for peptide labelling (ThermoFisher 
Scientific). 
(A) TMT general chemical structure showing the mass reporter, mass normaliser and NH2 
reactive group regions. The tags are shown with their masses and isotope positions (red dots). 
(B) Relative quantification of the samples after detection of the mass reporter ions generated in 
the second mass spectrometry (MS) step in a liquid chromatography coupled with tandem MS 
(LC-MS/MS). 
5.2 Samples selection 
ALS is an incurable and invariably fatal neurodegenerative disease were a 
significant diagnostic delay has hampered any progress towards developing 
effective treatment. This is mostly due to the extreme phenotypic heterogeneity 
of the disease and the lack of biomarkers to be used as surrogate markers of 
treatment response and for clinical stratification. Therefore, in order to limit the 
potential confounding effects of clinical heterogeneity of the disease, six ALS 
patients with the same El-Escorial criteria for diagnosis  (88) (stage of disease) 
were selected, all of whom showed limb-onset disease. Moreover, because ALS 
occurrence is also strongly age-related (183,184), an homogeneous group in 
terms of age of ALS onset was chosen (average63.87 ± 3.09 years old) (Table 
5.1). Age and gender-matched healthy controls were selected (HC; average 
64.16 ± 3.05 years old Table 5.1). The selected ALS patients showed also 
moderately homogeneous, moderate to severe, level of neurological impairment 
at the time of sampling as shown by the ALS Functional Rating Scale Revised 
(ALFRS-R, 28 ± 10.58), while speed of progression at the time of sampling (0.946 
± 0.47) was in keeping with a moderately to fast progressing ALS (Table 1).  
NCHs enrichment and separation from plasma samples was performed using the 
Brain-Plasma Protocol (BPP) described in Paragraph 2.2.2.1, the methodology 
shown to give the most comprehensive cover of the plasma protein profile. Total 
protein concentration was measured in plasma samples before and after the 
enrichment, in order to evaluate the relationship between plasma and NCHs 
protein concentration. Protein concentration in plasma NCHs and the ration 
between NCHs and plasma protein for each sample showed a higher variability 
in HC compared to ALS (Figure 5.2). There were no statistically significant 
differences between ALS and HC protein concentration in plasma and NCHs and 
in the respective ratios (Figure 5.2). 
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The plasma NCHs from the selected ALS patients and HC to be loaded on to the 
analytical channels of the TMTcalibrator™ as well as a 1:1 mixture of two ALS 
brain samples (processed as reported in Paragraph 2.5.2) to be loaded in the 
calibrant channels were subjected to quality check by gel electrophoresis (Figure 
5.3). 
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Sample 
ID 
Gender Ethnicity 
Age at sampling 
(year) 
El-Escorial 
Clinical 
Onset 
ALSFRS-
R 
Rate of progression at 
sampling 
ALS1 F Caucasian 61.37 
Definite 
ALS 
LL 32 0.737 
ALS2 F Caucasian 68.80 
Definite 
ALS 
UL 35 0.821 
ALS3 M Caucasian 60.18 
Definite 
ALS 
LL 35 0.729 
ALS4 M Caucasian 65.19 
Definite 
ALS 
UL 9 1.912 
ALS5 M Caucasian 64.79 
Definite 
ALS 
LL 22 0.750 
ALS6 F Caucasian 62.89 
Definite 
ALS 
LL 35 0.727 
HC1 F Caucasian 62.48 NA NA NA NA 
HC2 F Caucasian 67.50 NA NA NA NA 
HC3 M Caucasian 60.64 NA NA NA NA 
HC4 M Caucasian 68.28 NA NA NA NA 
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Sample 
ID 
Gender Ethnicity 
Age at sampling 
(year) 
El-Escorial 
Clinical 
Onset 
ALSFRS-
R 
Rate of progression at 
sampling 
HC5 M Caucasian 62.54 NA NA NA NA 
HC6 F Caucasian 63.53 NA NA NA NA 
Table 5.1. Clinical and demographic features of ALS patients and healthy controls from whom blood samples were collected for neurofilament-containing 
heteroaggregates (NCHs) enrichment and TMTcalibrator™ analysis. 
Light orange colour-code: amyotrophic lateral sclerosis (ALS) patients 
Light blue colour-code: healthy control (HC) samples  
NA: no data available. 
Sample ID: ALS= ALS patients; HC= Healthy Control 
Gender: M= Male; F= Female  
El-Escorial: diagnostic classification of ALS (88) 
Clinical Onset (site of initial clinical signs): LL= Lower Limbs; UL= Upper Limbs 
Age at sampling: age of the patient when blood sample was obtained  
ALSFRS-R (ALS Functional Rating Scale revised): level of neurological impairment across different clinical domains (1-48, higher neurological impairment with 
lower values) 
Rate of progression at sampling: calculated as 48 - ALSFRS-R score at sampling time/disease duration from onset of symptoms to sampling time
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Figure 5.2. NCHs enrichment performance in the ALS and HC plasma samples. 
Dot plots showing the protein concentration distribution of the plasma (A) samples before 
enrichment and NCHs (B) samples after enrichment. In (C) the amount of total protein in NCHs 
expressed as percentage (%) of the total protein in related plasma samples. The black dots 
represent the single data points of the samples obtained from the patients listed in Table 5.1, 
while the red triangles represent the mean value for each group (ALS: 91.4 µg/µl (A), 0.43 µg/µl 
(B), 0.0945 % (C); HC: 87.3 µg/µl (A), 0.35 µg/µl (B), 0.0932 % (C). 
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Figure 5.3. NCH samples quality check by Sodium Dodecyl Sulphate - PolyAcrylamide Gel 
Electrophoresis (SDS-PAGE). 
Plasma NCHs (ALS1 - 6 and HC1 - 6) and Brain lysates were loaded into a 3-8% Tris-acetate gel 
and stained with Imperial Blue Comassie after gel electrophoresis to evalute sample quality with 
regards to 1) protein expression profiles, solubilisation and presence of contaminants in each 
sample. A good and reproducible pattern of protein separation was seen in all samples with no 
evidence of contaminants. Marker: protein marker. 
5.3 TMTcalibrator™: experimental setting 
Once samples were quality checked, they were prepared for further analysis as 
described in Paragraph 2.5.2.1. Briefly, each sample was reduced with 
Dithiothreitol (DTT), alkylated with iodoacetamide (IAA) and later digested with 
trypsin to generate tryptic peptides which were desalted in a chromatographic 
step. At this stage, the peptides generated from the Brain sample were split in 
aliquots of 1:4:6:10 volumes, to provide the four calibrant samples to be used in 
the TMTcalibrator™ analysis. Finally, all samples underwent TMT labelling as 
reported in Table 5.2.  
After labelling, samples ALS1, ALS2, ALS3, HC1, HC2, HC3 and four calibrant 
samples (Cal1X, Cal4X, Cal6X and Cal10X) were joined in the 10plex1, while 
samples ALS4, ALS5, ALS6, HC4, HC5, HC6 and the same four calibrant 
samples in the 10plex2 (Table 5.2). The two 10plexes underwent basic reverse 
phase (bRP) fractionation generating eight fractions for each 10plex.  
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Sample ID Protein amount (µg) 10plex TMT reagent 
ALS1 40 1 TMT10-126 
ALS2 40 1 TMT10-127N 
ALS3 40 1 TMT10-127C 
HC1 40 1 TMT10-128N 
HC2 40 1 TMT10-128C 
HC3 40 1 TMT10-129N 
Cal1X 20 1 TMT10-129C 
Cal4X 80 1 TMT10-130N 
Cal6X 120 1 TMT10-130C 
Cal10X 200 1 TMT10-131 
ALS4 40 2 TMT10-126 
ALS5 40 2 TMT10-127N 
ALS6 40 2 TMT10-127C 
HC4 40 2 TMT10-128N 
HC5 40 2 TMT10-128C 
HC6 40 2 TMT10-129N 
Cal1X 20 2 TMT10-129C 
Cal4X 80 2 TMT10-130N 
Cal6X 120 2 TMT10-130C 
Cal10X 200 2 TMT10-131 
Table 5.2. ALS and HC analytical and brain calibrant channels in the two 10plexes 
experiments. 
In this table, we report 1) the amount of total proteins labelled for the TMTcalibrator experiment 
in each sample (Protein amount), 2) the 10plex experiment for each sample and 3) the relative 
TMT tag (TMT reagent). 
5.3.1 Injection conditions 
The liquid chromatography (LC) coupled with tandem mass spectrometry 
(MS/MS) analysis was set with a five hours elution gradient for the LC step, to 
allow a good resolution of the eluted peptides, and coupled with a Thermo 
Scientific™ Orbitrap Fusion Tribrid (Thermo Scientific) mass spectrometer. This 
combination provided higher resolution at the second MS scan improving 
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peptide-spectrum matches (PSMs) and relative quantification with the TMT 
labels.  
For the LC-MS/MS, 12 µg were loaded into the chromatographic column and 
each of the eight fractions obtained after bRP from each of the two 10plexes was 
injected in a double shot (e.g. injected twice), generating a total of 32 raw files. 
Peptides and proteins identification was carried out with the Proteome Discoverer 
1.4 (PD) and quantitative analysis was performed using the TMTcalibrator™ 
bioinformatics pipeline, consisting of the Calibrator Data Integration Tool (CalDIT) 
and the Feature Selection Tool (FeaST) (Figure 5.4). Following, the functional 
Analysis Tool (FAT) provided a comprehensive characterization of the output 
data. 
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Figure 5.4. TMTcalibrator™: bioinformatic pipeline. 
After MS/MS spectra (raw data) acquisition, the intensity of each channel was corrected for 
background and cross-talking between tags in the second mass spectrometer (MS2). Intensity 
values of the detected Peptide-Spectrum Matches (PSMs) were normalised with a reference 
value generated as the average of the Calibrant channels and this was followed by PSM-to-
peptide summarisation defined as “trimmed mean”. In this passage the data points considered as 
outliers in each analytical sample were removed stabilizing the mean before merging the data 
obtained from the two 10plexes analysed. Then, “not available data points (NA)” filtering, 
imputation and quantile normalization were performed on the merged data set, so that it was 
possible to perform a Principal Component Analysis (PCA) on the data acquired. It was also 
possible to evaluate the TMT batch effect within linear models for microarray data (LIMMA). After 
peptide-to-protein summarisation, statistical significance of the protein groups identified was 
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analysed with LIMMA-based t-test (p-Value < 0.05, Fold Change threshold = 1.5). PCA showed 
a separation between the ALS and HC protein groups in the first component of 41.17%. 
5.4 Bioinformatics pipeline 
After peptides and proteins identification obtained using Proteome Discoverer 
v1.4 (PD), a total of 679471 PSMs were identified, of which 323442 belonged to 
10plex1 (Table 5.3) and 356029 to 10plex2 (Table 5.4). These PSMs were 
grouped by PD in 99749 peptides. With CalDIT, the intensity distribution in the 
two 10plexes was corrected for cross-talk between different tags (185). The four 
calibrant channels were then normalised using the median values to evaluate 
variability and to generate reference values to be used in the normalisation 
process of the analytical sample intensities (expressed as log2; PSM intensity in 
the sample/PSM intensity of the reference value) (Figure 5.4).  
Following normalisation, the data obtained from the analytical channels were 
subjected to PSM-to-peptide summarisation, providing data sets with quantitative 
information on 82565 PSMs in 10plex1 and 85567 PSMs in 10plex2. At this stage, 
the calibrator channels were corrected according to the median intensity and 
normalised across the two 10plexes, to generate a data matrix with the intensities 
from each analytical sample for each peptide reported in the peptide list. 
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 ALS1 ALS2 ALS3 HC1 HC2 HC3 Cal1X Cal4X Cal6X Cal10X 
Total PSMs 323442 323442 323442 323442 323442 323442 323442 323442 323442 323442 
PSMs with 
quantitative data 
131473 144640 130907 110389 141858 178085 236983 291190 299265 307340 
Peptides 49688 52877 49597 42822 52134 58864 70059 78892 80159 81178 
Protein groups 7515 7645 7510 7080 7529 7808 8318 8907 9003 9096 
Table 5.3. Peptide and protein identification performance in 10plex1. 
Number of peptide-spectrum matches (PSMs), peptides and protein groups identified for each sample in 10plex1 using Proteome Discoverer 1.4 (PD). ALS and HC 
samples are shown in light-orange and light-blue colour-code respectively. 
Total PSMs: number of PSMs detected in 10plex1 
PSMs with quantitative data: number of peptide-spectrum matches (PSMs) containing quantitative data for the specific sample 
Peptides: number of identified peptides for that specific sample 
Protein groups: number of identified protein groups for that specific sample 
 ALS4 ALS5 ALS6 HC4 HC5 HC6 Cal1X Cal4X Cal6X Cal10X 
Total PSMs 356029 356029 356029 356029 356029 356029 356029 356029 356029 356029 
PSMs with 
quantitative data 
112219 166427 132753 153268 158746 198459 253218 316195 326344 336944 
Peptides 43203 57998 49641 54729 56251 63677 73704 82383 83563 84530 
Protein groups 7168 7945 7575 7808 7809 8097 8581 9192 9291 9393 
Table 5.4. Peptide and protein identification performance in 10plex2. 
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Number of peptide-spectrum matches (PSMs), peptides and protein groups identified for each sample in 10plex2 using Proteome Discoverer 1.4 (PD). ALS and HC 
samples are shown in light-orange and light-blue colour-code respectively. 
Total PSMs: number of all the PSMs detected in 10plex2 
PSMs with quantitative data: number of peptide-spectrum matches (PSMs) containing quantitative data for the specific sample 
Peptides: number of identified peptides for that specific sample 
Peptides: number of identified peptides for that specific sample 
Protein groups: number of identified protein groups for that specific sample
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Feature Selection Tool (FeaST) was then used to filter out the peptides with more 
than two “not available data point” (NA) from the ALS and HC experimental 
groups. FeaST was also used to impute the NAs for those peptides identified in 
at least four out of six analytical channels in each experimental group. In this way, 
FeaST generated a matrix with quantitative data for 37638 peptides represented 
in both ALS and HC experimental groups. This subset was then normalised again 
on calibrant quantile distribution and examined by linear models for microarray 
data (LIMMA)-based modified t-Test to evaluate a possible batch-effect of the 
TMT labels in the two 10plexes which may have affected the quantification of the 
samples. The TMT batch-effect was evaluated by principal component analysis 
(PCA) and quantified for the 21.78% of the variance between the two 
experimental groups (Figure 5.5A). After batch-effect removal, samples could not 
be separated based on the two different 10plexes and variation was reduced to 
15.95% (Figure 5.5B).  
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Figure 5.5. Principal component analysis (PCA) of the ALS and HC proteomic data for 
Tandem Mass Tag (TMT) batch-effect. 
(A) The figure shows the TMT batch-effect on the ALS and HC proteomic data without LIMMA 
test correction. PCA was performed to study the variance between the two 10plexes (TMT01 and 
TMT02) as dimension 1 and between the experimental groups (ALS and HC) as the dimension 
2. ALS and HC samples appeared to group according to the 10plex in which they were analysed, 
suggesting a strong batch effect. (B) After the TMT batch-effect removal by linear models for 
microarray data LIMMA, the PCA showed that the samples analysed by TMTcalibrator™ did not 
group according to the different TMT 10plexes and that there was minimal separation between 
ALS and HC datasets. 
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FeaST protein grouping and peptide-to-protein summarisation (Figure 5.4) 
generated a list of 4973 protein groups which were further analysed by LIMMA-
based t-test at protein level. Statistical analysis of the data at peptide and protein 
level resulted in 229 peptides (0.61%, of the identified peptides) and 285 protein 
groups (5.7%, of the identified proteins) which were statistically significant (Figure 
5.6).  
 
Figure 5.6. Volcano plots of the regulated features detected using TMTcalibrator™ and 
analysed by LIMMA. 
178 
 
The volcano plots show the distribution of the peptides (A) and proteins (B) identified in the TMT 
proteomic study according to their fold change (FC) expressed as log2 (fold change ALS/HC) 
(logFC) in the x axis and according to p-value expressed as –log10 (p-value) in the y axis. In (A), 
peptides were considered regulated if p-value < 0.005 and logFC <-1 or > 1. In (B), protein groups 
were considered regulated if p-value < 0.05 and logFC < -0.58 or > 0.58. Red dots are regulated 
features, yellow dots are features with a significant p-value (p < 0.05) and logFC between -0.58 
and 0.58 while green dots are not significant features. Uniprot Ids are reported beside the dots, 
with the specific peptide sequence in (A), with significant p-value. 
PCA analysis of the regulated features in the ALS vs HC TMT proteomic 
experiment showed a variance of 59.92% at peptide level and of 41.17% at 
protein level in the first dimension (Figure 5.7), supporting the observation of a 
significant difference in brain derived proteins in plasma NCHs from HC and from 
ALS individuals. ALS patients and HC proteomic datasets appeared grouped 
separately when the same regulated features were tested using relative 
clustering after LIMMA t-test analysis and represented using heatmaps (Figure 
5.8). 
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Figure 5.7. PCA of the regulated features identified in the ALS vs HC NCHs TMT proteomic 
analysis. 
PCA shows a good separation between the ALS and HC experimental groups regulated features 
at peptide (A) and protein (B) levels. The two PCAs were performed considering the variance 
between the two experimental groups (ALS and HC) as dimension 1 and the variance between 
10plexes (TMT01 and TMT02) as the dimension 2. The ALS and HC samples analysed are clearly 
grouped and separated in distinct experimental groups. 
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Figure 5.8. Heatmaps and clustering of the regulated features identified in the ALS vs HC 
NCHs TMT proteomics analysis detected using the LIMMA test. 
The heatmaps in (A) and (B) show the distribution of the regulated features, and relative 
clustering, at peptide and protein level respectively. The regulated features are distributed 
vertically, with the Uniprot IDs on the right-hand side and relative clustering on the left-hand side, 
while the analytical samples are distributed horizontally, with sample names at the bottom and 
relative clustering at the top of the heatmaps. ALS patients and the HC distributed in separate 
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clusters in both diagrams. The colour key histogram at the top left side shows the distribution of 
the features and the heatmap colour coding. 
5.5 FeaST analysis of regulated features at protein level 
The final list of proteins identified in plasma NCHs and related quantitative data 
produced by FeaST contained almost 5000 brain-derived proteins, including 
neurofilaments (Nf). All three Nf protein isoforms of interest were identified. Nf 
Light (NfL), Nf Medium (NfM) and Nf Heavy (NfH) were found at a relatively higher 
level in the ALS samples compare to HC (log2-fold change ALS/HC) (logFC) = 
0.093, 0.181 and 0.298, respectively) but none was significantly regulated (p= 
0.40, 0.16 and 0.06 respectively). Matching the FeaST protein list with the ALS 
gene list obtained from www.malacards.org (186), an integrated database of 
human diseases and their annotations, we found 24 proteins matching our list of 
protein and only Fused in Sarcoma RNA-binding protein (FUS) was found to be 
significantly regulated in ALS vs Control (p=6.96E-03) (Table 5.5).  
 
Gene 
name 
 Uniprot ID Protein name 
Unique 
peptides 
logFC 
p-
value 
FUS  P35637-2 
Isoform Short of 
RNA-binding protein 
FUS 
5 0.564 
6.96E
-03 
NEFH  P12036 
Neurofilament 
heavy polypeptide 
27 0.298 
6.36E
-02 
OPTN  Q96CV9 Optineurin 11 -0.243 
9.58E
-02 
UNC13A  Q9UPW8 
Protein unc-13 
homolog A 
11 -0.326 
9.75E
-02 
PON2  Q15165-3 
Isoform 3 of Serum 
paraoxonase/arylest
erase 2 
1 0.292 
1.46E
-01 
ANG  P03950 Angiogenin 1 -0.595 
1.67E
-01 
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Gene 
name 
 Uniprot ID Protein name 
Unique 
peptides 
logFC 
p-
value 
CHMP2B  Q9UQN3 
Charged 
multivesicular body 
protein 2b 
1 0.492 
1.90E
-01 
VCP  P55072 
Transitional 
endoplasmic 
reticulum ATPase 
65 -0.514 
2.16E
-01 
ATXN2  Q99700-2 
Isoform 2 of Ataxin-
2 
2 -0.445 
2.51E
-01 
ANXA11  P50995-2 
Isoform 2 of 
Annexin A11 
16 0.150 
3.01E
-01 
SOD1  P00441 
Superoxide 
dismutase [Cu-Zn] 
8 0.176 
3.39E
-01 
ERBB4  Q15303-4 
Isoform JM-B CYT-2 
of Receptor 
tyrosine-protein 
kinase erbB-4 
1 -0.284 
3.70E
-01 
TARDBP  Q13148 
TAR DNA-binding 
protein 43 
2 0.180 
3.85E
-01 
SQSTM1  Q13501 Sequestosome-1 2 -0.280 
4.00E
-01 
MATR3  P43243 Matrin-3 16 0.127 
4.03E
-01 
PFN1  P07737 Profilin-1 14 0.136 
4.08E
-01 
VAPB  O95292 
Vesicle-associated 
membrane protein-
associated protein 
B/C 
10 -0.094 
4.31E
-01 
EPHA4  P54764 
Ephrin type-A 
receptor 4 
13 -0.082 
5.37E
-01 
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Gene 
name 
 Uniprot ID Protein name 
Unique 
peptides 
logFC 
p-
value 
PON1  P27169 
Serum 
paraoxonase/arylest
erase 1 
14 0.123 
6.07E
-01 
TAF15  Q92804-2 
Isoform Short of 
TATA-binding 
protein-associated 
factor 2N 
3 0.067 
6.99E
-01 
UBQLN2  Q9UHD9 Ubiquilin-2 4 -0.065 
6.99E
-01 
HNRNPA
1 
 P09651-3 
Isoform 2 of 
Heterogeneous 
nuclear 
ribonucleoprotein 
A1 
8 -0.066 
7.50E
-01 
DCTN1  Q14203-6 
Isoform 6 of 
Dynactin subunit 1 
2 0.020 
9.34E
-01 
TBK1  Q9UHD2 
Serine/threonine-
protein kinase TBK1 
5 -0.004 
9.86E
-01 
Table 5.5. List of proteins from ALS genes found in the ALS vs HC TMTcalibrator™ data 
and level of regulation. 
The table outlines the ALS genes proteins and their regulation identified matching the ALS vs HC 
TMT-proteomic dataset against the gene classifiers include in the MalaCards Human Disease 
Databse 
(https://www.malacards.org/card/amyotrophic_lateral_sclerosis_1#RelatedGenes-table) 
(186), selecting only the “elite genes” which are those more likely to cause the disease. 38 elite 
genes were identified, of which 24 linked to ALS were detected in the list generated by the 
TMTcalibrator™ experiments. The “elite genes” not identified in the TMTcalibrator™ data set: 
PPARG Coactivator 1 Alpha (PPARGC1A), Triggering Receptor Expressed On Myeloid Cells 2 
(TREM2), NIMA Related Kinase 1 (NEK1), Amyotrophic Lateral Sclerosis 3 and 7 (ALS3, ALS7), 
Paraoxonase 3 (PON3), Chromosome 21 Open Reading Frame 2 (C21orf2), RNA Export 
Mediator GLE1 (GLE1), Cyclin F (CCNF), Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 
10 (CHCHD10), D-Amino Acid Oxidase (DAO), FIG4 Phosphoinositide 5-Phosphatase (FIG4), 
Chromosome 9 Open Reading Frame 72 (C9orf72) and Peripherin (PRPH). 
Uniprot ID: Uniprot database protein identifier 
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Gene name: the gene symbol used to represent a gene 
Protein name: protein full name recommended by Uniprot 
Unique peptides: number of peptide sequences unique to a protein group 
logFC: relative quantification with value expressed as log2(ALS/HC) intensities 
p-value: statistical significance for differential regulation between ALS and HC experimental 
groups 
Of the 5000 brain-derived proteins identified in the TMT Calibrator experiment, 
285 proteins showed a statistically significant regulation (p < 0.05). 158 were 
more highly expressed in HC (logFC < 0) with an average fold change of -0.667, 
while 127 showed a higher expression in ALS (logFC > 0) with an average fold 
change of 0.703. It is reasonable to think that all these regulated proteins are 
potential biomarker candidates of ALS as they are brain proteins in circulation, 
found in systemic aggregates, which present a differential expression in relation 
to the pathological state. Future work will have to include the selection of the best 
candidates to be considered for further validation in larger cohorts of ALS and 
HC, using a different methodological approach like immunodetection. The 
selection of the best candidates for future studies will hinge not only on the 
reported level of disease-regulation, but also on the functional role of the protein 
in the disease pathogenesis and availability of screening methods that would 
make high-throughput experiments easy to perform. Based on the overall findings 
so far, the ideal candidate biomarker of ALS would have to be central to the main 
pathogenic alterations in brain tissue and plasma that our proteomic study has 
identified like for example biochemical changes. The neurochemical marker will 
ideally be readily measurable and could possibly be used as measure of 
treatment response and of target engagement in new therapeutic strategies 
(187–190). For this reason, we will also include a functional study of the proteins 
identified within the TMT Calibrator proteomic data set, to gain insight into the 
biochemical and physiological changes that these candidates underpin in the 
context of the ALS pathology. 
5.6 Functional analysis 
As described in Paragraph 2.5.2.2, Functional Analysis Tool (FAT) was used to 
evaluate enriched and regulated functional categories among the reported 
peptides and proteins produced by FeaST. As our MS-based proteomic study 
focused primarily on peptide sequencing and identification, we deemed the 
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information obtained at peptide level more accurate. However, considering the 
overall aim to identify readily detectable biomarkers in plasma to help in ALS 
diagnosis, prognosis and patient stratification only information obtained at protein 
level were further considered.  
Briefly, the list of proteins generated was searched to identify specific functional 
categories, such as gene ontology (GO) terms and pathways through searches 
in multiple databases, and the output at defined statistical thresholds was a list of 
enriched and regulated pathways.  
FAT analysis of “regulated” features (Paragraph 2.5.2.2) proved to be more 
sensible to subtle changes in the data set compared to FAT analysis of “enriched” 
data and also more capable of highlighting the presence of categories otherwise 
not detectable by the enrichment analysis.  As already reported in Paragraph 
2.5.2.2, the ability to depict different functional terms in FAT analysis rests on the 
statistical methods applied to mine different databases with the submitted  protein 
lists. In contrast, FAT enrichment analysis performed at protein level was not 
effective in disclosing meaningful changes in our datasets. For this reason, FAT 
regulated analysis was used to evaluate the physiological and biochemical 
changes intrinsic to our datasets. 
Regulated FAT analysis (p-value < 0.05) identified 69 biochemical pathways, 77 
gene ontology (GO) biological process (BP), 10 GO molecular function (MF), 19 
GO cellular component (CC), 1 protein motif, 4 protein domain and 12 miRNA 
targets. The regulated pathway analysis pointed to relevant molecular 
mechanisms involved in ALS pathology and covered proteins acting as potential 
biomarkers.  
Within the top10 regulated pathways (Table 5.6), five out of the top10 were 
involved in metabolism of lipoproteins (lipoprotein metabolism, plasma lipoprotein 
assembly, remodelling and clearance, plasma lipoprotein assembly, lipid 
digestion, mobilization and transport, plasma lipoprotein remodelling), all showing 
a higher level of expression in ALS (median FC > 0). 
The significant representation of these pathways in our brain/NCHs proteomes 
reflects known changes of the ALS pathophysiology, where metabolism is 
thought to be switched from sugar and carbohydrate to lipid use (191–193). 
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Based on this observation, it may be reasonable to consider NCHs as a good 
readout of the pathological changes that are central to the pathogenesis of ALS. 
However, none of the single proteins belonging to these pathways showed a 
significant regulation (p-value < 0.05), making them less relevant as potential 
target biomarkers in ALS. 
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Pathway description 
Number of genes 
in the category 
p-Value Median logFC 
Lipoprotein metabolism [Reactome] 27 4.11E-04 0.19 
Dopamine Neurotransmitter Release Cycle [Reactome] 15 4.53E-04 0.24 
DCC mediated attractive signaling [Reactome] 8 6.65E-04 0.36 
Plasma lipoprotein assembly, remodeling, and clearance [Reactome] 25 8.03E-04 0.19 
Plasma lipoprotein assembly [Reactome] 13 1.65E-03 0.29 
Netrin-1 signaling [Reactome] 15 4.80E-03 0.20 
Lipid digestion, mobilization, and transport [Reactome] 36 5.25E-03 0.11 
Oncostatin M Signaling Pathway [Wikipathways] 21 8.09E-03 -0.13 
Plasma lipoprotein remodeling [Reactome] 9 8.16E-03 0.19 
CD28 dependent Vav1 pathway [Reactome] 6 8.35E-03 0.28 
Table 5.6. FAT analysis of the ALS vs HC TMT proteomic analysis: top10 regulated pathways. 
Pathway description: name of the pathway identified (reference database in square brackets, e.g. [Reactome]) 
Number of genes in the category: Number of genes included in the given pathway in Homo sapiens 
p-Value: Statistical significance calculated by the Mann-Whitney U test as described in Paragraph 2.5.2.2 
Median logFC: median value of expression (logFC values of the proteins included in the given pathway in Homo sapiens)
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The dopamine neurotransmitter release cycle pathway relates to biochemical 
mechanisms linked to dopamine (DA) biosynthesis: dopamine is loaded into 
vesicles which are then docked, primed and fused with the plasma membrane of 
synapses to release dopamine into the synaptic cleft. In the literature, IgG from 
ALS patients were found to block DA secretion from PC12 cell line (194), pointing 
towards the possible involvement of this pathway in ALS. Data analysis showed 
that protein lin-7 homolog B (LIN7B; unique peptide= 1, logFC= 0.529, pValue= 
0.0277) was the only significantly regulated protein. This protein takes part in the 
tripartite complex composed of LIN7 (LIN7A, LIN7B or LIN7C), CASK and 
APBA1, and may have the potential to couple synaptic vesicle exocytosis to cell 
adhesion in brain. Unfortunately, there is no literature linking these proteins to 
ALS. 
The Colorectal Carcinoma (DCC) mediated attractive signalling is intrinsic to the 
organisation of actin cytoskeleton after activation of a complex between DCC, 
protein tyrosine kinase 2/FAK and src family kinases. This pathway is not 
reported as linked to the pathogenesis of ALS or to neurodegeneration. No 
protein represented in this pathway was statistically regulated in our data set. 
Netrin-1 signalling includes proteins (Netrins) which are secreted and play a 
crucial role in neuronal migration and in axon guidance during the development 
of the nervous system. Among them, netrin-1 is the most studied member of the 
family and has been shown to play a crucial role in neuronal navigation during 
nervous system development mainly through its interaction with DCC and UNC5 
Netrin Receptor (UNC5) receptors. Of note Fused in Sarcoma (FUS) which is 
known as causative protein of ALS and found to be regulated in our dataset is 
known to be involved in Netrin signalling with the regulation of netrin-1 splicing 
(195). However, none of the proteins involved in the netrin-1 signalling pathway 
was found to be statistically regulated in our protein list. 
Oncostatin M (OSM) signalling pathway is part of the multifunctional cytokine 
interleukin 6 (IL6) - type cytokine family and it is mainly produced in immune cells. 
It is responsible of inducing transcription through different pathways, including the 
activation of caspase family members (CASP3, CASP7, CASP9) through the 
JAK2 module and has been implicated in biological mechanisms linked to 
apoptosis and neuronal protection (196). CASP3 regulation in our dataset was 
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very close to statistical significance and may be a good target for a larger scale 
validation experiment (unique peptide= 2, logFC= -0.708, p= 0.0544) . 
CD28 dependent Vav1 pathway is involved in T-cells activation by stimulation of 
Vav1 through CD28, inducing multiple biochemical pathways and several 
cytoskeleton-dependent processes. The regulation of this pathway may bear 
significance in the T-cell mediated immune response known to occur in ALS 
(197). No protein from this pathway was found to be statistically regulated. 
5.6.1 Identification of highly regulated proteins by FeaST analysis 
Functional analysis of the brain/plasma NCHs proteomes provided clues on the 
likely biochemical changes linked to ALS and also confirmed our hypothesis that 
NCHs may carry important information on the pathophysiological changes 
occurring in this neurological disorder. For the purpose of selecting the best 
targets for biomarkers analysis, the list of proteins obtained using FeaST was 
further filtered to identify those with a high level of regulation. Statistical 
significance (p-value < 0.05), number of unique peptides (≥ 2) and high regulation 
(logFC < -0.693 OR > 0.693) were set as main criteria. This additional filtering 
process generated a list of 48 protein groups that were matched to the regulated 
pathways identified by FAT to assess their relevance in the biochemical changes 
identified in ALS and as biomarkers (Table 5.7).
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Uniprot ID Gene name Protein name 
Unique 
peptides 
logFC p-value 
Q9P2W3 GNG13 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-13 2 -1.276 6.32E-03 
A0A0C4DH67 IGKV1-8 Immunoglobulin kappa variable 1-8 2 -1.273 1.39E-02 
O75157-2 TSC22D2 Isoform 2 of TSC22 domain family protein 2 2 -1.245 1.15E-02 
Q9NRZ5 AGPAT4 1-acyl-sn-glycerol-3-phosphate acyltransferase delta 2 -1.205 6.21E-04 
P35579 MYH9 Myosin-9 82 -1.000 2.70E-02 
Q9Y3E2 BOLA1 BolA-like protein 1 2 -0.994 3.48E-02 
Q5QJ74 TBCEL Tubulin-specific chaperone cofactor E-like protein 2 -0.941 1.50E-02 
Q53GQ0 HSD17B12 Very-long-chain 3-oxoacyl-CoA reductase 5 -0.910 7.70E-03 
Q9UHI5 SLC7A8 Large neutral amino acids transporter small subunit 2 2 -0.867 2.62E-02 
Q16718 NDUFA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 2 -0.862 4.52E-03 
Q9BU02 THTPA Thiamine-triphosphatase 2 -0.838 3.92E-03 
O75487 GPC4 Glypican-4 2 -0.834 4.10E-02 
O15084 ANKRD28 
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat 
subunit A 
3 -0.809 1.92E-02 
P29144 TPP2 Tripeptidyl-peptidase 2 37 -0.789 3.62E-02 
A8MWD9 SNRPGP15 Putative small nuclear ribonucleoprotein G-like protein 15 3 -0.768 1.36E-02 
Q9NX63 CHCHD3 MICOS complex subunit MIC19 10 -0.763 4.14E-03 
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Uniprot ID Gene name Protein name 
Unique 
peptides 
logFC p-value 
Q53H82 LACTB2 Endoribonuclease LACTB2 2 -0.756 5.56E-03 
P50238 CRIP1 Cysteine-rich protein 1 3 -0.742 2.61E-02 
P00813 ADA Adenosine deaminase 3 -0.733 1.16E-02 
P51116 FXR2 Fragile X mental retardation syndrome-related protein 2 3 -0.723 1.93E-03 
P40855 PEX19 Peroxisomal biogenesis factor 19 2 -0.722 9.35E-03 
P38919 EIF4A3 Eukaryotic initiation factor 4A-III 6 -0.709 7.35E-03 
Q9BYH1-3 SEZ6L Isoform 2 of Seizure 6-like protein 4 -0.697 8.24E-03 
Q9BV20 MRI1 Methylthioribose-1-phosphate isomerase 4 -0.692 3.74E-03 
P52788 SMS Spermine synthase 5 -0.689 2.44E-02 
Q99470 SDF2 Stromal cell-derived factor 2 2 -0.682 4.26E-03 
Q9NPB8 GPCPD1 Glycerophosphocholine phosphodiesterase GPCPD1 2 0.683 1.19E-02 
O14514 BAI1 Brain-specific angiogenesis inhibitor 1 2 0.697 9.31E-03 
Q6NXE6-2 ARMC6 Isoform 2 of Armadillo repeat-containing protein 6 2 0.700 1.87E-02 
Q99729-3 HNRNPAB Isoform 3 of Heterogeneous nuclear ribonucleoprotein A/B 3 0.706 5.29E-03 
Q9HD89 RETN Resistin 4 0.754 2.78E-02 
P55083 MFAP4 Microfibril-associated glycoprotein 4 2 0.761 1.09E-02 
Q06828 FMOD Fibromodulin 3 0.770 9.28E-03 
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Uniprot ID Gene name Protein name 
Unique 
peptides 
logFC p-value 
P45984-3 MAPK9 Isoform Beta-1 of Mitogen-activated protein kinase 9 2 0.789 2.87E-02 
Q9Y3C8 UFC1 Ubiquitin-fold modifier-conjugating enzyme 1 2 0.803 3.52E-02 
Q9NRA0-2 SPHK2 Isoform 2 of Sphingosine kinase 2 2 0.897 3.39E-02 
P04275 VWF von Willebrand factor 127 0.910 4.69E-02 
P16519-2 PCSK2 Isoform 2 of Neuroendocrine convertase 2 3 0.911 1.35E-02 
P35219 CA8 Carbonic anhydrase-related protein 2 0.925 5.23E-03 
Q9HAU0-2 PLEKHA5 
Isoform 2 of Pleckstrin homology domain-containing family A member 
5 
2 0.933 1.84E-02 
Q9Y328 NSG2 Neuron-specific protein family member 2 2 0.981 2.73E-03 
Q00537 CDK17 Cyclin-dependent kinase 17 2 1.043 4.11E-03 
O60814 HIST1H2BK Histone H2B type 1-K 2 1.049 6.97E-03 
P49406 MRPL19 39S ribosomal protein L19, mitochondrial 2 1.062 4.76E-03 
Q8IX12-2 CCAR1 Isoform 2 of Cell division cycle and apoptosis regulator protein 1 2 1.113 1.77E-03 
Q96F86 EDC3 Enhancer of mRNA-decapping protein 3 2 1.134 4.15E-02 
O15533-2 TAPBP Isoform 2 of Tapasin 2 1.224 1.09E-03 
P27449 ATP6V0C V-type proton ATPase 16 kDa proteolipid subunit 2 1.635 3.23E-02 
Table 5.7. Protein groups highly regulated in ALS vs HC identified by FeaST analysis of TMT calibrator NCHs proteome. 
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The initial protein list obtained using FeaST (Paragraph 5.5) was further filtered using stringent criteria including protein groups with at least 2 unique peptides, p-
Value < 0.05 and logFC < -0.693 OR > 0.693. 
Uniprot ID: Uniprot database protein identifier 
Gene name: the recommended gene symbol used to officially represent a gene 
Protein name: protein full name recommended by Uniprot 
Unique peptides: number of peptide sequences unique to a protein group 
logFC: relative quantification with value expressed as log2(ALS/HC) intensities 
p-value: statistical significance of the differential regulation between ALS and HC experimental groups
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In the context of our study, the intersection between the most regulated proteins 
(obtained by Feast analysis) and the top biochemical pathways in our proteome 
data (identified by FAT) provides a view of the more crucial aspects of the ALS 
pathological cascade. In particular, four biochemical pathways seem to represent 
the most consistent changes at a proteomic levels: metabolism of carbohydrates 
(p= 0.0099), lysosome (p= 0.0015), synthesis of phosphatidic acid (p= 0.0184) 
and wnt signalling pathway (p= 0.0337). The main aspects of these biochemical 
pathways will be briefly summarized below. 
5.6.1.1 Metabolism of carbohydrates 
The “metabolism of carbohydrates”, a category of the Reactome database, 
describes the extraction of energy from sugars and its storage as glycogen. As 
described in Chapter 4, molecular features linked to the usage of sugars for 
energy production (e.g. ATP) were identified as highly represented in the HC 
sample.  This pathway contains two highly regulated proteins: glypican-4 (GPC4) 
and fibromodulin (FMOD) (Table 5.7), which are also part of the 
glycosaminoglycans (GAGs) metabolism, a sub-pathway of “metabolism of 
carbohydrates” (Figure 5.9). GAGs are long, unbranched polysaccharides 
composed by a disaccharide unit of a hexosamine (either N-acetylgalactosamine 
(GalNAc) or N-acetylglucosamine (GlcNAc)) and an uronic acid (glucuronate or 
iduronate), which are heavily sulfated. Moreover, they are located primarily in the 
extracellular matrix (ECM) and on cell membranes, where the glycoproteins 
carrying these polysaccharides (also called proteoglycans (PGs)) are involved in 
structural and morphological changes but also in cell signaling (198). PGs are 
produced in the Golgi and degraded in the lysosome (Figure 5.9). In particular, 
FMOD and GPC4 are part of protein complexes involved in keratan sulphate (KS) 
and heparan sulphate (HS) PGs synthesis and degradation.  
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Figure 5.9. Metabolim of carbohydrates: Reactome database. 
The metabolism of carbohydrates is a complex interplay of pathways involved in energy 
production from sugars and its storage as ATP and glycogen. The red box highlight 
glycosamminoglycan metabolism. Image source https://reactome.org/PathwayBrowser/. 
Keratin sulphate (KS) is linked to several proteins that are expressed in the 
extracellular matrix (ECM) of connective and epithelial tissues, but also in the 
nervous system (199). This protein has been implicated in the pathogenesis of 
ALS, with the report  of changes of KS sulfonation levels of spinal cord microglia 
in SOD1G93A mice and ALS patients in the early and late phase of the disease 
(200,201).  
Proteoglycans carrying heparan sulphate (HS, HSPGs) are ubiquitously 
expressed and due to their location can function as receptors, which are possibly 
involved in aggregation processes (202,203). In particular, it has been shown that 
HSPGs are mediators of tau fibril binding and uptake in this protein’ seeding of 
aggregation in mouse and human cell lines (204). HS branches were shown to 
be responsible of fibril formation, acting as a scaffold that stabilises the oligomeric 
proto-filament structure.  This fibril formation process appears to be relevant also 
for prion protein, islet amyloid polypeptide, a-synuclein, amyloid-ß and tau  (205). 
It is therefore possible that that GAGs, in particular HSPG, could play a central 
role in protein aggregation biology that is a key pathological feature in ALS. 
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The review of our proteomic data on the GPC4 protein complex showed that 
biglycan (BGN; unique peptides= 8; logFC= -0.369; p= 0.024) was significantly 
regulated, adding substance to the potential role for GAGs metabolism 
involvement in the biochemical changes observed in ALS. Biglycan (BGN) is a 
protein involved in HSPGs synthesis and in chondroitin sulphate (CS) PGs 
synthesis and degradation. Chondroitin sulphate proteoglycans (CSPGs) are the 
major component of ECM in mammal’s central nervous system. Critically for ALS 
pathogenesis and neurodegeneration in general, an abnormal expression of CS 
proteoglycans has been shown in  astrocytes (206) and spinal motor neurons 
(207) of SOD1 transgenic rats, while CSPGs have been found inside of inclusion 
bodies in brain tissues from patients affected by several neurodegenerative 
diseases (208). 
5.6.1.2 Lysosome 
The KEGG database “lysosome” pathway encompasses the biochemical 
changes taking place during lysosomes formation. Lysosomes are membrane-
delimited organelles working as the main digestive compartment within the cells, 
thanks to the presence of hydrolytic enzymes that can break down different 
molecules. After synthesis in the endoplasmatic reticulum (ER), lysosomal 
enzymes are decorated with mannose-6-phosphate residues, which are 
recognized by mannose-6-phosphate receptors (M6PR and MPRI) in the trans-
Golgi network, then packaged into clathrin-coated vesicles and transported to late 
endosomes to fuse into the lysosome (Figure 5.10). Molecules are acquired for 
digestion in the lysosome by endocytosis, phagocytosis and autophagy (Figure 
5.10).  
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Figure 5.10. Lysosome pathway: KEGG database. 
The figure depicts the entire KEGG lysosome pathway with squared rectangles representing gene 
products (e.g. proteins) and rounded rectangles representing maps (e.g. other pathways). The 
objects filled in green indicated the genes/proteins involved in the pathway, while the boxes 
highlighted with a red outline and font indicated the genes/proteins significantly regulated in our 
data set.  
In our proteome, the lysosome pathway emerges as relevant at different levels: 
1) the regulation of key proteins like the V-type proton ATPase 16 kDa proteolipid 
subunit (ATP6V0C) (Table 5.7) , of cathepsin L1 (CTSL; unique peptides= 2, 
logFC= -0.529, p= 0.0115) and Cation-dependent mannose-6-phosphate 
receptor (M6PR; unique peptides= 2, logFC= 0.522, p= 0.0384) and 2) the 
regulation of the GO cellular component (CC) lysosome function-related clathrin-
coated vesicle membrane (p= 0.00751) and biological process (BP) adaptor 
protein (AP)-2 adaptor complex (p= 0.0115) emerging through FAT analysis. 
Lysosomal dysfunction is well described in ALS especially in relation with 
autophagy (autolysosome). It is not clear whether the lysosomal proteolytic 
cascade is synergic to or in opposition to activity of the proteasome, raising 
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questions regarding how protein degradation in ALS become affected in the 
pathological process (150,151). In sporadic ALS, it has been shown that 
molecular  pathways driving autophagy are activated specifically in motor 
neurons (209). Another important evidence of the involvement of autophagy in 
ALS comes from studies on the main ALS causative gene, C9orf72, which is 
supposed to play a central role in vesicle trafficking and autophagy initiation 
(210,211).  
ATP6V0C, a highly regulated protein identified in this pathway, is a proton-
conducting pore subunit of the membrane integral V0 complex of vacuolar 
ATPase, which is responsible for lysosome acidification. It has also a central role 
in cell homeostasis as part of gap-junction and neurotransmitter release when it 
is located in the plasma membrane (212,213). Its inhibition leads to apoptosis 
(214). 
CTSL is part of a class of proteins called cathepsins, a group of lysosomal 
proteases that are activated by the low pH and have a key role in cellular protein 
turnover. Cathepsins include different type of proteases (serine, aspartic and 
cysteine proteases) and CTSL is part of the cysteine protease. The hydrolytic 
activity of these proteins in is reduced in ALS and in other neurodegenerative 
diseases (215–217). Plasma levels of cathepsins in patients affected by 
Alzheimer’s disease were found to be higher than in HC but not specifically CTSL 
(218). Interestingly, through the activation of CASP3,  CTSL has a role in the 
cross-talk between autophagy and apoptosis in neuronal cell line exposed to 
dopamine (DA) (219). This connection could be of relevance in our study, since 
DA release cycle is one of the key pathways in our dataset (Table 5.6). Moreover, 
it has been shown that in a catechol-O-methyltransferase (COMT) drosophila 
model, a defect in CTSL trafficking to the lysosome leads to inability to sustain 
autophagy under stress (220) , adding evidence that autophagy impairment and 
CTSL trafficking are centrally placed in the pathogenesis of neurodegenerative 
disorders. 
The other differentially regulated protein found in this pathway was M6PR, which 
is involved in the transport of phosphorylated lysosomal enzymes from the Golgi 
complex and from the cell surface to lysosomes. Lysosomal enzymes bearing 
phosphomannosyl residues bind specifically to mannose-6-phosphate receptors 
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in the Golgi apparatus and the resulting receptor-ligand complex is transported 
to an acidic prelysosomal compartment where the low pH mediates the 
dissociation of the complex. This process was found to be impaired in a model of 
Parkinson’s disease suggesting that the altered lysosome activity may be a 
shared pathological feature across neurodegenerative diseases (221). 
5.6.1.3 Synthesis of phosphatidic acid 
The Reactome database “synthesis of phosphatidic acid (PA)” is about the de 
novo synthesis of PA (Figure 5.11). The pathway starts from the esterification of 
glycerol-3-phosphate (G3P) to lysophosphatidic acid (LPA) mediated by glycerol 
3-phosphate acyltransferase (GPAT), and then LPA is converted to PA by a LPA 
acyltransferase (AGPAT, also known as LPAAT) (Figure 5.12). PA can be also 
formed by phospholipases through hydrolysis of glycerophospholipids, such as 
phosphatidylcholine (PC) and phosphatidylinositol (PI) (Figure 5.11). Because 
PA is a key intermediate metabolite in the synthesis of membrane 
glycerophospholipids, it is also involved in acyl chain remodelling in plasma 
membrane via cleavage by phospholipases followed by re-acylation by 
acyltransferases (222–226). Acyl chains are responsible of membrane curvature 
playing a significant role in membrane vesicle fission and fusion events (227,228). 
The relevance of this pathway in our proteomic analysis relates also to the 
presence of regulated genes like AGPAT (Table 5.7) and lysophosphatidylcholine 
acyltransferase 1 (LPCAT1; unique peptides 1, logFC -0.622, p= 0.0156). 
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Figure 5.11. Synthesis of phosphatidic acid (PA): Reactome database. 
The figures shows the biochemical reactions in the synthesis of phosphatidic (PA), which is an 
intermediate of the glycerophospholipids metabolism. The boxes with brighter colours and the 
blue arrows show the reactions and the molecules taking part in PA synthesis. Green rounded 
circles indicate small molecules (e.g. PA), green rounded boxes indicate proteins, while cyan 
boxes indicate complexes. 
 
Figure 5.12. Phosphatidic acid synthesis from glycerol-3-phosphate. 
Glycerol-3-phosphate (G3P) is converted into lysophosphatidic acid (LPA) through esterification 
by the glycerol 3-phosphate acyltransferase (GPAT), followed by another esterification by LPA 
acyltransferase (AGPAT) to produce phosphatidic acid (PA). AGPAT consists of a complex of ten 
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enzymes. The two acyl chains (R1 and R2) are transferred to G3P and LPA from two molecules 
of acyl-coenzyme A (acyl-CoA1 and 1). Depending on the structure and length of R1 and R2 it can 
be later converted to phosphatidylcholine (PC) and phosphatidylinositol (PI). 
PA has not been directly linked to ALS; however it is synergic with LPA function 
which is involved in cell signalling pathways through G-protein-coupled receptors 
(GPCRs) and Ca2+ level intracellularly which can ultimately be detrimental to cell 
function (229). A further way in which LPA can modulate cell behaviour is by 
altering membrane dynamics and structure. It can stabilise the plasma membrane 
bilayer or induce monolayer curvature by endophilin or 50 kDa brefeldin A 
ribosylated substrate (BARS-50) activity, affecting endocytic and Golgi 
membrane fission (230). Endophilin-B2, identified as secondary isoform, was 
also found significantly regulated (SH3GLB2; unique peptides= 11, logFC= 
0.340, p= 0.0328).  
PA is also functionally linked to all types of phospholipids, biomolecules that have 
been described in ALS pathology. Phosphatidylcholine (PC) was found as highly 
discriminant of ALS pathology in a lipidomic study comparing CSF from ALS 
patients to a group of controls (231), while phosphatidylethanolamine (PE) has 
been evaluated as a cofactor in prion propagation in vitro (232). 
Glycerophospholipids are also involved in cell signaling, as their presence at the 
membrane surface in neurons can be a signal for phagocytosis and a marker for 
neuroinflammation, as seen in Alzheimer’s and Parkinson’s diseases (233,234). 
This suggests that an imbalance in PA (or of glycerophospholipids linked to PA) 
biosynthesis can have a role in neurodegenerative processes. To date, there has 
not been any published comprehensive evaluation of phospholipid expression in 
plasma from ALS patients. 
5.6.1.4 Wnt signalling pathway 
Wnt (wingless/integrated, named after studies conducted in Drosophila) proteins 
are secreted morphogens that are required for basic developmental processes, 
such as cell-fate specification, progenitor-cell proliferation and the control of 
asymmetric cell division, in many different species and organs (235–239). There 
are at least three different wnt pathways: the canonical pathway, the planar cell 
polarity (PCP) pathway and the wnt/Ca2+ pathway (Figure 5.13). The highly 
regulated protein found in this pathway is GPC4 (Table 5.7), which was also 
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involved in GAGs metabolism. Serine/threonine-protein phosphatase 2B catalytic 
subunit alpha (PPP3CA; unique peptides=1, logFC=0.983, p= 0.0147) was also 
found as regulated in this pathway. GPC4 takes part in PCP signalling, leading 
to the activation of the small GTPases RHOA (RAS homologue gene-family 
member A) and RAC1 (Ras-related C3 botulinum toxin substrate 1), which 
activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-
associated coiled-coil-containing protein kinase 1) and leads to remodelling of the 
cytoskeleton and changes in cell adhesion and motility (Figure 5.13). PPP3CA is 
part of the wnt-Ca2+ signalling mediated through G proteins and phospholipases 
and leads to transient increases in cytoplasmic free calcium that subsequently 
activate the protein kinase C (PKC) and calcium calmodulin mediated kinase II 
(CAMKII) and the phosphatase calcineurin (Figure 5.13). 
 
Figure 5.13. Wnt signalling pathway: KEGG database. 
The figure reports the KEGG pathway with squared rectangles representing gene products (e.g. 
proteins) and rounded rectangles representing maps (e.g. other pathways). The objects filled in 
green indicated the genes/proteins involved in the pathway in Homo sapiens and the boxes in red 
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outline and font indicate the genes/proteins significantly regulated in our data set. Knypek is 
GPC4, while CaN is the protein phosphatase 3 (PP3) complex including also PP3CA. 
Published data corroborates wnt signalling pathway involvement in ALS as a 
downstream effect of the neurodegeneration process and inflammation seen in  
SOD1G93A transgenic mice (240–242). However, wnt, and other proteins 
involved in this pathway were not significantly regulated in our data set.  
5.6.2 Other pathways of relevance in ALS 
Looking at the regulated pathway obtained from FAT analysis and matching ALS 
literature, it is worth mentioning: synaptic vesicle pathway (p= 0.00881), 
neurotransmitter release cycle (p= 0.0179), translocation of GLUT4 to the plasma 
membrane (p= 0.0191), SUMOylation of chromatin organisation proteins (p= 
0.0234) and SUMOylation of RNA binding proteins (p= 0.0247).  
Synaptic vesicle pathway, from the Wikipathways database, embodies the 
transmission of neurotransmitters from the presynaptic nerve to the synaptic cleft. 
Two proteins from this pathway were significantly regulated in our data set, 
protein/nucleic acid deglycase DJ-1 (PARK7; unique peptides= 19, logFC= 
0.445, p= 0.00666) and sodium/potassium-transporting ATPase subunit α2 
(ATP1A2; unique peptides= 35, logFC= 0.271, p= 0.0475). In particular, PARK7 
was found to affect disease progression rate in PARK7 knock-out SOD1G93A 
mouse model of ALS accelerating the disease course  (243), while PARK7 mRNA 
was found to be down-regulated in muscle tissue from SOD1G93A mice models of 
ALS (244). PARK7 may be involved in protein aggregation for its deglycase 
activity. Glycation and advanced glycation end-products (AGEs) have been found 
in protein aggregates as PTM in the context of studies on neurodegenerative 
diseases (245–248).  
Neurotransmitter release cycle (Reactome database) describes the multi-step 
process of synaptic vesicle progress into the synaptic cleft, upon depolarisation 
of the pre-synaptic membrane. Two proteins taking part in this pathway were 
significantly regulated in our data set: amine oxidase A (MAOA; unique peptides= 
10, logFC= 0.319, p= 0.0491) and LIN7B. However, none of these proteins have 
been previously linked with ALS pathophysiology. 
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Translocation of GLUT4 to the plasma membrane (Reactome database) 
describes the translocation of the glucose transporter GLUT4 to the plasma 
membrane, by intracellular vesicle, for glucose uptake from the bloodstream. This 
pathway has been recently described in plasma samples from ALS patients and 
SOD1G93A mice as the possible connection between the lactate, produced as the 
by-product of the cell metabolism, and chronic inflammation casuing 
neuromuscular junction disruption and motor neurons death (249). One protein 
has been found statistically regulated, ras-related protein rab-10 (RAB10; unique 
peptides= 7, logFC= -0.299, p= 0.0465) that has been associated with 
Parkinson’s disease (250).  
SUMOylation is a type of post translational modification (PTM) involved in several 
cellular processes, where a small ubiquitin-like modifier protein (SUMO) is 
attached or detached from a protein. The pathways, SUMOylation of chromatin 
organisation proteins and SUMOylation of RNA binding proteins (both from the 
Reactome database) cover the steps in which this PTM modifies chromatin 
organisation and alters RNA binding proteins interactions with nucleic acids. In 
these two pathways, only the small ubiquitin-related modifier 2 (SUMO2; unique 
peptides= 1, logFC= 1.127, p= 0.0138) was statistically regulated in the data set. 
SUMOylation has been described in ALS in the context of studies which have 
looked at protein aggregation (251,252). 
5.7 Validation of selected candidate biomarkers in plasma NCHs 
Taking together mass spectrometry data, the levels of regulation, the statistical 
significance and the role within pathway involved in ALS pathology, six proteins 
were selected for further validation by western blot (Table 5.8).  
Gene 
name 
Protein name LogFC Pathway 
FMOD Fibromodulin 0.77 
Glycosaminoglycans 
(GAGs) metabolism 
(Keratan sulfate) 
GPC4 Glypican-4 -0.834 
GAGs metabolism 
(Heparan sulfate) 
BGN Biglycan -0.369 
GAGs metabolism 
(Chondroitin/Dermatan 
sulfate) 
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Gene 
name 
Protein name LogFC Pathway 
M6PR 
Cation-dependent 
mannose-6-phosphate 
receptor 
0.522 Lysosome 
SH3GLB2 Endophilin-B2 0.34 Synthesis of PA 
PARK7 
Protein DJ-1 (or 
Protein/nucleic acid 
deglycase DJ-1) 
0.445 
Synaptic Vesicle 
Pathway 
Table 5.8. Biomarker candidates selected for further validation by Western Blot. 
Protein candidates extracted from regulated pathways and previously linked to ALS pathogenesis  
are selected for further validation by immunodetection. 
Gene name: the recommended gene symbol used to officially represent a gene 
Protein name: protein full name recommended by Uniprot 
logFC: relative quantification with value expressed as log2(ALS/HC) intensities 
Pathway: name of the pathway in which the protein was identified 
The validation was carried out on plasma NCHs extracted from ALS patients and 
HC (Table 5.9; Figure 5.14-Figure 5.19).
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Sample ID Gender Ethnicity El-Escorial 
Clinical 
Onset 
Age at visit 
(year) 
ALSFRS-R 
Rate of progression at 
visit 
ALS1* F Caucasian Definite ALS LL 61,11 - 61,99 19 – 36 0,649 - 0,997 
ALS2* F Caucasian Definite ALS UL 68,45 - 68,8 35 0,821 - 1,111 
ALS3* M Caucasian Definite ALS LL 59,62 - 61,18 35 – 38 
0,436 –  
0,853 
ALS4* M Caucasian Definite ALS UL 64,40 - 65,82 8 – 12 
1,423 –  
2,369 
HC3 M Caucasian NA NA 60.64 NA NA 
HC6 F Caucasian NA NA 63.53 NA NA 
HC7 F Caucasian NA NA 60.3 NA NA 
HC8 F Caucasian NA NA 66.4 NA NA 
HC9 F Caucasian NA NA 63.1 NA NA 
HC10 M NA NA NA 56.6 NA NA 
Table 5.9. Demographic and clinical features of ALS patients and HC selected for the validation of six relevant protein biomarkers in plasma NCHs.  
In light orange background the Amyotrophic Lateral Sclerosis (ALS) patients and in light blue background the healthy control (HC).  If the enriched fractions were 
obtained using more than one time point plasma sample for a single patient, the range values for age at visit, ALSFRS-R and progression rate were reported. HC3 
and HC6 are the same samples listed in Table 5.1; *: samples obtained from the same ALS patients listed in Table 5.1, but at different time points. 
Sample ID: ALS= ALS patients; HC= Healthy Control 
207 
 
Gender: M= Male; F= Female  
El-Escorial: diagnostic classification of ALS diagnosis (88) 
Clinical Onset (site of initial clinical signs): LL= Lower Limbs; UL= Upper Limbs 
Age at sampling: age of the patient at blood sampling 
ALSFRS-R (ALS Functional Rating Scale revised): level of neurological impairment across different clinical domains (1-48, with higher neurological impairment 
with lower values) 
Rate of progression at sampling: calculated as 48 - ALSFRS-R score at sampling time/disease duration from onset of symptoms to sampling time
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Figure 5.14. Western blot analysis of Glypican-4 (GPC4) in plasma NCHs from ALS patients 
and healthy controls.  
The image was acquired with a Chemi-Doc Camera (Bio-Rad), while band densities analysed by 
Image Lab software (Bio-Rad). Samples were normalised to HC6 density and the average values, 
with relative standard deviation, for the ALS (n=4) and Control (n=4) groups were plotted onto the 
chart. The immunodetection confirmed the presence of the protein target at the expected 
molecular weight in plasma NCHs from ALS and HC samples, but contrary to what shown by the 
TMTcalibrator™ experiment, with a higher content in the ALS group (logFC= -0.834). 
 
Figure 5.15. Western blot analysis of Endophilin-B2 (SH3GLB2) in plasma NCHs from ALS 
patients and healthy controls.  
The image was acquired with a Chemi-Doc Camera (Bio-Rad), while band densities analysed by 
Image Lab software (Bio-Rad). Samples were normalised to HC6 density and the average values 
with relative standard deviation for the ALS (n=4) and Control (n=4) groups were plotted onto the 
chart. A brain lysate sample was also included (red band, indicating signal saturation) which 
showed an endophilin-B2 band at a lower molecular weight than the bands detected in plasma 
NCHs. In line with the TMTcalibrator™ experiment data, the immunodetection confirmed the 
presence of the protein target in plasma NCHs from ALS and HC samples with a higher level of 
expression in the ALS group (logFC= 0.34). 
209 
 
 
Figure 5.16. Western blot analysis of Fibromodulin (FMOD) in plasma NCHs from ALS 
patients and healthy controls  
The image was acquired with a Chemi-Doc Camera (Bio-Rad), while band densities analysed by 
Image Lab software (Bio-Rad). Samples were normalised to HC6 density and the average values 
with relative standard deviation for the ALS (n=4) and Control (n=4) groups were plotted onto the 
chart. The immunodetection confirmed the presence of the protein target at the expected 
molecular weight in plasma NCHs from ALS and HC samples, but contrary to what shown by the 
TMTcalibrator™ experiment, with a higher expression in the Control group (logFC= 0.77). 
 
Figure 5.17. Western blot analysis of Biglycan (BGN) in plasma NCHs from ALS patients 
and healthy controls  
The image was acquired with a Chemi-Doc Camera (Bio-Rad), while band densities analysed by 
Image Lab software (Bio-Rad). Samples were normalised to HC6 density and the average values 
with relative standard deviation for the ALS (n=4) and Control (n=4) groups were plotted onto the 
chart. The immunodetection revealed two bands, one at 49KDa (lower) and the other one at 
62KDa (upper) in line with the manufacturer (Cambridge Bioscience) data on U-138 MG cell line 
lysate. The relative amount of the two bands showed a different trend for the lower and the upper 
bands across patients and controls as shown on the graph on the right-hand side. Contrary to 
what shown by the TMTcalibrator™ experiment (logFC= -0.369), the sum of the densitometric 
values for each individuals showed a slightly higher total BGN signal in the ALS group (1.47 for 
Control and 1.67 for ALS). 
210 
 
 
Figure 5.18. Western blot analysis of protein/nucleic acid deglycase DJ-1 (PARK7) in 
plasma NCHs from ALS patients and healthy controls.  
The image was acquired with a Chemi-Doc Camera (Bio-Rad), while band densities analysed by 
Image Lab software (Bio-Rad). Samples were normalised to HC6 density and the average values 
with relative standard deviation for the ALS (n=4) and Control (n=4) groups were plotted onto the 
chart. The immunodetection revealed two bands for plasma aggregates samples at 49 and 62KDa 
(defined in the graph as lower and upper respectively), while according to the Manufacturer 
(Cambridge Bioscience) one band only at 25KDa is supposed to be detected. A brain lysate 
sample included in the western blot (red band, indicating saturation) showed only one band at 
28KDa, suggesting that the western blot probing conditions were specific for the PARK7 protein 
and that the higher than expected molecular weight band identified in the plsma NCHs could be 
related to the formation of aggregated forms. Contrary to what shown by the TMTcalibrator™ 
experiment (logFC= 0.445), the densitometric signal was almost the identical for the lower and 
upper band and also for the sum of the two. 
 
Figure 5.19. Western blot analysis of Cation-dependent mannose-6-phosphate receptor 
(M6PR) in plasma NCHs from ALS patients and healthy controls.  
The image was acquired with a Chemi-Doc Camera (Bio-Rad), while band densities analysed by 
Image Lab software (Bio-Rad). Samples were normalised to HC6 density and the average values 
with relative standard deviation for the ALS (n=4) and Control (n=4) groups were plotted onto the 
chart. The immunodetection revealed several bands for plasma aggregates samples with the two 
most intense at 49 and 62KDa (defined in the graph lower and upper respectively), while 
Manifacturer (Insight Biotechnology) reports a detection range of ≈35 and ≈60KDa. A brain lysate 
sample included in this experiment showed two bands at 38 and 49KDa, suggesting that the 
probing conditions could be specific for the M6PR protein. To quantify the signal, taking into 
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account only the bands at 49 and 62KDa, the relative intensityof the two bands showed a different 
trend for the lower and the upper bands as shown in the figure, while the sum of the two bands 
intensities was slightly higher in the Control group, contrary to what shown by the TMTcalibrator™ 
experiment data (logFC= 0.522). 
From the six candidates tested on plasma NCHs, endophilin-B2 (SH3GLB2) was 
the only protein that showed the same trend of protein regulation comparing ALS 
vs HC identified in the TMTcalibrator™ experiment, with a similar level of 
regulation (logFC= 0.34 in TMTcalibrator™ and log2(ALS/HC)= 0.437 in WB 
analysis), while the other candidates showed an opposite trend of regulation 
(GPC4, FMOD, BGN and M6PR) or no regulation at all (PARK7). However, it is 
worth reporting that GPC4 (Figure 5.14) and FMOD (Figure 5.16), still showed a 
significant level of differential expression between ALS and HC (in particular 
FMOD that was three-fold more expressed in HC compared to the ALS, while 
GPC4 was almost two-fold higher in ALS than HC). 
Interestingly, three protein candidates (endophilin-B2, PARK7 and M6PR) 
(Figure 5.15, Figure 5.18 and Figure 5.19) were detected at a higher MW in 
plasma NCHs than in brain lysate. This difference could be related to different 
PTM patterns encountered in tissues as opposed to fluids and to the state of 
aggregation. In fact, Uniprot database confirmed the presence of several PTMs 
for these three proteins. PARK7 can be subjected to lipidation with palmitoyl in 
three residues, while M6PR can be glycosilated in five different  residues and 
endophilin-B2 can be phosphorylated in two residues. The different tissues and 
sample type (lysate and aggregates) could justify different level of modification 
and so the final molecular weight at which the proteins were detected. The same 
could be applied to BGN where the two bands obtained in the WB (Figure 5.17) 
could represent different glycosylation levels in six different residues.  
The potentially high level of PTMs that is possible to encounter in protein 
aggregates, especially those coming from blood that can form AGEs, in addition 
to the changes occurring through regulated enzymatic processes like the effect 
of proteases could explain the different level of regulation between 
TMTcalibrator™ and WB data. Unfortunately, this study was conducted without 
including any biological PTM (e.g. phosphorylation) during PSM search of the 
output MS data after spectra acquisition, making impossible to evaluate the NCH-
proteome in a more accurate manner. On the other hand, including these PTMs 
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without specific sample preparation for peptide enrichment would have given an 
inaccurate quantification and regulation. Enrichment of peptides carrying a 
specific PTM requires a higher amount of starting material, which is a limiting 
factor in any NCHs enrichment process (more than 2 ml of starting plasma 
material per sample only for mass spectrometry analysis would be needed). The 
high volume of specimen required is probably the main limit associated to the 
study of protein aggregates.  
Another important factor that may affect the level of protein regulation in ALS and 
in HC, which is investigated using two different methodologies (TMTcalibrator™ 
and WB), is probably intrinsic to the TMTcalibrator™ bioinformatic pipeline. In 
fact for both experimental groups (ALS and HC), the workflow for quantification 
analysis considers only the peptides detected in the calibrant channels (in our 
case brain) that are also identified in the analytical channels (in our case plasma 
NCHs). This means that a number of peptides derived from our selected 
candidates, which may be constitutively expressed only in plasma and not in 
brain, may escape quantification and downstream functional analysis in the TMT 
bioinformatic process of quantitation. On the contrary, immunodetection in WB 
may detect the whole spectrum of peptides (both from plasma and from brain) 
giving a different final result in terms of overall quantification compared to TMT 
calibrator. In addition, proteins detected in brain lysate (Figure 5.15, Figure 5.18 
and Figure 5.19) may have a different MW suggesting different PTM patterns, 
adding an additional bias and confounding factor in the levels of protein regulation 
obtained in the proteomic experiment. 
5.8 Validation of selected candidate biomarkers in neat and depleted 
plasma 
In order to evaluate the potential of the selected protein as biomarkers, the same 
validation in ALS vs HC was extended to neat plasma and to albumin and IgGs 
depleted plasma. We have tested the hypothesis that direct plasma analysis 
without having to rely on the process of NCHs extraction would simplify the 
analysis, improving rapidity and high throughput and eventual translation into 
diagnostic tools in clinical application. This second round of validation was carried 
on a different set of ALS patients and HCs (Table 5.10). 
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The presence of the six biomarker candidates (FMOD, GPC4, BGN, PARK7, 
SH3GLB2 and M6PR) was evaluated by western blot loading 80 µg of proteins 
for each depleted plasma sample and 100 µg for each neat plasma sample 
(Figure 5.20-Figure 5.25). In order to evaluate the relative quantification for 
protein expression, we considered to include an internal control in western blot 
analysis. However, it has been shown that ALS patients have an imbalanced 
production for all the proteins suggested as internal controls in blood plasma, 
such as albumin, IgGs and ferritin. For this reason, no internal loading control 
was used in these experiments. 
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Sample ID Gender Ethnicity El-Escorial Clinical onset Age at visit (years) ALSFRS-R 
Rate of 
progression 
A1 M Caucasian suspected ALS L(LL) 65.2 39 0.335 
A2 M Asian definite ALS R and LL 61.9 36 2.666 
A3 F Caucasian probable ALS L(LL) 69.5 37 0.257 
A4 F Caucasian definite ALS B 68.4 38 0.89 
A5 M Caucasian possible ALS B 67 43 0.365 
A6 M Caucasian probable ALS B 82.5 27 2.096 
C1 M Caucasian NA NA 63.9 NA NA 
C2 F Caucasian NA NA 65.9 NA NA 
C3 M Caucasian NA NA 68.3 NA NA 
C4 M Caucasian NA NA 73.1 NA NA 
C5 M Caucasian NA NA 60.3 NA NA 
Table 5.10. Demographic and clinical features of ALS patients and healthy controls selected for the validation of six relevant protein biomarkers in neat 
and depleted plasma.  
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In light orange colour the Amyotrophic Lateral Sclerosis (ALS) patients and in light blue background the healthy control (HC).   
Sample ID: ALS= ALS patients; HC= Healthy Control 
Gender: M= Male; F= Female  
El-Escorial: diagnostic classification of ALS diagnosis (88) 
Clinical Onset (site of initial clinical signs): L= Limbic; LL= Lower Limbs; B= Bulbar; R= Respiratory 
Age at sampling: age of the patient at blood sampling 
ALSFRS-R (ALS Functional Rating Scale revised): level of neurological impairment across different clinical domains (1-48, with higher neurological impairment 
with lower values) 
Rate of progression at sampling: calculated as 48 - ALSFRS-R score at sampling time/disease duration from onset of symptoms to sampling time
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Figure 5.20. Immunodetection of FMOD in depleted and neat plasma. 
(A) and (B) show immunodetection and relative quantification, of FMOD in samples listed in Table 
5.10. Quantification was performed normalising on C3 for (A) and C4 in (B). 
FMOD was detected in both plasma sample types depleted (Figure 5.20A) and 
neat (Figure 5.20B) plasma. C5, A1 and A4 did not show a complete band profile. 
Quantification of the blots showed that FMOD is present in plasma and depleted 
plasma at the same concentration for ALS and Control groups. This result is in 
contrast to the analyses in NCHs, with the TMTcalibrator™ showing higher 
FMOD expression in the ALS samples (Table 5.8) and the immunodetection in 
which FMOD was higher in the Control group (Figure 5.16). 
217 
 
 
Figure 5.21. Immunodetection of GPC4 in depleted and neat plasma. 
(A) and (B) show immunodetection and relative quantification of GPC4 in samples listed in Table 
5.10. Quantification was performed normalising on C3 for (A) and C4 in (B). 
Immunodetection of GPC4 was difficult, in fact the bands detected in the depleted 
plasma (Figure 5.21A) were very faint, while in neat plasma (Figure 5.21B) two 
samples, C5 and A1 did not show any band. Quantification of the target was not 
consistent in the two sample types (Figure 5.21). In depleted plasma, the Control 
groups showed a 30% higher GPC4 content than ALS (Figure 5.21A), but with a 
higher variability as C1 showed a very faint band. This trend was in line with 
quantitative MS data (Table 5.8). On the other hand, neat plasma showed a much 
higher content in the ALS group (Figure 5.21B), more than three-fold, as obtained 
from plasma NCHs (Figure 5.14). 
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Figure 5.22. Immunodetection of BGN in depleted and neat plasma. 
(A) and (B) show immunodetection and relative quantification of BGN in samples listed in Table 
5.8. Quantification was performed normalising on C3 for (A) and C4 in (B).  
Detection of BGN showed to be problematic in depleted plasma (Figure 5.22A), 
where four samples (C3, A6, A2 and A1) showed very faint immunoreactive 
bands, while in neat plasma BGN was easily detected in most of the samples 
(Figure 5.22B). In line with detection in plasma NCHs (Figure 5.17), two bands 
were detected for the same protein which presented a different trend of regulation 
with the Control group showing a higher expression of BGN than ALS (Figure 
5.22). However, these data are in line with MS quantitative data (Table 5.8). 
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Figure 5.23. Immunodetection of PARK7 in depleted and neat plasma. 
(A) and (B) show immunodetection of PARK7 in samples listed in Table 5.10. Quantification was 
possible only in depleted plasma (A) normalising each value on C3.  
PARK7 was detected in all the depleted plasma samples, showing a slightly 
higher expression (about 10%) in the ALS group compared to Control (Figure 
5.23A) while PARK7 was detected only in half of neat plasma samples (Figure 
5.23B). Both Control neat plasma samples showed no PARK7 expression (Figure 
5.23B). The same antibody detected two bands in NCHs (Figure 5.18), instead 
of one in neat plasma (Figure 5.23), suggesting that the nature of the sample can 
affect not only the overall detection but also selection of different species of the 
same protein. 
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Figure 5.24. Immunodetection of SH3GLB2 in depleted and neat plasma. 
(A) and (B) show immunodetection of SH3GLB2 (endophilin-B2) in the samples from the ALS 
patients and HC listed in Table 5.10. In both blots (A and B), Endophilin-B2 was detected in 
several bands and samples had different bands. In addition, depleted plasma (A) and neat plasma 
(B) showed different band profiles for SH3GLB2.  
SH3GLB2 was detected in several bands (Figure 5.24), showing a different 
western blot profile from the one seen in plasma NCHs (Figure 5.15). Not all 
bands were present in all the samples, indicating also an inter-individual 
variability (Figure 5.24). The unclear pattern of the bands did not allow accurate 
quantification. 
 
Figure 5.25. Immunodetection of M6PR in neat plasma. 
The figure shows immunodetection of M6PR in samples from the ALS patients and HC listed in 
Table 5.10. Quantification was performed normalising each value on C4. Two bands were 
detected for M6PR, “low” and “high”, indicated by the arrows on the left-hand side of the blot.  
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M6PR could not be detected in depleted plasma in all samples tested. In addition, 
M6PR expression in neat plasma was minimal particularly in the HC group 
(Figure 5.25). The lower expression affected detection, but overall M6PR 
expression was 70% higher in the ALS group compared to HC (Figure 5.25). This 
result is in contrast to the trend of M6PR expression in plasma NCHs (Figure 
5.19) and in line with MS data (Table 5.8).  
5.9 Analysis of NCHs proteomic data without the calibrant channels 
The TMTcalibrator workflow is designed to analyse in the analytical channels only 
those peptides that are expressed in the calibrant channels. Therefore, in our 
experimental setting this proteomic technique excludes the detection of those 
peptides that are likely to come from proteins that are typically present in plasma 
and that may be part of the NCHs under investigation (and not expressed in 
brain). For this reason and in order to provide a more comprehensive cover of all 
the molecules that assembles in the aggregates, we have looked in the datasets 
to uncover information related to  NCHs proteins that have plasma origin. 
The search performed after spectra acquisition with proteome discoverer 1.4 (PD) 
identified a total of 679471 PSMs, of which 323442 in TMTplex01 and 356029 in 
TMTplex02. 1.59% of the total  PSMs identified (specifically 5147 in TMTplex01 
and 5682 in TMTplex02) were not detected in any calibrant channels and in all 
analytical channels of the two TMTplexes. Taking into account only the PSMs 
belonging to single proteins (i.e. not shared among more than one protein group), 
101 and 82 protein groups were identified in TMTplex01 and TMTplex02 
respectively (Figure 5.26). Excluding three proteins only identified in the 
TMTplex01, the PSMs belonging to this set of proteins, with relative quantitative 
data, were not taken into consideration for quantitative analysis by the 
bioinformatic pipeline as they did not represent brain proteins. This has certainly 
affected the ultimate quantitative comparison of NCHs and their relative 
composition of plasma and brain-derived proteins.  
Other proteins that could have the potential to represent good disease biomarkers 
in ALS are those included in plasma NCHs that are derived from plasma (i.e. not 
detected in brain calibrant) and that may be detected in only one of the two 
experimental groups (i.e. ALS or HC). However, no representative protein was 
detected from plasma NCHs, suggesting that the peptides in the calibrant 
222 
 
channels saturate signal acquisition hiding most of the non-calibrant derived 
peptides. 
 
Figure 5.26 Proteins identified in the TMT 10plexes with no reference to the calibrant 
channels 
Protein groups identified in TMTplex01 (TMT01) and in TMTplex02 (TMT02) derived from the 
PSMs identified in all the analytical channels and simoultaneously in no calibrant channels. The 
Venn diagram shows a comparison across the two TMTplexes and the protein lists generated by 
FeaST (FeaST). 70 proteins were shared among TMTplexes and Feast proteins, 28 between 
FeaST and TMT01, 12 between FeaST and TMT02, while no proteins were shared between 
TMTplex01 and TMTplex02. 
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5.9.1 Brain-derived exclusive proteins for each experimental group 
Another information that could be useful in this experimental approach for 
biomarkers are the peptides, with relative proteins, shared between the calibrant 
(i.e. brain) and only one of the two experimental groups, here after called 
exclusive proteins. This could be investigated in the matrix generated by CalDIT 
before quantitative comparison performed by FeaST, here after called pre-FeaST 
matrix, where all the peptides identified in the Calibrant channels in both 
TMTplexes and semi-quantitative data from the analytical channels are included. 
Pre-FeaST matrix contained 99750 peptides identified through PD search in both 
TMTplexes. Of these 99750 peptides 15290 (15.33%) were not identified in both 
ALS and HC channels, while 37638 peptides (37.73%) were identified in both 
experimental groups in at least four channels. This share of information was then 
analysed through FeaST and FAT, and the results have been already presented 
above in this chapter. These numbers suggest that some useful information for 
biomarkers study could have been filtered out. In fact, 40021 peptides (40.12%) 
were identified in at least 4 samples in ALS experimental group, and the 65.46% 
(26198 peptides) of these were identified in all 6 ALS samples (26.26% if 
considering the pre-FeaST matrix), while 42937 peptides (43.04%) identified in 
at least 4 HC samples, of which the 65.00% (27910) were identified in all HC 
samples (27.98% if considering the pre-FeaST matrix). Thus, there is still a small 
share of information containing semi-quantitative data of brain-derived peptides 
in plasma NCHs that is exclusive for ALS or HC experimental group (2.39% and 
5.31% of the pre-FeaST matrix for ALS and HC, respectively). 
As mentioned above, presence or absence of a specific peptide is given by the 
identification of at least four samples in both experimental groups. Thus, 
identification of a peptide in four samples from one experimental group and three 
sample from the other group represents the limit condition for the absence of that 
specific peptide in following FeaST analysis. At the same time this is the minimum 
condition that implies exclusive proteins for the two experimental groups, as it 
defines the identification of that peptide in one experimental group while the 
absence in the other one. However, the peptides identified with such a small 
difference in number of positive/negative samples for the identification of a 
peptide are very unlikely to be exclusive proteins. To increase likelihood of 
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characterising brain-derived proteins that are exclusive of the two conditions 
tested, ALS and healthy states, only the peptides identified in at least four 
samples in ALS or HC group and at the same time in none of the samples of the 
second experimental group were considered in the following analysis. 
5.9.1.1 Exclusive proteins in ALS 
In pre-FeaST matrix, 46 peptides were identified in at least four ALS samples and 
absent in all HC samples. Matching the protein groups identified through these 
peptides, with the protein list obtained from FeaST, five protein groups could be 
classified as ALS exclusive (Table 5.11). 
Gene 
name 
UniProt 
ID 
Protein name 
Number 
of 
peptides 
Number 
of 
PSMs 
Number of 
positive ALS 
samples 
DCUN1D3 Q8IWE4 
DCN1-like protein 
3 
1 2 4 
NOTCH2 Q04721 
Neurogenic locus 
notch homolog 
protein 2 
1 4 4 
PUS1 Q9Y606-2 
Isoform 2 of tRNA 
pseudouridine 
synthase A, 
mitochondrial 
1 2 4 
CAMK2D Q13557-4 
Isoform Delta 4 of 
Calcium/calmodul
in-dependent 
protein kinase 
type II subunit 
delta 
1 1 4 
PRKAA2 P54646 
5-AMP-activated 
protein kinase 
catalytic subunit 
alpha-2 
1 5 5 
Table 5.11. Table with ALS exclusive proteins 
Gene name: the recommended gene symbol used to officially represent a gene 
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Uniprot ID: Uniprot database protein identifier 
Protein name: protein full name recommended by Uniprot  
Number of peptides: number of peptides identified in at least four ALS samples and in zero HC 
samples 
Number of PSMs: number of PSMs detected for each specific peptide 
Number of ALS samples: number of ALS samples in which each peptide was detected 
5.9.1.2 Exclusive proteins in HC 
For HC experimental group, 169 peptides potentially belonging to exclusive 
proteins were identified. Matching the list of protein groups obtained from these 
169 peptides with the list of protein obtained after FeaST, six protein groups were 
characterized (Table 5.12). 
Gene 
name 
UniProt ID Protein name 
Number 
of 
peptides 
Number 
of 
PSMs 
Number of 
positive HC 
samples 
CEP170 Q5SW79-2 
Isoform 2 of 
Centrosomal 
protein of 170 kDa 
1 3 4 
CSPG5 O95196-2 
Isoform 2 of 
Chondroitin 
sulfate 
proteoglycan 5 
1 2 4 
SCN8A Q9UQD0-5 
Isoform 5 of 
Sodium channel 
protein type 8 
subunit alpha 
1 2 4 
MRPS34 P82930 
28S ribosomal 
protein S34, 
mitochondrial 
1 2 4 
RBKS Q9H477 Ribokinase 1 2 4 
ANKRD35 Q8N283 
Ankyrin repeat 
domain-containing 
protein 35 
1 1 4 
Table 5.12. Table with HC exclusive proteins 
Gene name: the recommended gene symbol used to officially represent a gene 
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Uniprot ID: Uniprot database protein identifier 
Protein name: protein full name recommended by Uniprot  
Number of peptides: number of peptides identified in at least four HC samples and in zero ALS 
samples 
Number of PSMs: number of PSMs detected for each specific peptide 
Number of HC samples: number of HC samples in which each peptide was detected 
5.10 Conclusion 
The use of TMT calibrator proteomics described in this chapter has been highly 
effective and ultimately has succeeded in identifying a significant number (almost 
5000) of brain-derived proteins in plasma NCHs, while increasing exponentially 
the detection of low abundance proteins like neurofilaments (Nf) in the mix of 
proteins normally populating a complex matrix like plasma, both in its soluble and 
aggregated state. We consider this a significant achievement and a major step 
forward in the use of proteomics to unravel the complex molecular framework of 
biofluids in search of biochemical markers of disease. MS proteomics is normally 
limited by the interference of high and relatively high abundance proteins that 
may also have relevance as biomarkers, but that ultimately limit the process of 
identification of less represented proteins coming from the brain. Together with 
neurofilaments (Nf), the list of ALS-relevant proteins identified using the ALS-
related gene list database (Table 5.5) which have been detected in our 
brain/plasma NCHs experiment are also normally escaping detection by different 
standard proteomic techniques in virtue of their low-abundance in biofluids.  
The NfH isoform in proteins aggregates showed almost statistically significant 
regulation (p=0.06) when comparing ALS and HC NCHs adding to previously 
reported data in plasma which support the use of this protein as a marker of 
neurodegeneration. The confirmation that proteins like Nf can be packaged into 
circulating aggregates obtained by TMT proteomics as well as using gel 
separation and TEM should raise important question on the importance of the 
state of relevant biomarkers (i.e. soluble vs aggregated) when they are the target 
of novel diagnostic tools based on immunodetection. 
Another known and important protein detected in this study is FUS, which showed 
to be expressed differently between ALS and HC groups in NCHs. FUS is known 
to be a key protein ALS protein; FUS gene mutations are causative of ALS and 
these genetic defects lead to deranged protein translation and and altered cell 
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homeostasis (253–256). However, FUS was not linked to any regulated pathway 
obtained from our FAT functional analysis.  
Those proteins detected by MS which were not processed through the 
TMTcalibrator™ workflow have been assessed as potential biomarker 
candidates looking at whether they were uniquely present or absent in ALS. 
However, few of these proteins were singled out and all were identified by one 
unique peptide and maximum five PSMs, not providing strong evidences at MS 
level for further development of these proteins as biomarkers. The absence of 
representative plasma proteins within the NCHs must be attributed to the 
TMTcalibrator™ setting, where the calibrant represents more than the half of the 
entire amount of proteins loaded in each TMTplex. In this way, the signal from 
brain-derived peptides (i.e. calibrant channels) prevails over non-brain-derived 
peptides, especially in the data dependent acquisition setting used in this 
workflow.  Hence, equally informative signals coming from plasma may be lost as 
the platform privileges the detection of signals of brain origin.   
Functional analysis of the TMT calibrator data has shown features which are in 
keeping with the ALS pathobiology, confirming the reliability of the approach 
adopted in this study. In addition, it was possible to find biochemical pathways 
that had not been previously linked to ALS, suggesting new research avenues in 
this field and the importance of NCHs as conduits of pathology and testbeds to 
discover novel biomarkers and therapeutic leads. Increasing stringency of our 
bioinformatic analysis, we have been able to generate a list of potential biomarker 
candidates for ALS to be considered for future validation studies. These are brain 
proteins in circulation found in systemic aggregates, whose regulation is in 
relation to the pathological state. The assessment of these clusters of proteins 
allows us to appreciate functional and biochemical changes with a high degree 
of affinity to known pathogenic mechanisms already described in ALS and to 
novel molecular pathways. Future work will have to include the selection of the 
best candidates to be considered for further validation in larges cohorts of ALS 
and HC, using a different and high-throughput methodological approach like 
immunodetection.  
In this study, the involvement of glycosaminoglycan metabolism, lysosome, 
synthesis of phosphatidic acid and synaptic vesicle pathway was investigated by 
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immunodetection of FMOD, GPC4, BGN, M6PR, SH3GLB2 and PARK7. 
Unexpectedly, the western blot analysis in plasma NCHs did not confirm the 
same regulation showed by proteomics analysis in largely the same individuals 
evaluated by TMTcalibrator™. MS and antibody-based techniques have different 
analytical sensitivity and specificity.  Protein quantification by MS relies first of all 
on the number of PSMs and peptides identified in the complex mix of proteins 
subjected to analysis. A number or most of peptides belonging to target proteins 
may not be detected, possibly because of the low peptide abundance in respect 
to other co-eluting peptides or for the presence of PTMs not included in the 
search step. Our effort to extend the validation by immunodetection to total 
plasma and depleted plasma samples was useful to study the potential to test 
these molecules in a technically less challenging method, ultimately without the 
need for NCHs extraction. The differences in protein expression in the study 
groups seen using MS and immunodetection could be justified by the different 
samples used in the western blot and MS analysis and by the biology of the 
protein targets which condition their detection using different methods. However, 
PARK7 showed presence exclusively in ALS plasma samples. This would 
suggest further validation steps by increasing the number of samples and arrive 
to an accurate estimate of the potential of this protein candidate as biomarker. 
In conclusion, apart from those proteins which control lipoproteins homeostasis, 
the pathways we have singled out using a pioneering tissue/fluid proteomics do 
not seem to have been previously linked to the pathogenesis of ALS, suggesting 
novel potential routes for investigation into neurodegeneration and ALS. It is also 
fair to mention that most of the data and literature available is limited to 
microorganisms and cell models, while there is almost no data on blood 
circulating protein aggregates, their composition and putative role in the organism 
homeostasis and therefore, it is important to remain cautious in any speculation 
on the relevance of our data. Future studies will have to be undertaken using cell 
and/or animal models to establish whether the molecular pathways we have 
identified in our Brain/plasma NCHs proteomic studies are truly implicated in the 
pathogenesis of ALS or are part of other pathogenic mechanisms more broadly 
implicated in neurodegeneration. 
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6 Altered biochemical properties in neurofilament-
containing heteroaggregates (NCHs)  
6.1 Introduction and aim 
In consideration of the presence of protein aggregates which have been linked to 
the seeding behavior of disordered protein (e.g. oxidized proteins), it has been 
proposed that the pathogenesis of Amyotrophic Lateral Sclerosis (ALS) may have 
features in common with other rapidly developing neurodegenerative diseases 
like Prion’s disease (80,144,145,257). The data reported in Chapter 4 showed a 
degree of protein resistance to digestion with trypsin of these formations (Figure 
4.19). These preliminary data require further investigations to ascertain whether 
NCHs may truly present some of the altered biochemical properties seen in prion 
disease. 
To shed some light on this possibility, plasma NCH samples obtained from 
individual patients affected by ALS along with healthy controls (HC) are examined 
by transmission electron microscopy (TEM) and tested for resistance to digestion 
with a number of proteases. This Chapter will be divided into two parts. The first 
part will show new data collected by TEM, while in the second section we will 
describe NCHs resistance to digestion using Trypsin, Chymotrypsin, 
Enterokinase and Calpain. The effect of the same proteases (excluding trypsin 
the effect of which has already been tested in Paragraph 4.6) will also be assayed 
in brain NCHs to shed light to the biochemical behavior of NCHs coming from 
different tissues. This new set of experiment has the purpose of testing the prion-
like disease hypothesis in the field of neurodegenerative diseases studies and in 
the context of ALS. 
6.2 Transmission electron microscopy (TEM) imaging on NCHs 
To evaluate possible differences in the macromolecular structures present in 
plasma NCHs from ALS and healthy individuals, I have analysed by TEM three 
HC samples (HC4, HC5 and HC6 listed in Table 6.1) and three ALS samples 
(ALS1*, ALS3* and ALS5* listed in Table 6.1). 
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Sample ID Gender Ethnicity El-Escorial Clinical Onset Age at visit (year) ALSFRS-R Rate of progression at visit 
ALS1* F Caucasian Definite ALS LL 61,11 - 61,99 19 - 36 0,649 - 0,997 
ALS2* F Caucasian Definite ALS UL 68,45 - 68,80 35 0,821 - 1,111 
ALS3* M Caucasian Definite ALS LL 59,62 - 61,18 35 - 38 0,436 - 0,853 
ALS4* M Caucasian Definite ALS UL 64,40 - 65,82 8 - 12 1,423 - 2,369 
ALS5* M Caucasian Definite ALS LL 63,05 - 64,79 22 - 37 0,623 - 0,801 
HC1 F Caucasian NA NA 62.48 NA NA 
HC2 F Caucasian NA NA 67.50 NA NA 
HC3 M Caucasian NA NA 60.64 NA NA 
HC4 M Caucasian NA NA 68.28 NA NA 
HC5 M Caucasian NA NA 62.54 NA NA 
HC6 F Caucasian NA NA 63.53 NA NA 
Table 6.1 List of samples selected for further transmission electron microscopy analysis (TEM) and digestion by proteases.  
In light orange background the Amyotrophic Lateral Sclerosis (ALS) patients and in light blue background the healthy control (HC).  If the enriched fractions were 
obtained using more than one time point plasma sample for a single patient, the range values for age at visit, ALSFRS-R and progression rate were reported. HC3 
and HC6 are the same samples listed in Table 5.1; *: samples obtained from the same ALS patients listed in Table 5.1, but at different time points. 
Sample ID: ALS= ALS patients; HC= Healthy Control 
Gender: M= Male; F= Female  
El-Escorial: diagnostic classification of ALS diagnosis (88) 
Clinical Onset (site of initial clinical signs): LL= Lower Limbs; UL= Upper Limbs 
Age at sampling: age of the patient at blood sampling 
231 
 
ALSFRS-R (ALS Functional Rating Scale revised): level of neurological impairment across different clinical domains (1-48, with higher neurological impairment 
with lower values) 
Rate of progression at sampling: calculated as 48 - ALSFRS-R score at sampling time/disease duration from onset of symptoms to sampling time
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Analysis of these samples confirmed the presence of amorphous electron-dense 
NCHs (Figure 6.1), including round particles of different size in both HC and ALS 
samples (Figure 6.2).  
 
Figure 6.1. NCH amorphous globular macrostructures. 
A representative micrograph showing an amorphous globular formation in aggregates enriched 
fractions. This image was captured from the grid loaded with HC6 sample. 
TEM analysis of the NCHs fractions from HC uncovered the presence of round 
small formations within and outside the body of the bigger globular electron-
dense formations representing the NCHs under investigation. These particles 
may be micelles as reported in the literature. In the context of our experiments, it 
is likely that they may be composed of lipids, detergents or lipoproteins (167,258). 
Due to the nature of the samples and the enrichment process none of these 
options could be discarded. However, we did not detect the same particles in the 
brain samples analysed in Paragraph 4.4.1 despite the amount of lipids in brain 
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tissue and the fact that the same aggregates enrichment process was applied. 
We could speculate that these particles are in fact made of lipoproteins, such as 
very low-density lipoproteins (VLDL), low-density lipoproteins (LDL) and high-
density lipoproteins (HDL) (Figure 6.2). In support of this hypothesis, lipoproteins 
were also detected by mass spectrometry (MS) and biochemical pathways 
involving these proteins were significantly regulated in the proteomic study of the 
NCHs fraction (Table 5.6). 
 
Figure 6.2. Particles identified in the aggregates enriched fractions. 
A representative micrograph showing presence of particles (or micelles) in aggregates enriched 
fractions. The image is captured from the grid loaded with the ALS5* sample and show an 
electron-dense area surrounded with micelles of different sizes (highlighted by the red arrows). 
Inspection of the grids prepared with NCHs enriched from ALS patients, showed 
the presence of small filamentous fragments with a rough surface (Figure 6.3) 
that were not detected in HC grids. Although this is far from being certain and 
difficult to prove in the context of our experiment, these fragments visually 
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resemble the formations observed in brain enriched fractions shown in Figure 
4.10 .  
 
Figure 6.3. Details of particles detected in TEM micrographs of ALS NCHs. 
((A) ALS1* grid with a 13 nm thick and 70 nm long fragment. (B) ALS3* grid with two fragments 
both with a 20 nm thickness. The lower fragment is 120 nm long and while the upper fragment is 
145 nm long. (C) ALS5* grid with a 16.5 nm thick and 130 nm long filament. 
This type of particles was found only in the ALS samples and they were similar 
although shorter to those found in ALS Brain NCHs (recalling prion-like 
structures), albeit slightly thicker. To date, there is no evidence in the literature of 
circulating particles in blood stream of ALS patients and animal models, with an 
appearance recalling prion proteins. Further investigation on the nature of these 
particles will require 1) a more extensive comparison with brain aggregates, 2) a 
bigger number of samples and 3) comparative studies with prion particles 
obtained from positive control samples (e.g. Creutzfeldt-Jakob disease). 
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6.3 NCHs resistance to digestion 
One of the main biochemical characteristics of proteins behaving like prions is 
their resistance to digestion with proteases (146). We have already shown 
preliminary data on plasma and brain NCHs in Chapter 4, where ALS and HC 
plasma NCHs and ALS brain NCHs samples tested showed a degree of 
resistance to trypsin digestion (digested samples appeared like a light smear in 
the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Figure 4.16). In the same experimental setting, neither neurofilament heavy 
(NfH) (Figure 4.17) nor transactive DNA binding protein (TDP43) (Figure 4.18) 
showed resistance to trypsin digestion, while a small portion of ubiquitinated 
proteins was still detectable after digestion of brain aggregates (Figure 4.19). 
To further investigate resistance to protease digestion, NCHs enriched from the 
ALS and HCs plasma samples listed in Table 6.1 were treated with trypsin, 
chymotrypsin, enterokinase and calpain, as described in Paragraph 2.6. The 
digestion patterns were evaluated by gel electrophoresis followed by zinc staining 
to highlight the general digestion profiles and by NfH immunodetection to test any 
resistance to protein digestion of this specific protein. 
All NCHs samples from ALS patients and HCs listed in Table 6.1 were ran after 
digestion with different proteases along with the undigested matched sample 
(Figure 6.4) and subjected to zinc staining. In total, six gels were ran to evaluate 
digested and undigested NCHs from ALS and HCs (including one ALS and one 
HC sample in each gel). The aim was to identify gel profiles indicative of (partial 
or total) resistance to protease digestion. For internal normalization in the 
quantitative analysis of the digestion profiles, we have used the gel marker as 
described in Paragraph 2.6.1. To test NfH protease resistance in the same NCHs, 
NfH immunodetection was performed in the same gels in digested and 
undigested samples. 
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Figure 6.4. SDS-PAGE of ALS and HC NCHs samples before and after digestion with 
proteases.  
The figure shows an example of gel electrophoresis and zinc staining used for the analysis of 
protease digestion in pairs of ALS and HC samples. This gel is reported as ALS1_HC1 and shows 
products of trypsin chymotrypsin, calpain and enterokinase digestions generated from ALS1* and 
HC1 (along with the same undigested samples as reference). 
4.03 µg of total proteins were loaded in each lane (samples ALS1*-5* and HC2-
6) along with 10 µl of marker in each gel. For HC1 samples, 2.23 µg were loaded 
in each lane because of the low protein concentration in these samples. The 
coefficient of variation (CV%) of the total intensity calculated on the undigested 
lane for each individual did not indicate equal loading for all samples (Table 6.2). 
Because unequal loading may have affected the final results, a correction factor 
was generated for each sample in order to reduce the bias related to different 
protein loading. Correction factors (CFs) were calculated as the ratio between the 
total intensities of each undigested sample (i.e. sum of all the bands) and the 
marker total intensities from the same gel (Table 6.3). For the quantification of 
each band from digested and undigested samples, each band intensity was first 
normalised with the closest band of the gel marker and then further normalised 
with the CFs specifically calculated for each sample in the experiment. 
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Because NCHs samples generated from HC1 had a low protein concentration, 
the amount of total protein loaded was different from the other ALS and HC 
samples and required an additional loading factor (LF) to be calculated before 
protease digestions data analysis in order to have an even measurement of 
intensities. Hence, the maximum possible amount was loaded for each HC1 
sample, especially to increase peptides detection for the digested samples where 
most of the proteins are supposed to be hydrolysed, and LFs calculated as the 
ratio between the µg loaded for each sample undergoing digestion by trypsin, 
chymotrypsin, calpain or enterokinase and the related HC1 undigested sample 
(Table 6.4). Each LF was then applied together with the HC1 CF (Table 6.4) for 
the final analysis.
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Total 
intensity 
for: 
Gel1 
(ALS1_HC1) 
Gel2 
(ALS2_HC2) 
Gel3 
(ALS3_HC3) 
Gel4 
(ALS4_HC4) 
Gel5 
(ALC5_HC5) 
Gel6 
(HC6) 
Mean 
St. 
Dev. 
CV% 
Marker 107704 109638 102576 114133 100891 95666 105102 6664 6.3 
ALS 62481 57628 58192 55143 46977 - 56084 5735 10.2 
HC 40800 59041 39941 46063 40622 50107 46095 7477 16.2 
Table 6.2. Marker, undigested ALS and HC sample intensities.  
The total bands intensity is obtained as the sum of the intensities of all bands in a lane after the images were processed by ImageJ, and it is shown for the the gel 
marker, for ALS and HC undigested samples in each gel (Gel1-6). Mean, standard deviation (St. Dev.) and coefficient of variation (CV%) are shown for each group. 
The low CV% of the marker confirmed equal loading which could be used as reliable reference signal. A higher CV% was calculated for ALS and in particular for 
HC samples, despite attempts to obtain equal loading. In grey colour-code the Mean, St. Dev. and CV% calculated for the total intensities. 
 ALS1* ALS2* ALS3* ALS4* ALS5* HC1 HC2 HC3 HC4 HC5 HC6 
Correction 
Factors 
0.58 0.56 0.57 0.48 0.47 0.38 0.54 0.39 0.40 0.40 0.52 
Table 6.3. Correction factors (CFs) for each ALS and HCs sample calculated using undigested samples and marker total intensities.  
The correction factors (CFs) were applied to quantify differences in NCHs profiles obtained by SDS-PAGE from undigested and digested samples. Each band 
under analysis, was first normalized with the marker band closer to the molecular weight (MW) of the bands under analysis and then divided by the sample CF. 
ALS1*-5* and HC1-6 indicates the samples used in this experiment with their specific CF. 
 
239 
 
HC1 samples 
 Undigested Trypsin Chymotrypsin Calpain Enterokinase 
Sample 
loaded (µg) 
2.23 3.27 3.32 3.34 3.45 
Loading 
Factor 
1 1,466837 1,492731 1,498645 1,550701 
Correction 
Factor 
0,3788 0,5557 0,5655 0,5677 0,5874 
Table 6.4. Loading and correction factors for the HC1 samples.  
To adjust for the uneven loading of HC1 samples, loading factors (LFs) were calculated to correct intensity values and allow statistical analysis. The CFs (Table 
6.3) were adjusted for the different amount of proteins loaded for each HC1 sample with the relative LFs.
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6.3.1 Undigested samples 
The gel profiles of the undigested NCHs fractions from ALS patients and from 
HCs enriched from plasma were evaluated taking into account the adjustments 
for unequal samples loading reported above (Figure 6.5). 
 
Figure 6.5. Undigested plasma ALS and HC NCHs profile.  
(A) Gel profile after zinc staining of undigested plasma NCHs samples including ALS (ALS1*-5*) 
and HC (HC1-6). (B) Quantitative analysis of the band profile comparing ALS and HCs. Here 
bands at 190 KDa molecular weight (MW) were normalised with the closest  Marker band at 171 
KDa, the 122 KDa bands with the Marker band at 117 KDa, the 70 KDa bands with the Marker 
band at 71 KDa, the 62-57 KDa range bands with the Marker band at 55 KDa, the 47 KDa bands 
with the Marker band at 55 KDa and the 41 KDa bands with the Marker band at 41 KDa. *= p-
Value < 0.05. 
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The profile of the undigested plasma NCHs from ALS and HC samples shared 
bands at the following molecular weight (MW): 190, 122, 70, 47 and 41 KDa as 
well as an area between 62 and 57 KDa (in this MW range, it was not possible to 
define a single band in all the samples under analysis) (Figure 6.5A). Plasma ALS 
NCHs also showed a band at 268/238 KDa, but this was not taken into 
consideration because three out of six HC samples did not display the same band 
(Figure 6.5A). Quantitative analysis of these bands between the two groups and 
statistical analysis showed that bands at 122 and 70KDa were more intense in 
the HC NCHs group (p= 0.004 and 0.006 respectively), while the band at 47 KDa 
was more intense in the ALS NCHs group (p= 0.006) (Figure 6.5B). 
 
Figure 6.6. NfH profile in undigested plasma NCHs.  
242 
 
(A) Western blot against NfH revealed bands at 460 KDa, 268 KDa and 41 KDa. (B) Quantitative 
analysis of the bands detected, including the sum of the three bands detected (SUM), the ratio 
between the 460 KDa band the SUM (460/SUM), the ratio between the 268 and 460 KDa bands 
(268/460) and the sum of 268 and 41 KDa bands (268+41). Band densities were normalised on 
ALS1*. *= p-Value < 0.05. 
Western blot against NfH in the undigested plasma NCHs revealed three bands 
at 460, 268 and 41 KDa (Figure 6.6A). Quantitative analysis of the NfH bands in 
ALS and HC samples showed that the overall NfH intensity (the sum of the three 
NfH bands: SUM) was higher in the ALS samples compared to HC samples 
although not statistically significant (p= 0.52; Figure 6.6B), while the ratio between 
the intensity of the 460 KDa band and the overall NfH intensity (460/SUM), the 
ratio between the intensities of the 268 and the 460 bands (268/460) and the sum 
of the bands at 268 and 41 KDa (268+41) showed a statistically significant higher 
expression in ALS compared to HCs (p= 0.032, 0.018 and 0.049 respectively; 
Figure 6.6B). These data are in line with previous NfH quantification in plasma 
NCHs. It is possible to postulate that the relative quantification of different NfH 
species (fragments) in plasma NCHs may be more informative than other more 
general NfH quantification. 
6.3.2 Trypsin digestion 
Trypsin is a serine protease, which cuts peptide chains at lysine or arginine. This 
proteolysis has been previously reported to be ineffective in prion digestion (146). 
The same enzyme was extensively used in sample preparation for our MS-based 
proteomics experiments that makes up the work presented in this thesis. 
Therefore, the analysis of NCHs resistance to protein digestion can help in 
defining possible shortfall in MS analysis of circulating aggregates. 
The plasma NCHs profiles after trypsin digestion showed few bands ranging from 
71 KDa (ALS3*, HC1, HC2 and HC6) to a lower molecular weight (Figure 6.7A). 
There was a high sample-to-sample variability with regards to the detected 
bands. The HC group showed a slightly higher degree of resistance (Figure 6.7A). 
However, the only band shared by all ALS and HC samples at 45 KDa was slightly 
more intense in ALS samples (Figure 6.7B). 
NfH detection after digestion showed similar results (Figure 6.8). Most of the 
samples did not show any NfH band, while ALS5*, ALS3* and HC5 showed a 
243 
 
clear NfH positive band around 41 KDa (Figure 6.8). The overall results may 
indicate a degree of NCHs resistance to trypsin digestion, supporting the need to 
consider alternative proteases for future NCHs analysis by MS-based bottom up 
proteomics (Figure 6.7A). Also, NfH in an aggregated-state showed a certain 
degree of resistance which was certainly more pronounced in ALS samples. This 
biochemical change could have had a potential effect in this protein quantification 
in the reported MS experiments (Figure 6.8). In our in TMTcalibrator™ proteomic 
study, NfH was (almost significantly) up-regulated in ALS NCHs compared to HC 
(Paragraph 5.5). This observation and the incomplete digestion by trypsin would 
support further studies into the role of this Nf isoform in the pathogenesis of ALS. 
 
Figure 6.7. Plasma NCHs profile after trypsin digestion.  
(A) Plasma NCHs from ALS (ALS1*-5*) and HC (HC1-6) digested with trypsin. (B) Quantitative 
analysis of the common band detected at 45 KDa and normalised with the adjacent Marker band 
at 41KDa. 
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Figure 6.8. NfH profile in plasma NCHs digested with trypsin. 
Western blot against NfH revealing a band around 41 KDa for ALS5*, ALS3* and a much fainter 
band at the same MW for the HC5 sample, while all other samples show a complete digestion. 
These findings indicate a degree of resistance to digestion with trypsin for NfH included in NCHs. 
6.3.3 Chymotrypsin digestion 
Chymotrypsin is a serine protease that hydrolyzes peptide bonds with aromatic 
or large hydrophobic side chains (tyrosine, tryptophan, phenylalanine, methionine 
and leucine). This protease was tested because it is included in the same family 
of trypsin, and both proteases were detected in proximity of Nf aggregates in 
motor neuron axons in spinal cord from ALS patients (259). 
 
Figure 6.9. Plasma NCHs profile after chymotrypsin digestion.  
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Plasma NCHs samples from ALS (ALS1*-5*) and HC (HC1, HC3-6) digested with chymotrypsin. 
This digestion profile is represented by a few and faint bands, suggestive of a very low degree of 
resistance to digestion. Due to the low intensity of the bands and the background it was not 
possible to quantitate and compare the two experimental groups. HC2 was not included in the 
experiment as there was not enough NCH material for the digestion. 
Plasma NCHs showed a very low or no resistance to digestion with chymotrypsin 
(Figure 6.9). ALS NCHs samples showed a very faint band around 41 KDa that 
was not visible in HC sample, while both experimental groups showed the same 
band below 31 KDa (Figure 6.9). However, due to low band intensity and staining 
background, it was not possible to perform a reliable quantification. 
 
Figure 6.10. NfH profile in plasma NCHs digested with chymotrypsin. 
Western blot against NfH following NCHs chymotrypsin digestion revealing a band at around 41 
KDa for ALS4*, HC6 and HC5 samples only, indicating a positive but low degree of resistance to 
digestion with chymotrypsin for the NfH fraction included in NCHs. 
As for trypsin digestion, after chymotrypsin digestion we have detected NfH 
bands only in three samples including ALS4*, HC6 and HC5 (Figure 6.10). This 
result is complementary to that of trypsin digestion, where aggregated NfH in ALS 
samples showed a higher degree of resistance than HC, which showed higher 
resistance to chymotrypsin (Figure 6.8 and Figure 6.10).  
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6.3.4 Calpain digestion 
Calpain is a calcium dependent non-lysosomal cysteine protease ubiquitously 
expressed, with a wide range of targets and it is known to carry out an uncomplete 
hydrolysis of its targets because of the amino acid sequence, not well defined 
yet, and of the substrate’s tertiary structure specificity (260–262). It has a wide 
range of substrates, including Nf, and it has been linked to axonal dysfunction 
and Nf degeneration (263). In addition, data produced by our research group 
include the determination of high level of calpain in CSF from ALS patients 
(unpublished data). 
 
Figure 6.11. Plasma NCHs profile after calpain digestion. 
(A) Plasma NCHs samples from ALS (ALS1*-5*) and HC (HC1-6) digested with calpain. (B) 
Quantitative analysis of the band profile. In this experiment, NCHs bands at 180 KDa were 
normalised with the 171 KDa Marker band, the 140 KDa bands with the 171 KDa Marker band, 
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the 110 KDa bands with the 117 KDa Marker band, the 80 KDa bands with the 71 KDa Marker 
band, the 67 KDa bands with the 71 KDa Marker band, the 57 KDa bands with the 55 KDa Marker 
bands and the 47 KDa bands the 55 KDa Marker band. Bands lower than 47KDa were not 
considered because it was difficult to discriminate from the background. *= p-Value < 0.05. 
The digestion with calpain showed a very low specificity of the protease for 
plasma NCHs, with a significant degree of protease resistance (Figure 6.11A). In 
fact, all the samples showed after digestion several bands ranging from 180 KDa 
to 31 KDa, with ALS2*, ALS3*, ALS4*, HC4 and HC5 showing also bands at 
higher molecular weight (up to 238 KDa) (Figure 6.11A). Quantitative analysis of 
these bands between the ALS and HC  groups showed that bands at 180, 110, 
67 and 57 were more intense in HC NCHs compared to ALS (p= 0.036, 0.025, 
0.021 and 2e-5 respectively), while the band at 47 KDa was more intense in ALS 
NCHs compared to HC (p= 0.045) (Figure 6.11B). Overall, for the bands 
represented in all samples after digestion, HC plasma NCHs seemed to be more 
resistant to calpain digestion than ALS plasma NCHs, showing a higher intensity 
for the bands detected (Figure 6.11B). 
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Figure 6.12. NfH profile in plasma NCHs digested with calpain. 
(A) A) Western blot against NfH revealed two bands at 58KDa and 41KDa, shared across all the 
samples. HC6, ALS4*, HC5, ALS3* and ALS2* show other bands at higher MW, (B) Quantitative 
analysis of the bands detected including the sum of the 58 and 41 KDa bands (SUM) and the 
ratio between the 58 and 41 KDa bands (ratio) showed a higher, but not statistically significant, 
intensity in HC compared to ALS (p= 0.14). Band densities were normalised on ALS1* and 
corrected for the NfH content in each sample (Figure 6.6A). 
NfH detection after digestion with calpain showed a wide range of 
immunoreactive peptides, mostly unique for each of the samples under 
investigation (Figure 6.12A). Only two peptides were shared across all the 
samples, one detected at 58 KDa and the other one at 41 KDa (Figure 6.12A). 
Band intensities after digestion depend on aggregated NfH susceptibility to 
digestion, but also on the NfH content of the sample. For this reason, to improve 
accuracy of the quantitative analysis on NfH digestion, the 58 KDa band 
intensities were corrected for NfH intensity detected at 460 and 268 KDa in the 
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original undigested sample, while the 41 KDa band intensities were corrected for 
the overall amount of undigested NfH (Figure 6.6A). With this correction, NfH 
density for 58 and 41 KDa bands as well as the sum of the two (SUM) was still 
higher in HC than ALS plasma NCHs (Figure 6.12B). However, these differences 
were not statistically significant (p= 0.18, 0.13 and 0.14 respectively). Also, ALS 
vs HC differences in the ratio between 58 and 41 KDa bands (ratio) showed a 
non-statistically significant higher value for HC compared to ALS (p= 0.11) 
(Figure 6.12B). 
Despite a wide range of substrates, calpain is reported to have a very specific 
hydrolytic activity and the profile generated in plasma NCHs confirms this 
observation (Figure 6.11A). Also, the different composition of plasma NCHs 
across samples as reported in Chapter 5 would support our finding of an extreme 
variability in digestion products across samples. Moreover, the different digestion 
patterns seen in NfH immunodetection after calpain digestion (together with the 
well-known calpain specificity to different three-dimensional structures of target 
substrates) would suggest that NCHs and their NfH content enriched from ALS 
and HC have different conformations. This result puts more emphasis on the work 
done so far on imaging by transmission electron microscopy (TEM). The higher 
level of NfH reactive bands in HC plasma NCHs, compared to ALS, would 
suggest a lower level of phosphorylation of this protein in HC (33), considering 
that phosphorylation is a well-known factor affecting proteolysis. 
6.3.5 Enterokinase digestion 
Enterokinase (also called enteropeptidase) cleavage site specificity is aspartate-
aspartate-aspartate-aspartate-lysine and it is known to convert trypsinogen to 
trypsin. It has been shown to be active on proenzymes like chymotrypsinogen, 
procarboxypeptidases and proelastases and to act specifically on NfH (38,264). 
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Figure 6.13. Plasma NCHs profile after enterokinase digestion. 
(A) Plasma NCHs samples from ALS patients (ALS1*-5*) and HC (HC1-6) digested with 
enterokinase. (B) Quantitative analysis of the band profile. In this experiment, bands at 68 KDa 
were normalised with the 71 KDa Marker band, the 58 KDa bands with the 55 KDa Marker band, 
the 48 KDa bands with the 55 KDa Marker band. Bands below 48 KDa were not considered 
because it was difficult to discriminate them from the background. *= p-Value < 0.05. 
Despite the known effect of enterokinase in the activation of trypsin and 
chymotrypsin, plasma NCHs digestion by enterokinase did not resemble the 
digestion profiles generated by these two enzymes in the same NCHs (Figure 6.7 
and Figure 6.9). Enterokinase digestion of plasma NCHs generated three bands 
at 68, 58 and 48 KDa in all samples tested, with ALS2*, ALS3* and ALS4* showed 
also bands at 117 and 171 KDa (Figure 6.13A). Quantitative analysis of these 
bands between ALS and HC samples showed that bands at 68 and 58 were more 
intense in the HC NCHs compared to ALS (p= 0.009 and 0.004 respectively), 
while the band at 48 KDa was more intense in the ALS NCHs compared to HC 
(p= 0.005) (Figure 6.13B).  
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The NfH immunodetection profile after digestion revealed two different profiles 
between ALS and HC plasma NCHs samples (Figure 6.14A). All the samples 
shared a band at 50 KDa, but the ALS samples only also showed bands at 171 
(not for ALS1*) and 31 KDa, not expressed by the HC samples (Figure 6.14A). 
The only band shared across all the plasma NCHs samples at 50 KDa was 
equally expressed between ALS and HC samples (Figure 6.14B).  
Based on the data outlined in this paragraph, enterokinase seems to be very 
active in the test NCHs. In line with previous report of the proteolytic activity of 
enterokinase on NfH, the NfH profile in the ALS group suggests the presence of 
disease-specific changes in the NfH protein in NCHs, which may be at both 
biochemical (e.g. phosphorylation or glycosylation) or structural level. 
Interestingly, the peptide observed at 31 KDa in our experiment of NCHs 
eneterokinase digestion in ALS samples could be in line with the findings from 
Petzold et al., who have reported the presence of two non-phosphorylated NfH 
peptides (35–39 kDa, called NfH835-1026, and 25–28 kDa, called NfH852-986, 
fragments of similar size (38). The other immunoreactive bands identified in this 
study, including the one at 171 KDa specific for ALS seem not to have been 
previously reported in the literature. 
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Figure 6.14. NfH profile in plasma NCHs digested with enterokinase. 
(A) Western blot against NfH revealed one band at 50 KDa shared across all the samples. With 
the exclusion of ALS1*, all ALS samples also show two more bands at 171KDa and 31KDa not 
detected in HC samples. (B) Quantitative analysis of the band profile. Band densities were 
normalised on ALS1* and corrected for the NfH content in each sample (Figure 6.6A). 
6.3.6 ALS brain NCHs digestion patterns 
The resistance to protease digestion was tested also on brain NCHs, using 
chymotrypsin, calpain and enterokinase (Figure 6.15). Trypsin digestion on this 
sample was already tested in Paragraph 4.6. The gel profiles (Figure 6.15A) after 
protease treatment showed a complete digestion with chymotrypsin (lane 2), 
while digestion with enterokinase and calpain (lane 3 and 4 respectively) showed 
a darker area between 55 and 41 KDa, suggesting accumulation of the hydrolytic 
peptides.  
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Figure 6.15. ALS brain NCHs digestion with proteases. 
Zinc staining (A) and anti-NfH western blot (B) of brain NCHs digested with chymotrypsin, 
enterokinase and calpain and of the same undigested samples. In (B), pictures of the same gel 
were taken at different exposure times to maximise band visualization (lane 1 at 10.1 seconds, 
lane 4 and 5 at 58.4 seconds and lane 2 and 3 at 278.8 seconds). 
NfH in brain NCHs showed very faint bands after digestion with the three 
enzymes suggesting a low resistance degree to digestion for this protein in the 
aggregated forms in brain (Figure 6.15B). Interestingly, chymotrypsin and 
enterokinase digestions (lane 2 and 3 respectively) generated two 
immunoreactive areas, rather than distinct bands, at higher molecular weight than 
the NfH detected in undigested brain lysate and NCHs (lane 5 and 1 respectively, 
Figure 6.15B). Calpain digestion showed two faint bands at about 171 KDa. It 
was the enzyme with the lowest hydrolytic activity on aggregates and NfH among 
the three tested in this experiment (lane 4, Figure 6.15B). 
The presence of NfH species in digested brain NCHs at higher MW than that 
exhibited by undigested brain NCHs is difficult to interpret. This may be related 
to the dynamic of aggregation of NfH and of other co-aggregating proteins at high 
molecular weight and to their behaviour in the presence of proteases (Figure 
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6.15B). Alternatively, this could be due to the general low solubility of the 
aggregates in non-urea buffers (see Paragraph 2.6). 
6.4 Conclusion 
In this Chapter, we have built on our initial data to provide a comprehensive 
characterization of plasma and brain NCHs using imaging by transmission 
electron microscopy (TEM) and testing proteases resistance. 
A relevant finding in our TEM work to characterize the morphology of plasma and 
brain aggregates is the identification of small filament-like particles similar to 
those detected in brain NCHs in the NCHs enriched plasma fraction (Figure 4.10 
and Figure 6.3). This may suggest a cross talk between brain and systemic 
circulation as these macromolecular structures may find their way from the CNS 
to the peripheral circulation. However, this observation may also indicate that 
proteins like Nf, perhaps in a disordered state, may have a similar seeding effect 
in brain and plasma although the composition of co-aggregated proteins may be 
different in different matrices.  Against the hypothesis that brain and plasma 
NCHs are closely related and perhaps also biologically similar in the formation of 
these aggregates is the observation that the digestion patterns of plasma and 
brain NCHs were completely different when using a number of hydrolytic 
enzymes (Figure 6.9-Figure 6.15). This discrepancy may point towards an over-
interpretation of the TEM data, where morphology may not necessarily have the 
biological and functional meaning, particularly when it is not possible to speculate 
any further on the microstructure of these formations. However, it is also 
important to recognise that our TMT calibrator results show how a substantial 
number of proteins which are part of the neuronal and axonal network are also 
detected within peripheral aggregates, a finding that suggest a strong biological 
link between brain and circulating macromolecules. To further investigate these 
particles from a morphological point of view, we will have to rely on NCHs 
enrichment on a larger number of plasma and brain samples and consider 
inclusion of positive controls like for example prions particles. 
Despite the presence of commonalities in the overall protein composition, the 
study of the protease digestion patterns in brain and plasma NCHs (Figure 6.15A) 
revealed a completely different activity of the hydrolytic enzymes used for the 
digestion experiments. While brain NCHs digestion with chymotrypsin, 
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enterokinase and calpain did not show any relevant form of resistance to 
digestion, plasma NCHs treated with the same proteases, and in particular with 
calpain and enterokinase (Figure 6.11 and Figure 6.13), generated a more 
complex pattern of digestion supporting the idea that the plasma protein mix 
including those of potential brain origin, acquire different biochemical properties 
once in circulation. Our data may also support the development of a new concept 
of biomarker where circulating NCHs may be a disease signature not only in 
virtue of their structure/composition but also for their functional role. Experiments 
on cell viability should be undertaken to evaluate possible toxicity of these 
aggregates. 
Plasma NCHs digestion experiments showed a substantially different interaction 
between aggregates and proteases in ALS and healthy state. The digestion 
profiles showed both quantitative (Figure 6.11B and Figure 6.13B; i.e. the same 
bands in the gel digestion profiles showed different intensities across samples) 
and qualitative differences, where condition-specific digestion patterns showed 
bands appearing in one experimental group only (Figure 6.13A). The same 
condition-specific digestion profiles were identified when testing NfH 
susceptibility to protease digestion. NfH showed a degree of protease resistance 
in some of the samples particularly with calpain and enterokinase digestion and 
clear differences were detected between the ALS and the HC samples. While no 
definitive conclusion can be drawn from the analysis of relatively small number of 
samples, it is tempting to speculate that these features may be linked to the 
pathogenesis of the disease or play an important role in its development. 
Extending this investigation to a large number of samples to include, for example, 
non-neurological controls with other human conditions may be a way forward in 
the characterization of this finding. In addition, since resistance to protease 
digestion of NCHs enriched from different tissues may be the consequence of 
different PTM loads and types, which are well-known to condition structure and 
biochemical properties of molecules, it will be important to undertake proteomic 
studies which are geared towards the detection of the spectrum of relevant PTMs. 
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7 Summary and conclusion 
In this thesis, I have developed a multi-modal experimental approach to study 
protein aggregation in blood in relation to the development of neurodegeneration. 
I have focused on this biological phenomenon after observing the behavior of 
axonal proteins like neurofilaments when they reach the blood stream after their 
release from degenerating neurons and axons. We have therefore concentrated 
on Neurofilament-Containing Heteroaggregates (NCHs) in blood and compared 
these formations to the well-known process of protein aggregation occurring in 
brain. What we find is that circulating NCHs retain molecular features of brain 
aggregation and they acquire biochemical properties that may be specific of 
pathological states characterized by neurodegeneration. Our data strongly 
support further investigations into these biological substrates as they may be 
relevant in the development of novel disease biomarkers and therapeutics for 
neurodegenerative diseases. 
I have first tested methodologies for the enrichment of NCHs from blood and brain 
tissue (Chapter 3). Then NCHs composition was studied by mass spectrometry 
(MS)-based proteomics. NCHs composition was characterized in blood and brain 
samples from individuals with amyotrophic lateral sclerosis (ALS), a fatal 
neurodegenerative disorder, and in plasma samples from matched healthy 
controls (HC). Functional analysis of the NCHs proteomes from healthy and 
disease states has highlighted the presence of biochemical differences in protein 
degradation (proteasome activity) and energy metabolism 
(glycolysis/gluconeogenesis, carbon metabolism and pentose phosphate) 
already described in ALS literature (Chapter 4).  
After having confirmed that NCHs are able to depict the biochemical and 
pathophysiological changes that may accompany the development of a 
neurodegenerative disorder, a quantitative analysis with the innovative 
TMTcalibrator™ workflow was undertaken using plasma NCHs enriched from six 
ALS patients and six matched HC (Chapter 5). This platform has the unique 
added value of being able to analyse tissues and fluids in the same round of 
experiments, dissecting fluid proteins that are also expressed in tissue. Thanks 
to this novel experimental approach, we have been able to detected and quantify 
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almost 5000 brain-derived proteins in plasma NCHs, with 285 of these showing 
a significant level of regulation (p < 0.05) in ALS compared to controls. Functional 
analysis has identified regulated pathways known to be involved in ALS pathology 
and in protein aggregates homeostasis including lysosome as well as lipoprotein 
and glycosaminoglycan metabolisms. Using immunodetection we have not been 
able to fully replicate the level of regulation in selected protein candidates 
obtained using the TMTcalibrator™ workflow. Taking into account the differences 
across different methodologies of protein detection, it will be certainly important 
to extend validation to a larger number of protein candidates that have emerged 
from our proteomic experiments. 
Our hypothesis of NCHs representing a sound source of biomarkers in 
pathological condition is based not only on the MS-based proteomics data, but 
also on experiments in which we have tested their resistance to protease 
digestion (Chapter 6). The different digestion patterns in NCHs from ALS and HC 
observed using several proteases strengthen the hypothesis that these 
formations may go through disease-specificity biochemical changes, 
representing proteome differences in specific conditions, that could be ultimately 
exploited for the development of innovative disease biomarkers. 
Ultimately, we believe that Neurofilament Heavy (NfH) may acquire a pro-
aggregating tendence (Chapter 3) and as for many other proteins, this biological 
feature may be enhanced in neurodegenerative conditions. NfH is currently used 
as one of the possible biomarkers of ALS that is tested by simple plasma 
quantification. In this thesis, we have shown that NfH within heterogeneous 
aggregates has the potential to be be as informative as its soluble version. The 
relevance of different NfH species in their aggregated form was also highlighted 
by the experiments carried out with protease enzymes. In particular, enterokinase 
showed digestion-products specific for ALS plasma NCHs that were not present 
in HC plasma NCHs. The lack of peptides detected with a normal mass 
spectrometry analysis, probably due to the very low amount of these proteins in 
blood in respect of other more abundant proteins, indicates that immunoassays 
are still the best method for neurofilaments detection and quantification. 
However, the data showed in this thesis suggest the presence of specific isoforms 
of NfH that could be relevant for diagnosis, supporting the idea of specific studies 
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to evaluate the isoforms differences. This requires the development of specific 
methodologies for enrichment that would increase the chance of detection with 
other analytical instruments, such as mass spectrometry. 
Another important data set generated in this project comes from the transmission 
electron microscopy (TEM) analysis of the NCHs fractions. These data somehow 
confirmed the validity of our NCHs enrichment protocol as a sound method for 
protein aggregates analysis (Chapter 3), showing macromolecular (mostly 
amorphous) formations in the extraction products. Despite in ALS literature there 
is no mention of prion-like structures in brain aggregates, TEM has also identified 
formations which may have resemblance to prion-like proteins (Chapter 4) (see 
figures in (165–167)). However, because of the absence of quality controls 
included in this set of experiments and the lack of references in literature, we 
cannot speculate any further and we will need further analysis and validation with 
a larger set of experiments. 
The low number of samples tested in these experiments is not sufficient for a full 
evaluation of the diagnostic potential and of the involvement in the pathogenesis 
of ALS of NCHs. However, our work represents the ground for future validation 
of the biomarker candidates proposed in this thesis and the use of NCHs as 
surrogate of standard soluble molecules. In addition, testing these particles using 
established cell bioassays will give us information on the biological properties of 
these formation and eventual toxicity. This will be an important step towards 
understanding whether and how NCHs could be exploited for therapeutic purpose 
and to establish novel biomarkers. 
The laborious methodology, the high volume of plasma required as well as the 
low high-throughput capacity of this approach does not suggest a possible 
application for NCHs in clinical practice. However, this project showed the 
potential of these particles for research studies aimed at biomarkers discovery, 
with the possibility to determine possible candidates that can be further 
developed for possible diagnostic tools in clinical practice. 
In conclusion, combining a pioneering TMTcalibrator™ workflow with a range of 
biochemical and imaging techniques has been a valuable effort in the 
characterisation of a poorly understood phenomenon and in the discovery of a 
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potentially new field of investigation in the ever-growing medical and social 
emergency caused by neurodegenerative disorders.  
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